


EVER2008

Programme book



October 1-4, 2008
Portoroz, Slovenia

21 CME credits

www.ever.be

NEW
in glaucoma



taflotan[®]
tafluprost

**The first preservative-free
prostaglandin**

- **Effective IOP reduction**
- **No adverse reactions from preservatives**
- **Especially for glaucoma patients with dry/sensitive eyes**



15 µg/ml tafluprost

taflotan[®]
The preservative-free prostaglandin.

Abbreviated Prescribing Information TAFLOTAN[®] (tafluprost 0.0015% eye drops, solution). **Presentation:** Low-density polyethylene single-dose containers packed in foil pouch. Each single-dose container has a fill volume of 0.3 ml and there are 10 containers in each foil pouch. The following pack sizes are available: 30 x 0.3 ml and 90 x 0.3 ml. One ml of eye drops contains 15 micrograms of tafluprost. **Indication:** Reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension in patients who would benefit from preservative-free eye drops or who are insufficiently responsive or intolerant or contra-indicated to first line therapy, as monotherapy or as adjunctive therapy to beta-blockers. **Dosage and Administration:** The recommended dose is one drop of TAFLOTAN[®] in the conjunctival sac of the affected eye(s) once daily in the evening. Not recommended in children or adolescents (under the age of 18). In renal or hepatic impairment use with caution. **Contraindications:** Hypersensitivity to tafluprost or to any of the excipients. **Precautions:** Before treatment is initiated, patients should be informed of the possibility of eyelash growth, darkening of the eyelid skin and increased iris pigmentation. Some of these changes may be permanent, and may lead to differences in appearance between the eyes when only one eye is treated. Caution is recommended when using tafluprost in aphakic patients, pseudophakic patients with torn posterior lens capsule or anterior chamber lenses, or in patients with known risk factors for cystoid macular oedema or iritis/uveitis. There is no experience in patients with severe asthma. Such patients should therefore be treated with caution. **Interactions:** Specific interaction studies with other medicinal products have not been performed with tafluprost. **Pregnancy:** Do not use in women of childbearing age/potential unless adequate contraceptive measures are in place. **Driving:** Tafluprost has no influence on the ability to drive. **Undesirable Effects:** The most frequently reported treatment-related adverse event was ocular hyperaemia. It occurred in approximately 13% of the patients participating in the clinical studies with tafluprost in Europe and the US. Other side effects include: Common (1% to 10%): eye pruritus, eye irritation, eye pain, changes in eyelashes, dry eye, eyelash discoloration, foreign body sensation in eyes, erythema of eye lid, blurred vision, increased lacrimation, blepharal pigmentation, eye discharge, reduced visual acuity, photophobia, eyelid oedema and increased iris pigmentation and headache. Uncommon (0.1% to <1%): superficial punctate keratitis (SPK), asthenopia, conjunctival oedema, blepharitis, ocular discomfort, anterior chamber flare, conjunctival follicles, allergic conjunctivitis, anterior chamber cell, conjunctival pigmentation and abnormal sensation in eye, hypertrichosis of eyelid. **Overdose:** If overdose occurs, treatment should be symptomatic. **Special Precautions for Storage:** Store in a refrigerator (2°C - 8°C). After opening the foil pouch keep the single-dose containers in the original foil pouch, do not store above 25°C, discard an opened single-dose container with any remaining solution immediately after use. **MA Number:** 67942.00.00. **MA Holder:** Santen Oy, Niittyhaankatu 20, 33720 Tampere, Finland. **Date of Preparation:** May 2008.

Santen



Word from the president



Harminder S DUA
EVER President 2008

Dear Delegates and Guests

An ideal medical scientific conference represents the interaction of minds and hearts fostering the exchange of knowledge with understanding and compassion. It provides an environment where the youngest learner can rub shoulders with the oldest teacher and have his questions answered and equally, question the answers. Both teacher and taught are enriched by the experience with the ultimately beneficiary being the trusting patient.

The European Association for Vision and Eye Research (EVER) has embraced these ideals and proudly notches its first landmark, the successful completion of the 10th anniversary conference in 2007. This landmark encompasses EVER's marriage with ACTA Ophthalmologica as its official journal. The vision of its founding members unfolds as the Association and its conferences attain international stature and prestige.

The annual congress provides a balance of clinical, translational and basic research information and knowledge delivered through special interest symposia, free papers, courses and discussions. In the true European tradition, work blends with enviable social events for all attendees, providing further opportunities for personal interaction, creating new links and friendships and strengthening old ones.

I am confident that the 2008 conference will provide all the above and more. I extend a very warm welcome to all at picturesque Protoroz. Enjoy the blend of diet for the mind and the palate.

Yours sincerely

Harminder Singh Dua
President, EVER

About EVER

EVER is a non-profit organisation. The aims of the Association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

EVER is currently the leading ophthalmological research association in Europe which covers all areas of ophthalmology and visual sciences.

Membership

Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research, who meet the requirements established by the EVER Board. To become a member, a candidate should apply on the member's module, on www.ever.be and fill in the name of an EVER member who will endorse their application. If candidates do not know a member who can endorse their application, they should write to the EVER office, who will take appropriate action. The candidate becomes a member upon recommendation by the EVER board and upon payment of the dues.

As EVER member your benefits are:

- reduced fee for the annual meeting
- possibility of organizing Special Interest Symposia (SIS) during the annual meeting
- voting rights for the election of the Board Members
- free electronic subscription to Acta Ophthalmologica, the EVER journal
- travel grants for best paper in each section
- quarterly E-Newsletter

Elections

This year new representatives of the scientific sections Lens and Cataract and Retina/Vitreous will be elected through electronic voting. The result of the elections will be announced at the General Assembly on Saturday, October 4, 2008.

The scientific sections will hold their Business Meetings on Friday, October 3, 2008 from 13:05 till 14:05. sandwiches and refreshments is provided. The agenda is available on page 44.

The following 3 sections will nominate candidates for the succession of their representatives in the Board of EVER for elections in 2009:

- Anatomy/Cell Biology
- Molecular Biology/Genetics/Epidemiology and
- Vision sciences/Electrophysiology/Physiol. Optics

The statutes and by-laws are available on the website: www.ever.be » [about](#) » [statutes](#)

Executive Committee



Harminder S Dua
President



Selim Orgul
Vice President



Bahram Bodaghi
Secretary General



Pinar Aydin
Treasurer



Tero Kivelä
Programme Secretary



Charles Riva
President Elect



Uwe Pleyer
Past President



Ralph Michael
Vice-president Elect

EVER Office



Christy Lacroix, Assistant
Marlene Verlaeckt, Executive Officer
Bruno Van Damme, Webmaster

*Kapucijnenvoer 33, 3000 Leuven, Belgium
marlene.verlaeckt@ever.be • www.ever.be*

Section Chairs



Erich Knop
ACB



Philippe Kestelyn
COS



Thierry Zeyen
G



Carl Herbolt
IM



Ralph Michael
LC



Marcela Votruba
MBGE



Lene Martin
NSPH



Charlotta All-Ericsson
PO



Leopold Schmetterer
PBP



Charles Riva
RV



Graham Holder
VEP

Regional representatives



Francesco Bandello
Italy



Rimvydas Asoklis
East Europe



Pinar Aydin
Greece, Balkan, Middle-East

Local representative



Marko Hawlina
Slovenia



Amanda Churchill
Advisor

Co-opted

Programme Committee 2008



ACB	=	Anatomy/Cell Biology	Erich Knop
COS	=	Cornea/Ocular Surface	Jean-Jacques Gicquel
G	=	Glaucoma	Ingeborg Stalmans
IM	=	Immunology/Microbiology	Carl Herbolt
LC	=	Lens and Cataract	Jan Olof Karlsson
MBGE	=	Molecular Biology/Genetics/ Epidemiology	Bart Leroy
NSPH	=	Neuro-ophthalmology/Strabismology/ Paediatric Ophthalmology/ History of Ophthalmology	Pinar Aydin
PBP	=	Physiology/Biochemistry/Pharmacology	Steffen Heegaard
PO	=	Pathology/Oncology	Neville Osborne
RV	=	Retina/Vitreous	Constantin Pournaras
VEP	=	Vision Sciences/Electrophysiol./Physiological Optics	Werner Spileers

Venue

EVER 2008 will be held at the Bernardin Convention Center in Portoroz, Slovenia (visit the website on www.h-berardin.si/en/congress_centre).

The pre-congress programme starts on Monday, September 29 with a two-day Joint Meeting for Residency Programme directors from Eastern Europe (by invitation).

On Tuesday, September 30 we will host for the first time a one-day ARVO Foundation course on Clinical Trials. We recommend participation.

The scientific programme of the EVER congress starts on Wednesday, October 1 at 12:00 and concludes on Saturday, October 4 at 19:15..

Registration

Everyone attending the scientific sessions—whether or not an EVER member, invited speaker, accompanying person or presenter—must register and pay the registration fee.

The early registration deadline is September 1, 2008. On-site registration will be open from Wednesday on October 1, 11:00.

Please note that:

- being or becoming an EVER member – or having an abstract accepted – does not imply that you are registered
- if you register as a member-in-training, you need to prove your traineeship with a document signed by the Head of your Department
- registering as an accompanying person entitles you to attend the EVER social events, but not the scientific programme

Cancellation policy

Refunds – up to 75% of the registration fee – will be granted for any cancellation received in writing, prior to September 20, 2008. Refunds will not be granted for later cancellation or no-shows.

Registration fees (in EUR) after Sept. 1, 2008

EVER member	350	275 *
SIS-invited speaker	350	275 *
Member-in-training	175	140 *
Non-member	570	460 *
Non-member-in-training	280	220 *
ARVO Clinical Trials Course	140	140 *
Course	50	30 *
Accompanying person	115	115 *

* Citizens of these listed countries only: Albania, Algeria, Armenia, Belarus, Bosnia and Herzegovina, Bulgaria, Congo, Croatia, Czech Republic, Egypt, Estonia, Georgia, Hungary, India, North Korea, Latvia, Libya, Lithuania, Macedonia, Moldova, Montenegro, Morocco, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Tunisia, Turkey, Ukraine.

The list of countries will be updated annually and is based on the membership roster.

Website

The EVER website www.ever.be has a central role in the EVER organisation. At this website, you can

- obtain up-to-date information about the scientific programme and the EVER 2008 meeting and view the status (session, hour, place) of your presentation
- pay on-line and obtain an overview of past payments
- look for other EVER members
- access general information about EVER
- access Acta Ophthalmologica, the EVER journal
- go to useful links
- express your vote for officers
- print your CME certificate after the congress



Travel

Portoroz can be reached from Trieste airport (Italy) and from Ljubljana airport (Slovenia).

A congress shuttle service is available. **Please book in advance** through www.ever.be » housing and transfer.

- Congress transfer service* from Ljubljana and Trieste airport to Portoroz: on arrival dates September 30 and October 1.
- On departure dates October 4 and October 5.
- One-way shuttle bus transfer:
Ljubljana airport to Portoroz:
30 EUR per person (90min.)
Trieste airport to Portoroz:
25 EUR per person (90min.).
- Private transfer: individual service, private car or van transfer with English-speaking driver can be organised. Please contact the technical organiser for more details at housing@cd-cc.si.

* Arrivals: The congress transfer service reserves the right to combine transfers for participants of the EVER congress with a maximum waiting time of 1 hour
Departures: Please reconfirm your departure transfer at least 48 hrs prior to your departure at the housing desk.

Tourist information

Slovenia is a country where the Alps meet the sea, a country of geographical diversity and natural beauty that you will be able to observe already on the way from Ljubljana airport to the town of Portoroz. Portoroz and Piran are two towns next to each other. The old tradition of Piran is matched with modern amenities in hotels that offer relaxing atmosphere and splendour.

The congress center is situated right in the middle of the two. The towns have many places offering pleasant atmosphere, with seafood restaurants and delicious wines.



Weather

October is an excellent time to visit Slovenia. It is the latter part of the warmest and driest time of the year.

Liability

The organisers cannot accept liability for personal accidents, loss of or damage to private property of participants and accompanying persons either during, or directly arising from the Meeting. Participants should make their own arrangements with respect to health and travel insurance.

Social programme

The social programme is open for all participants and registered accompanying persons:

- Wednesday 19:00, EVER Welcome reception
- Saturday 20:00, EVER Farewell dinner

Coffee

Included in the registration fee are the coffee and soft drinks throughout the meeting from 09:30 until 11:00 and from 15:30 until 17:30 and the [sandwiches and refreshments](#) at the time of section business meetings on Friday 13:05-14:05.

Internet access

Wi-Fi internet access will be provided in Foyer next to hall Europa A.

Scientific programme access

Visit www.ever.be for the most up-to-date scientific programme.

The abstracts will be published on-line in a special issue of Acta Ophthalmologica.



Business meetings

EVER business meetings of the scientific sections

Friday, 13:05-14:05

RV / PBP in Hall Europa A

IM / NSPH in Hall Europa B

COS / ACB in Hall Emerald I

LC / MBGE in Hall Emerald II

VEP in Hall Mediteranea I

PO in Hall Adria

European Vision Institute, EVI

Friday, 13:30-15:00: Steering Committee Meeting (Aurora)

Friday, 15:00-16:00: EVI General Assembly (Aurora)

Ophthalmic Oncology Group, OOG

Saturday, 17:45-19:15, in Hall Adria

Photographs




It is strictly forbidden to take photographs or videos of the presentations in the lecture Halls.

Withdrawals



First authors unable to attend EVER for reasons beyond their control, may request permission of the Programme Secretary to have another author present the paper. Alternatively, they should send a written notice of withdrawal to the EVER Office before September 20, 2008.

No shows

Please note that any first author, whose paper or poster, once it has been accepted, is not presented without a valid excuse, will be prohibited from presenting papers at EVER for the next two years.



Aurora: - Educators joint meeting (Monday & Tuesday)
- EVI meeting (Friday)



Guidelines for speakers

Handling presentations at EVER 2008

EVER 2008 offers a high-performance network between all the different presentation rooms.

All presenters must read the following instructions:

The supported software for presentation is PowerPoint.

Include your conflict of interest statement in the first slide

Oral presentations in the free paper sessions are limited to eight minutes, followed by four minutes of discussion. The session chairman will strictly enforce this schedule.

Rapid fire presentations should last no longer than 3-4 minutes with a 2 further minutes for questions from the audience. Do not use more than 2-3 PowerPoint slides for this presentations.

In the Speaker's room Mediteranea II, a technician helps the speaker to transfer his or her presentation into the central congress network. When the transfer is complete, the technician performs a quick run of the presentation so the speaker can check whether the presentation runs correctly and all parts of the presentation are copied.

Inside each presentation Hall, a technical assistant starts each presentation at the right time using one of the fixed computers connected to the central congress network.

We do not allow the use of personal laptops for presentations*. If you bring your laptop to the congress, the technician will copy the files on your hard disk of the laptop into the central congress network, so the laptop will no longer be needed.

Of course, the easiest way is to bring your presentation on CD, DVD or memory stick. E-mailing or uploading of presentations will not be encouraged but can be used in special circumstances.

When a speaker wants to modify the presentation after it has been transferred to the central congress network, it can of course be updated to the new version upon request.

Centrally stored data will be deleted at the end of the congress so no copyright issues will arise.

* In rare circumstances, the technician will allow the use of personal laptops. For example, when the presentation has been created with Apple Keynote or movie creating software.

Guidelines for posters

The poster exhibition takes place in Hall Europa C. Posters must be brought to the congress by the presenting author and should not be mailed in advance. The required dimensions are 95 cm (wide) by 180 cm (high). NOTE: **Portrait shape**. Include your conflict of interest statement in your poster.

Each poster is exhibited for one day only. All posters should be erected between 08:00 and 09:00 hrs on the day of presentation and must not be removed until 19:00 hrs. EVER is not responsible for any poster left behind at the end of the day.

You will find the number of your posterboard in one of the poster sessions of this programme book.

You are required to stand beside your poster during the poster session. On Thursday and Friday from 16:45 to 17:40, on Saturday from 15:50 to 16:40. During this time, moderators will be voting which poster should win the poster prize.

Some authors of posters, selected by the programme committee will be invited to give a brief **rapid fire** oral presentation.

Poster prizes

A poster prize of 100 EUR will be awarded for the best poster in each section. The winners will be chosen by the moderators and will be announced in the General Assembly meeting on Saturday, 4 October.



EVER travel grants



We are pleased to announce that the following 11 members have received a travel grant of 400 EUR each from the EVER Sections:

- Anatomy/Cell Biology:
Pavlina TSOKA, Heraklion, Crete, Greece
Quantification of the photoreceptors of healthy retinas in rat by flow cytometry (P405)
- Cornea / Ocular Surface:
Manuela LANZINI, Chieti, Italy
In vivo confocal microscopy in the diagnosis of corneal conjunctivalization (6232)
- Glaucoma:
Michael INBAL, Haifa, Israel
Interactions between trabecular meshwork cells and lens epithelial cells – a possible mechanism in infantile aphakic glaucoma (4455)
- Immunology/Microbiology:
Raquel GINEYS, Paris, France
Interest of an interferon-gamma release assay for diagnosing tuberculosis-related ocular inflammation (6423)
- Lens and Cataract:
Carla MÁRQUES, Coimbra, Portugal
Protein quality control and ubiquitin proteasome system: implications on cataract (P464)
- Molecular Biology/Genetics/Epidemiology:
Marzena GAJECKA, Poznan, Poland
Genetics of high myopia in Polish families (6353)
- Neuro-ophthalmology/Strabismology/Paediatric/History:
Eleni PAPAGEORGIU, Larissa, Greece
Driving performance in patients with homonymous visual field defects and healthy subjects in a standardized virtual reality environment (4421)
- Pathology/Oncology:
Francesca URBAN, Padova, Italy
Photodynamic therapy of circumscribed choroidal hemangioma: comparison of dosage and timing (6263)
- Physiology/Biochemistry/Pharmacology:
Alexandre FERNANDES, Coimbra, Portugal
25-Hydroxycholesterol increases IL-8 production in the RPE by activation of PI3K and p38 MAPK pathways (P584)
- Retina/Vitreous:
Christoph EHLKEN, Freiburg, Germany
EphB4 is expressed in preretinal neovascularization in a mouse model of oxygen-induced retinopathy (P652)
- Vision Sciences/Electrophysiol./Physiological Optics:
Archana PRADEEP, Leicester, UK
Can amblyopia treatment be optimised? (5224)

TFOS awards 2008




We are pleased to announce that the following three researchers have received a travel award from the Tear Film and Ocular Surface Society for the three best abstracts submitted to EVER 2008 by young researchers in the cornea section:

- **Ammar MIRI, Nottingham, UK**
Long term results of Limbal stem cell transplantation in ocular surface disease (5333)
- **Waldir NEIRA, Helsinki, Finland**
Corneal morphology, topography and sensitivity in a family with inherited recurrent corneal erosions (P556)
- **Liza VERA, Rouen, France**
Outcome of transplanted mesenchymal stem cells in the alkali burned cornea (P542)




Pirano Tartini, violinist and composer (1692)



Monday
29 September


EVER
08

A global heritage of innovation



With a wide range of products in every area of eye care, Bausch & Lomb Pharmaceuticals spans the globe with innovative solutions that meet the diverse needs of patients and practitioners.

Aurora Joint M.	<i>Ophthalmology Residency Program Directors Course — PART I</i> Educating the Educators Conference (by invitation)	08:30 – 17:30
<p>Ophthalmology Residency Program Directors Course : Joint Meeting for Residency Programme directors from Eastern Europe The following organisations will contribute to the course : ICO / EBO / SOE / EUPO / EVER</p>		
		
08:30	Welcome, Introduction to special guests and recognition of sponsors — Dr. Marko Hawlina	
08:35	Welcome and recognition of sponsors — Dr. Bruce Spivey	
08:40	Participant Introduction — As a group	
08:50	Course Overview and Objectives — Dr. Karl Golnik	
08:55	Getting started: A glossary of terms you will need for this course — Dr. Andrew Lee	
<p>CURRICULUM DEVELOPMENT</p>		
09:05	The International Council of Ophthalmology Resident-Specialist Curriculum: Why you don't have to reinvent the wheel — Dr. Andrew Lee	
09:15	Small Breakout Groups charged to discuss the ICO Curriculum as a template to be adapted for local needs	
10:05	Coffee Break	
10:30	Large Group reconvenes to discuss small group recommendations — Dr. Eduardo Mayorga	
11:15	The ICO Program Director website (WORD) — Dr. Eduardo Mayorga	
11:30	Other internet resources — Dr. Karl Golnik	
11:45	Questions and Answers	
12:00	Lunch	
13:00	Curriculum Development — Dr. Karl Golnik	
13:30	Small Groups charged with developing a curriculum for a topic chosen from ICO Curriculum	
14:30	Large Group reconvenes to discuss small group ideas and comments — Dr. Andrew Lee	
15:00	Coffee Break	
<p>INSTRUCTION METHODS</p>		
15:30	Adult Learning Principles — Dr. Andrew Lee	
15:40	Teaching Evidence Based Medicine — Dr. Eduardo Mayorga	
15:55	Teaching in the Clinic — Dr. Karl Golnik	
16:10	Teaching in the Operating Room — Dr. Eduardo Mayorga	
16:25	Improving Lecture Skills — Dr. Karl Golnik	
16:40	Teaching Professionalism — Dr. Andrew Lee	
17:00	Questions and Answers	
17:30	ADJOURN	
19:30	Dinner with all participants on the boat Laho http://www.laho.net/	





EVER

Tuesday

30 September

08

Aurora	<i>Ophthalmology Residency Program Directors Course — PART II</i>	08:30 – 16:30
Joint M.	Educating the Educators Conference (by invitation)	
<p>Ophthalmology Residency Program Directors Course : Joint Meeting for Residency Programme directors from Eastern Europe The following organisations will contribute to the course : ICO / EBO / SOE / EUPO / EVER</p>		
		
08:30	The Accreditation Council for Graduate Medical Education's (ACGME) General Competences in the USA — Dr. Andrew Lee	
08:45	The 360 Degree Evaluation — Dr. Eduardo Mayorga	
09:00	The Resident Portfolio and Journal Club — Dr. Andrew Lee	
09:15	The Ophthalmic Clinical Evaluation Exercise (OCEX) and On Call Tool (OCAT) / Practical application of OCEX — Dr. Karl Golnik	
09:25	The Surgical Skill Checklist and Ophthalmic Surgical Assessment of Technique and skills (OSATS) — Dr. Andrew Lee	
09:40	Methods of Assessment and tools in the toolbox — Dr. Karl Golnik	
10:00	Coffee Break	
10:30	The Integral Role of Feedback — Dr. Andrew Lee	
10:45	Approch to resident feedback: role play — Dr. Karl Golnik / Dr. Eduardo Mayorga	
11:00	The Role of the Program Director - Not necessarily a Chairman — Dr. Andrew Lee	
11:15	Program director Collaboration: The United States Model - A Method for Program Director Improvement and Recognition — Dr. Karl Golnik	
11:30	Large Group Discussion	
12:00	Lunch	
13:00	The EBO strategy to harmonise training in Europe — Dr. Marie-José Tassignon	
13:20	Reducing Differences in Education between East & West — Dr. Marko Hawlina	
13:40	How to deal with the European heritage — Dr. W. Aclimandos	
14:00	Unified in training: EBO-SOE-EUPO-EVER — Dr. Tero Kivelä	
14:20	Coffee Break	
14:40	The point of view of SOE in Promoting Education — Dr. Stefan Seregard	
15:00	The point of view of EUPO in Promoting Education — Dr. Werner Spileers	
15:20	The point of view of EVER in Promoting Education — Dr. Harminder S Dua	
15:40	Appraisal and Assessment — Dr. Harminder S Dua	
16:00	EBO Ophthalmic Curriculum and Accredited Courses — Dr. Marie-José Tassignon	
16:20	Meeting summary — Dr. Andrew Lee	
	Closing remarks — Dr. Bruce Spivey / Dr. Marko Hawlina	
	ADJOURN	

Adria	ARVO Foundation:	08:00 – 16:30
Course	Design, conduct and management of clinical trials in eye research	




Testing new strategies for the treatment or prevention of eye diseases will ultimately require clinical trials, the basic methodology that supports evidence-based medicine. While grounding in appropriate clinical trials methodology can require years of training and /or experience, short courses to introduce key topics and provide links to more detailed material are critical to imparting the basics elements needed to conceptualize a well designed and run clinical trial. While short courses on basic clinical trial methods and issues are available, clinical trials in eye disease present unique challenges, due to the presence of two eyes. This course on clinical trials specifically for vision researchers will greatly enhance the understanding of current issues, state of the art approaches to problems in clinical trials and how to conduct a trial in ophthalmology.

Expert faculty will present key elements in the design, construct and execution of a clinical trial. Topics include randomization, criteria for eligibility and impact on generalizations, and role of standardization and special facets of multi-center trials. Faculty will include biostatisticians, and clinicians experienced in the design and implementation of clinical trials in eye disease.

Participants need to register to the EVER congress and register for the course.
Lunch is included in the course fee.

08:00		Check-in
08:15	2161	Principles of clinical trials WORMALD R
09:00	2162	Design of clinical trials: Introduction to study design and levels of evidence in medicine ROSSETTI L
09:45		Break
10:00	2163	European Union Clinical Trials Directives DANIELSON L
10:45	2164	Operational Aspects: Practical aspects of conducting a trial RIBEIRO L
11:30	2165	Interim monitoring and analysis: Statistics in clinical trials MUSCH D
12:30		Lunch
13:15		Practicum: Design a trial
15:00		Presentation of designs and discussions
16:00	2166	Summary: Presentation of a current trial in Europe WORMALD R





EVER

Wednesday
1 October

08

Mediterranea I	EGS: Neuroprotection Special Interest Group	08:30 – 11:30
Joint M.	M Francesca CORDEIRO, Ingeborg STALMANS	
	Clinical trial design in neuroprotection for glaucoma Speakers include: - LARSSON LI, Pfizer Global Pharmaceuticals - DE MIGUEL V, Allergan - RUSCIANO D, SOOFT Italia	


Europa A	IM: Course 1: Optical Coherence Tomography OCT in inflammatory and retinal diseases	12:00 – 14:15
Course	Carl P HERBORT, Marc D DE SMET	
	Optical Coherence Tomography (OCT) has gradually invited itself into everyday practice. The imaging quality is steadily improving with new generations of instruments giving fascinating insight into the retina. Although OCT investigation gives stunning pictures of the retina it is basically imaging those structures for which imaging access was already possible. The novelty is, with the new machines especially, the degree of precision of the information we can gather: A corollary to this first point, is the fact that we can get this information instantly without invasive procedures. For conditions such as choroidal neovessels, much closer follow-up has allowed, in parallel with the availability of potent intravitreal anti-VEGF therapy to improve drastically the management of AMD cases. In inflammatory diseases the availability has changed our attitude in the management of CME, increasingly based on OCT profile rather than strictly functional parameters. In diabetic maculopathy also OCT came along with the advent of new performing therapies the effect of which can so be optimally verified. The drawbacks of OCT is the fact that information is lost or OCT is impossible in turbid media and that the information on the underlying choroid is limited. Many cases will be presented and discussion especially on inflammatory and AMD cases will be possible.	
12:00	3211	Introduction ; the principles of OCT DE SMET MD–Antwerp
12:20	3212	Contribution of OCT to evaluate macular disease in JIA associated uveitis BODAGHI B, DUCOS G, KODJIKIAN L, TERRADA C, TRAN C, CASSOUX N, LEHOANG P–Paris, Lyon
12:35	3213	OCT imaging in uveitis: advantages and limits HERBORT CP, DE SMET MD–Lausanne, Amsterdam
12:50	3214	Advantages and limits of OCT for inflammatory macular edema BOUCHENAKI N–Geneva
13:05	3215	OCT in diabetic macular edema ABU EL ASRAR AM–Ryadh
13:20	3216	Comparison of microperimetry and OCT retinal thickness in uveitis TAKEUCHI M–Tokyo
13:35	3217	Advances in optical coherence tomography for age-related macular degeneration NERI P–Ancona
13:50	3218	Enhanced, OCT-assisted management of choroidal neovessels in AMD HERBORT C–Lausanne
14:05		Cases and discussion (all faculty)

Europa B	NSPH: Course 2: Visual field evaluation	12:00 – 14:15
Course	Ulrich SCHIEFER, Eleni PAPAGEORGIOU, Matthias MONHART	
	This is an interactive course, primarily aiming at residents and other EVER participants, who are especially interested in functional diagnostics using perimetry. Major topics of this course are: (1) Indications for visual field testing (2) Overview of perimetric methodologies (including confrontation visual field testing) (3) How to look at perimetric printouts? (4) Methods of quality and plausibility control with regard to perimetric results (5) Interpretation of perimetric records (recognition of scotoma patterns / scotoma classification) (6) Perimetric follow-up	

Emerald II	PO: Course 3: Time-to-event data: applications in ophthalmic research	12:00 – 14:15
Course	Tero KIVELÄ, Bertil DAMATO	
	Time-to-event data, also known as survival statistics, were developed originally for cancer research, but they have much wider applicability in medical research. After attending this course, the attendees will recognise when they would benefit from using time-to-event analysis in their research, what are the prerequisites for such an analysis, and how published results of these analyses are to be interpreted. The methods covered include standard Kaplan-Meier analysis and Cox proportional hazards regression, with an introduction of some advanced methods such as cumulative incidence analysis and neural networks.	
12:00	3241	Kaplan-Meier analysis and Cox proportional hazards regression KIVELÄ T–Helsinki
12:40	3242	Neural networks compared with Cox regression DAMATO B, TAKTAK A, ELEUTERI A–Liverpool
13:20	3243	Cumulative incidence analysis and relative survival KIVELÄ T–Helsinki

Adria	NSPH: Course 4: EBO Review Course : Neuro-ophthalmology		12:00 – 14:30
Course	François-Xavier BORRUAT, Antonella BOSCHI, Karl GOLNIK, Aki KAWASAKI		
	<p>Course Format: Formal lectures, multiple choice questions and case presentations. This course will focus on the evaluation of the patient with acute visual loss in two scenarios: part I is the patient with acute visual loss and unilateral disc swelling and part II is the patient with acute visual loss and a normal fundus. Three didactic lectures will review the important points of the history and examination as well as the usefulness of common ancillary tests in formulating a differential diagnosis. Thereafter, 5 unknown cases will be presented to the audience who will use the information given in lectures to discuss and solve the case. The 5 cases will be of increasing difficulty so that each case highlights a specific aspect of the evaluation and thus broadens the differential diagnosis. The goal of the course is to give the attendee the fundamentals information and mock experience in the evaluation of such patients so that the attendee may feel confident in the real-life situation.</p>		
	PART I PATIENT WITH ACUTE VISUAL LOSS AND UNILATEAL DISC SWELLING		
12:01	3261	History GOLNIK K–Cincinnati	
12:11	3262	Examination of the patient with visual loss and unilateral disc swelling KAWASAKI A–Lausanne	
12:21	3263	Ancillary testing and differential diagnosis BORRUAT FX–Lausanne	
12:31		Case Presentations (Mock exam style) - all faculty	
13:21		Pauze	
	PART II PATIENT WITH ACUTE VISUAL LOSS AND NORMAL FUNDUS		
13:32	3264	History BOSCHI A–Brussels	
13:42	3265	Examination of the patient with visual loss and normal fundus KAWASAKI A–Lausanne	
13:52	3266	Ancillary testing and differential diagnosis LEE A–Iowa	
14:02		Case Presentations (Mock exam style) - all faculty	
14:30		End of session	

Europa A	COS: Course 5: Corneal Infectious Disease		14:30 – 16:45
Course	Jean-Jacques GICQUEL, Harminder S DUA		
	<p>Acanthamoeba keratitis, infectious crystalline keratopathy, fungal keratitis and atypical mycobacterial keratitis have emerged as important types of infectious keratitis. These corneal infections have often been associated with contact lens wear, with corneal surgery such as radial keratotomy or penetrating keratoplasty and with the uncontrolled use of topical steroids. The clinical setting of each of these infections is important in alerting the clinician to the possible diagnosis. There have been improvements in rapid diagnostic techniques for such infections in the last years. Treatment has also improved, but remains a difficult problem, especially for Acanthamoeba. In this course, we'll give you an overview of recent developments in the clinical and histopathologic methods for diagnosis and treatment options of these corneal infections.</p>		
14:30	3311	Corneal bacterial diseases CREUZOT CP, BRON AM–Dijon	
14:50	3312	Epidemiology of corneal viral infections LABETOULLE M–Kremlin-Bicêtre	
15:10	3313	Herpetic keratitis BOURCIER T–Strasbourg	
15:30	3314	Parasitic corneal infections GICQUEL JJ–Poitiers	
15:50	3315	Fungal infections KESTELYN P–Gent	
16:10	3316	Infectious crystalline keratopathy and its management DUA HS, SAID DG–Nottingham	



Europa B	VEP: Course 6: Electrophysiology	14:30 – 16:45
Course	Graham HOLDER	
	The Course will give an overview of the clinical value of electrophysiological testing using clinical cases to demonstrate specific points.	
14:30	3321	Introduction to tests and ISCEV standard HOLDER GE–London
15:00	3322	Electroretinography LEROY BP–Ghent
15:30	3323	Pattern electroretinography and imaging of the macula HAWLINA M–Ljubljana
16:00	3324	Making the diagnosis HOLDER GE–London

Emerald I	NSPH: Course 7: MRI in everyday practice	14:30 – 16:45
Course	Pinar AYDIN	
	Magnetic Resonance Imaging (MRI) of brain and orbit is very useful in daily ophthalmology and neuro-ophthalmology practice. As ophthalmologists we need to learn what to order, when to order and how to interpret the results. This course aims to provide practical, clinical information and clues to make life easier with MRI.	
14:30	3331	Clinical decision for and with MRI PLANT G–London
15:20	3332	Imaging posterior visual pathways SIBTAIN N–London

Mediterranea I	PO: Course 8: EBO Review Course: Ophthalmic oncology	14:45 – 16:45
Course	Laurence DESJARDINS	
	<p>The aim of the course is to give an overview of the main intraocular, conjunctival lids and orbital tumours in adults and children. The techniques useful for diagnosis and the main differential diagnosis will be reviewed. Current management of the most frequent tumours will be described. This will include the management of uveal melanoma, retinal tumours, conjunctival and lid tumours and orbital tumours; clinical cases will be presented.</p>	
	 european board of ophthalmology	
14:45	3351	Diagnosis of intraocular and conjunctival tumours KIVELÄ T–Helsinki
15:05	3352	Management of uveal tumors DAMATO B, COUPLAND SE–Liverpool
15:25	3353	Management of retinal tumors DESJARDINS L–Paris
15:45	3354	Management of conjunctival tumors MIDENA E–Padova
16:05	3355	Lid tumors SEREGARD S–Stockholm
16:25	3356	Orbital tumors PRAUSE J–Copenhagen



Opening Ceremony

Welcome

17:00 – 17:15

Europa A

Welcome by the President EVER 2008

Harminder DUA — President



AER Lecture

17:20 – 18:00

Europa A

Much ado about nothing

Gijs VRENSSEN, Zeist - Netherlands

Introduction by Anthony BRON



European Ophthalmic Heritage

18:05 – 18:20

Europa A

Anton Banko, the Slovenian inventor behind the success of Charles Kelman

Marko HAWLINA, Ljubljana - Slovenia

Introduction by Tero KIVELÄ



EVER Lecture

18:25 – 19:00

Europa A

The taming of the shrew or corneal transplantation: past, present and future

Uwe PLEYER, Berlin - Germany

Introduction by Harminder DUA



Miha Debevec


Social


19:00-21:00

in S. Bernardin

EVER Welcome reception with musical entertainment

www.mihadebevec.com





Thursday
2 October
08

Europa A *RV: EURETINA session: Role of inflammation in the progression of diabetic macular edema* 08:15 – 09:45
 Joint M. Jose CUNHA-VAZ



08:15	4111	Diabetic macular edema. Clinical characterization CUNHA-VAZ J–Coimbra
08:30	4112	New developments in OCT evaluations BERNARDES R, CUNHA-VAZ J–Coimbra
08:45	4113	Perspectives for detection of photoreceptor changes SAHEL JA–Paris
09:00	4114	Role of inflammation in blood-retinal barrier breakdown: animal models AMBROSIO AF, LEAL EC, MANIVANNAN A, CUNHA-VAZ J, FORRESTER JV–Coimbra, Aberdeen
09:15	4115	Inflammatory markers in diabetic macular EDELMAN JL, NEHME A, KIRWIN S–Irvine
09:30	4116	Treating inflammation in DME. Combination treatments BANDELLO F–Udine

Europa B *NSPH: Amblyopia* 08:15 – 09:45
 SIS Pinar AYDIN, Lene MARTIN

08:15	4121	History of amblyopia GRZYBOWSKI A–Pozna
08:37	4122	Form deprivation amblyopia - a treatable cause of blindness SJÖSTRAND JB–Gothenburg
08:59	4123	Occlusion therapy BERK AT–Izmir
09:21	4124	Medical treatment CAMPOS E–Bologna

Emerald I *ACB: Retinal pigment epithelium* 08:15 – 09:45
 SIS Kai KAARNIRANTA, Hannu UUSITALO



08:15	4131	Inflammation in AMD pathology NOWAK JZ–Lodz
08:37	4132	Signaling pathways in innate immunity SALMINEN A–Kuopio
08:59	4133	Complement factor H and factor B expression in RPE cells XU H, CHEN M, FORRESTER JV–Aberdeen
09:21	4134	Inflammatory gene defects in AMD IMMONEN I–Helsinki

Emerald II *LC: Cell signalling in the lens - part I* 08:15 – 09:45
SIS Michael WRIDE

supported by 

- 08:15 4141 Sustained BMP signaling induces the lens placode
GUNHAGA L, SJÖDAL M, EDLUND T–Umeå
- 08:35 4142 A role for canonical WNT signaling in lens development
DELONGH R–Parkville
- 08:55 4143 TGFbeta/Smad signalling, transdifferentiation and matrix contraction
DAWES LJ, ELDRED JA, DUNCAN G, SLEEMAN M, ANDERSON IK, REDDAN JR, WORMSTONE IM–Norwich, Cambridge, Rochester
- 09:15 4144 TGFbeta signalling through Smad-independent mechanisms in human lens cells
WORMSTONE IM, ELDRED JA, DAWES LJ, REDDAN JR, WANG L–Norwich, Rochester

Mediterranea I *G: Stop glaucoma: progress(ion) in neuroprotection* 08:15 – 09:45
SIS Ingeborg STALMANS, M Francesca CORDEIRO

 ALLERGAN

- 08:15 4151 Monitoring retinal ganglion cells in vivo
PAQUES M, SAHEL JA–Paris
- 08:37 4152 Determining rates of visual field progression in glaucoma
CHAUHAN B–Halifax
- 08:59 4153 Is brimonidine better at stabilizing visual field than timolol?
KRUPIN T–Chicago, IL
- 09:21 4154 The future of neuroprotection in glaucoma therapeutics
WHEELER LA–Irvine

Adria *FRO: Belgian Fund for Research in Ophthalmology 1* 08:15 – 09:45
Joint M. Marie - José TASSIGNON, Philippe KESTELYN



- 08:15 4161 Gene transfer of disease regulated promoters during experimental autoimmune uveitis
CHTARTO A–Brussels
- 08:25 4162 Identification and characterization of novel disease genes for Leber Congenital Amaurosis (LCA)
COPPIETERS F–Gent
- 08:35 4163 Study of candidate genes for ocular anterior segment dysgenesis (ASD)
D'HAENE B–Gent
- 08:45 4164 Osmotic stress regulation of aquaporin 4 expression in a human retinal pigmented epithelial cell line
JANSSENS S–Brussels
- 08:55 4165 Study of the role of P2Y6 receptors in the development of experimental autoimmune uveitis
JUDICE DE MENEZES RELVAS L–Brussels
- 09:05 4166 AAV mediated SOCS1 gene expression in ARPE cells in an immune rejection model of xeno-graft for AMD diseases
KOCH P–Brussels

Keynote Lecture *A new era for age-related macular degeneration: insights pertaining to a key role for the complement system*
10:00 – 10:40
Europa A Gregory HAGEMAN, Coralville, IA - USA
Introduction by Charles RIVA



Plenary session *EVER Strategic planning session*
10:45 – 11:05
Europa A Harminder S DUA, Nottingham - UK
President EVER 2008



Europa A **ARVO Session: Making the case for funding eye research** 11:30 – 13:00
 Joint M. Joanne ANGLE



- 11:30 4211 European vision research - An independent point of view
VON BONHORST C–Brussels
- 11:50 4212 International research funding advocacy: The US experience
ANGLE J–Rockville, Maryland
- 12:10 4213 Advocating for research funding: The India experience
BALASUBRAMANIAN D–Hyderabad
- 12:30 4214 The role of the European Vision Institute (EVI) for supporting vision research in Europe
ZRENNER E–Tübingen

Europa B **NSPH: Neuro-ophthalmic diagnoses not to be missed** 11:30 – 13:00
 SIS Aki KAWASAKI, François-Xavier BORRUAT

- 11:30 4221 Papilledema due to cerebral venous thrombosis
BOSCHI A–Brussels
- 11:40 4222 Hypertensive retinopathy mimicking papilledema
LEE A–Iowa
- 11:50 4223 Pituitary apoplexy
KAWASAKI A–Lausanne
- 12:00 4224 Wernicke encephalopathy
BORRUAT FX–Lausanne
- 12:10 4225 Acute painful ophthalmoplegia: infectious considerations
GOLNIK K–Cincinnati
- 12:20 Case presentations with audience participation
All faculty

Emerald I **ACB: Functional anatomy of anterior segment** 11:30 – 13:00
 FP Erich KNOP, Fatima PEDROSA DOMELLOF

- 11:30 4231 Existence of limbal epithelial crypt within the infant limbus
YEUNG AM, TINT NL, HOPKINSON A, DUA HS–Nottingham
- 11:42 4232 Microarray study of limbal epithelial crypt demonstrates its putative limbal stem cell niche characteristics
KULKARNI B, FOSTER T, YEUNG AM, TIGHE P, HOPKINSON A, DUA HS–Nottingham
- 11:54 4233 Limbal microenvironment can induce transdifferentiation of hair follicle stem cells into corneal epithelial-like cells
BLAZEJEWSKA EA, SCHLOETZER-SCHREHARDT U, KRUSE FE–Erlangen-Nuernberg
- 12:06 4234 The effect of spongy layer (sl) isolated from amniotic membrane on ocular cells growth
LAZUTINA E, SULEMAN H, DUA HS, TINT NL, JAMES DK, HOPKINSON A–University of Nottingham, University of Nottingham
- 12:18 4235 Distribution of BIG-H3 protein in primary and recurrent granular corneal dystrophy
AKHTAR S, ALMUBRAD TM, OGBUEHI KC, BRON AJ–King Saud University, Riyadh
- 12:30 4236 Anterior segment imaging with fourier-domain optical coherence tomography system compared to time-domain OCT
NOWINSKA A, WYLEGALA E, MILKA M, MANKOWSKI W–Katowice

Emerald II **LC: Cell signalling in the lens - part II** 11:30 – 13:00
 SIS Michael WRIDE



- 11:30 4241 Role of gap junction proteins in primary fiber cell elongation
GRAW J, PUK O, HORSCH M, BECKERS J–Neuherberg
- 11:50 4242 Cholesterol oxides, signal transduction and cell dysfunction in the lens: a bizarre love triangle
PEREIRA P, FERNANDES AF, FERREIRA J, BRITO A, GIRAO H–Coimbra
- 12:10 4243 SUMOylation during nuclear degradation in lens fibre cells
PRESCOTT AR–Dundee
- 12:30 4244 New blood for hemoglobin in the lens: roles in stem cell differentiation and fibre cell organelle loss?
WRIDE MA, MANSERGH FC, HUNTER SM, GEATRELL JC, JARRIN M, POWELL K, EVANS MJ–Dublin, Cardiff

Mediterranea I ISCEV session

11:30 – 13:00

Joint M. Colin BARBER, Alma Patrizia TORMENE



11:30	4251	Functional correlates of abnormally increased annular fundus autofluorescence in different retinal dystrophies ROBSON AG, MICHAELIDES M, SAIHAN Z, BIRD AC, FITZKE F, HOLDER GE, MOORE AT, WEBSTER AR—London
11:42	4252	Summary of the findings of the RLBP1 mutations affecting the visual cycle known so far with extremely prolonged dark adaptation in the RP of Bothnia type BURSTEDT MSI, SANDGREN O, GOLOVLEVA I, WACHTMEISTER L—Umeå
11:54	4253	Improving the diagnostic potential of the photopic electroretinogram (ERG) with refined mathematical tools LACHAPPELLE P, JAUFFRET C, GARON ML, MIKULA M, MYSORE N, RACINE J—Montréal, Québec., Montréal, Québec, Montreal, Québec.
12:06	4254	Erg explorer: a software for post-processing, analysing, and reporting of electrophysiological data STRASSER T, WILKE R, MESSIAS A, ZRENNER E—Tuebingen
12:18	4255	Improvement of visual acuity and visual evoked patterned potentials done at different spatial frequencies after rehabilitation in 45 subjects affected by Cerebral Visual Impairment. RUBERTO G, ANGELI R, PEZZOTTA S, BERTONE C, ANTONINI M, FAZZI E, TINELLI C, BIANCHI PE—Pavia
12:30	4256	Flash vep anomalies in infants with delayed visual maturation (dvm) SJÖSTROM A, KRAEMER M—Göteborg
12:42	4257	Protection of the photoreceptors in ROP (retinopathy of prematurity) FULTON AB, HANSEN RM, AKULA JD, MOSKOWITZ A, HARRIS M—Boston MA

Adria FRO: Belgian Fund for Research in Ophthalmology 2

11:30 – 13:00

Joint M. Marie - José TASSIGNON, Philippe KESTELYN



11:30	4261	Functional MRI of the superior colliculus in dissociated vertical deviation LEYSEN I—Antwerp
11:40	4262	Analysis of a potential new model for neurovascular coupling in retina and its relation to the retinal relaxing factor MAENHAUT N—Gent
11:50	4263	Utility of FISH in diagnosis and therapy of ocular melanocytic lesions SCHAUWVLIEGHE PP—Gent
12:00	4264	Modulation of wound healing after glaucoma surgery VAN BERGEN T—Leuven
12:10	4265	Anti-PLGF, a safer alternative to anti-VEGF in the treatment of AMD? VAN DE VEIRE S—Leuven
12:20	4266	Inflammatory cytokines in the tears of patients with vascularized corneas VAN GRASDORFF S—Antwerp
12:30	4267	Cultivated stem cell transplantation for the treatment of limbal stem cell deficiency ZAKARIA N—Antwerp

Europa A Lunchtime CIS by THEA - Ocular inflammation and infection, what's new in 2008

13:05 – 14:05

CIS Bahram BODAGHI



13:05	4271	MIC and clinical efficacy. From systemic to ocular breakpoints PLEYER U—Berlin
13:15	4272	Efficacy and safety of a 3 day treatment using azithromycin 1.5% in purulent bacterial conjunctivitis COCHEREAU I—Paris
13:25	4273	Guidelines for managing post operative inflammation using topical steroids or NSAIDs HERBORT C—Lausanne
13:35	4274	Eye and virus. What's new ? BODAGHI B—Paris

Europa A *RV: Novelties in basic research in vitreoretinal surgery* 14:15 – 15:45
SIS Elisabeth VAN AKEN, Marc D DE SMET



- | | | |
|-------|------|---|
| 14:15 | 4311 | Pharmacological vitreous remodelling through non-enzymatic disruption of the protein matrix
VECKENEER M, DERYCKE L, CHARIF H, LUIDER T, CORNELISSEN R, VAN AKEN E—Rotterdam, Ghent |
| 14:37 | 4312 | Regulators of angiogenesis in the vitreous
BISHOP PN, LE GOFF MM, TAKANOSU M, HENRY SP, MAYNE R—Manchester, Birmingham, Houston |
| 14:59 | 4313 | Biochemical markers in the vitreous
VAN AKEN E—Ghent |
| 15:21 | 4314 | Enzymatic vitreolysis promises and potential pitfalls
DE SMET MD—Antwerp |
| 15:43 | 4315 | Micro Incisional Vitrectomy (MIVS): a new device for trocar insertion
RIZZO S, GENOVESI-EBERT F—Pisa |

Europa B *NSPH: Dr, the eyes won't keep still* 14:15 – 15:45
Workshop Graham HOLDER

- | | | |
|-------|------|---|
| 14:15 | 4321 | The ophthalmological approach
SPILEERS W—Leuven |
| 14:37 | 4322 | Genetic determinants of abnormal eye movements
LEROY BP—Ghent |
| 14:59 | 4323 | The neurological approach to ocular instability
MILEA D—Copenhagen |
| 15:21 | 4324 | The role of electrophysiology
HOLDER GE—London |

Emerald I *ACB: The lid margin - the ultimate border of the tear film* 14:15 – 15:45
SIS Erich KNOP, Nadja KNOP, Anthony J. BRON

- | | | |
|-------|------|---|
| 14:15 | 4331 | Zonal differentiation of the epithelium including the lid wiper at the human lid margin
KNOP E, KNOP N, ZHIVOV A, KRAAK R, KORB D, GREINER JV, GUTHOFF R—Berlin, Hannover, Rostock, Boston |
| 14:30 | 4332 | Structure of the lid margin in laboratory animals
KNOP N, KNOP E—Hannover, Berlin |
| 14:45 | 4333 | Compartmental factors influencing tear film osmolarity
BRON AJ, TIFFANY JM, GAFFNEY EA—Oxford |
| 15:00 | 4334 | Lid wiper epitheliopathy, ocular surface and tear film in symptomatic contact lens wearers
PULT H, PURSLOW C, MURPHY PJ, BERRY M—Cardiff, Bristol |
| 15:15 | 4335 | New surgical techniques for reconstruction of the lid margin
GICQUEL JJ—Poitiers |

EVER-ACTA
Lecture
16:00-16:40
Europa A

Unraveling the genetics of exfoliation glaucoma
Fridbert JONASSON, Reykjavik, Iceland
Introduction by Einar STEFANSSON

Acta Ophthalmologica



Emerald II **LC: Epidemiology of cataract** 14:15 – 15:45
 SIS Giovanni MARAINI, Per SÖDERBERG

- 14:15 4341 Genetic epidemiology in age-related cataract research
 GRAW J, KLOPP N, ILLIG T, WELZL G, HOLLE R, WICHMANN HE, MEISINGER C–Neuherberg
- 14:33 4342 Genetics in exfoliation syndrome and age-related cataract
 JONASSON F–Reykjavik
- 14:51 4343 Genetic epidemiology studies of cataract in a population-based biobank
 MCCARTY CA–Marshfield
- 15:09 4344 Risk factors for cataract in India: the INDEYE study
 CAMPARINI M, MARAINI G, MURTHY GVS, RAVINDRAN RD, CHAKRAVARTHY U, FLETCHER AE–Parma, New Delhi, Pondicherry, Belfast, London
- 15:27 4345 Multivitamin-mineral supplementation and age-related cataract. The Italian-American controlled clinical trial
 MARAINI G–Rockville, MD

Mediterranea I **G: Biomechanical aspects of intraocular pressure measurements** 14:15 – 15:45
 SIS Konstantin KOTLIAR

- 14:15 4351 Mathematical models of intraocular pressure measurements and ocular rigidity
 KOTLIAR K, KOSHITS IN, LANZL IM–Munich, St. Petersburg
- 14:30 4352 Ocular rigidity and hydrodynamics of the human eye
 PALLIKARIS IG, GINIS HS, DASTIRIDOU AI, DE BROUWERE D, KYMIONIS G, TSILIMBARIS MK–Heraklion
- 14:45 4353 Biomechanics of the eye tunic, especially the sclera and the cornea
 SPOERL E, TERAI N, BOEHM AG, RAISKUP-WOLF F, PILLUNAT LE–Dresden
- 15:00 4354 Assessment of ocular response analyzer advantages for IOP measurements in children with progressive myopia
 IOMDINA E, IVASHCHENKO ZH, TARUTTA E, EREMINA M–Moscow
- 15:15 4355 The estimation of intraocular pressure after refractive surgery. Statistical and simulation data
 BAUER SM, KACHANOV AB, SEMENOV BN–St. Petersburg
- 15:30 4356 The mechanical response of lamina cribrosa to the elevated intraocular pressure
 VORONKOVA E–St. Petersburg

Adria **CONCORDIA: European ophthalmology: myth or reality?** 14:15 – 15:45
 Workshop Bruce SPIVEY, Marie - José TASSIGNON

- 14:15 4361 The EBO heritage: past, present and ... Concordia
 KIVELÄ T–Helsinki
- 14:30 4362 The role of supranational societies in education
 SPIVEY B–San Francisco
- 14:45 4363 Future strategies of EBO
 HAWLINA M–Ljubljana
- 15:00 4364 New strategies of SOE uniting the european national societies
 SEREGARD S–Stockholm
- 15:15 4365 European network on education in ophthalmology
 TASSIGNON MJ–Antwerp
- 15:30 Discussion

Poster session 1
 16:45-17:40
 Europa C

Posters on pages 36-37

Anatomy/Cell Biology - Neuro-Ophthalmology/Strabismology/Paediatric Ophthalmology/History - Vision Sciences/Electrophysiology/Physiological Optics - Lens/Cataract - Molecular Biology/Genetics/Epidemiology

Luc MISSOTTEN, Erich KNOP, Gordon PLANT, Irene GOTTLÖB, Anthony ROBSON, John BARBUR, Jan-Olof KARLSSON, Alfred WEGENER, Amanda CHURCHILL, Marcela VOTRUBA

Europa A ***RV: Diabetic retinopathy - Growth factors*** 17:45 – 19:15
 FP Francesco BANDELLO, Jose CUNHA-VAZ

17:45	4411	Towards a blood test for diabetic retinopathy SHALCHI Z, BUTT A, SMITH S, POWRIE J, JANIKOUN S, SWAMINATHAN R—London
17:57	4412	Autofluorescence and microperimetry in clinically significant diabetic macular edema BOTTEGA E, VUJOSEVIC S, PILOTTO E, BENETTI E, CASCIANO M, MIDENA E—Padova, Rome
18:09	4413	Segmentation of spectral domain OCT volume scans of patients with no or minimal diabetic retinopathy VAN DIJK HW, VAN VELTHOVEN MEJ, GRAVIN-HAEKER M, KOK PHB, VERBRAAK FD, ABRAMOFF MD—Amsterdam, Iowa City
18:21	4414	Risk markers for progression of mild nonproliferative retinopathy to clinically significant macular edema in type 2 diabetic patients PEREIRA I, NUNES S, RIBEIRO ML, BERNARDES R, CUNHA-VAZ J—Coimbra
18:33	4415	Screening diabetic retinopathy using a wide field imaging system ARNDT C, NABHOLZ N, BOUSQUET E, NGUYEN F—Montpellier
18:45	4416	Is diabetic retinopathy an inflammatory, oxidative stress, genetic, mediated process ? DE SOUZA RAMALHO P, PEREIRA DA SILVA A, PEGO P, BICHO MP—Lisbon, Lisbon University
18:57	4417	Enhanced levels of VEGF and reduced levels of VEGFxxx in the vitreous of patients with retinal vein occlusion MICHELS D, RENNEL ES, FELTGEN N, MARTIN G, STAHL A, HANSEN LL, AGOSTINI HT—Freiburg, Bristol

Europa B ***NSPH: Neuro-ophthalmology*** 17:45 – 19:15
 FP Lene MARTIN, Aki KAWASAKI

17:45	4421	Driving performance in patients with homonymous visual field defects and healthy subjects in a standardized virtual reality environment PAPAGEORGIOU E, HARDIESS G, VONTHEIN R, SCHOENFISCH B, MALLOT H, SCHIEFER U—Tübingen
17:57	4422	Reading strategies in nystagmus THOMAS MG, PROUDLOCK FA, MCLEAN RJ, GOTTLÖB I—Leicester
18:09	4423	The extraocular muscles in Amyotrophic Lateral Sclerosis (ALS)? PEDROSA DOMELLOF F, BRÄNNSTRÖM T, ANDERSEN PM, LIU JX—Umea
18:21	4424	A comparison of clinical and eye movement characteristics between albinism and idiopathic infantile nystagmus with and without mutations in the FRMD7 gene KUMAR AS, GOTTLÖB I, PROUDLOCK FA, THOMAS S—Leicester
18:33	4425	Torsional optokinetic nystagmus in strabismus PROUDLOCK FA, FAROOQ SJ, MCLEAN RJ, GOTTLÖB I—Leicester
18:45	4426	Optical Coherence Tomography testing : possible biomarker value in multiple sclerosis? RADOVIC N, PAVLOVIC D—Belgrade
18:57	4427	The lot of shaken baby syndrome (SBS) cases: Follow-up of visual outcome and cognitive function <i>rf</i> PINELLO L, ROSA RIZZOTTO M, MAIMONE P, MAZZAROLLO M, MANEA S, FACCHIN P—Padua

Emerald I ***VEP: Vision sciences 1*** 17:45 – 19:15
 FP Graham HOLDER, Bart LEROY

17:45	4431	The role for stimulus timing in local retinal responses: global propagation of retinal inhibition, in space and time CASTELO-BRANCO M, MAIA-LOPES S, REIS AA, MATEUS C, SEBASTIAO AR, STASCHE M, FINGER J, NUNES S—Coimbra, Wiesbaden
17:57	4432	Electrophysiological measurement of macular pigment distribution using annular stimuli: implications for colour vision testing ROBSON AG, PARRY NRA—London, Manchester
18:09	4433	What limits chromatic sensitivity in normal and colour deficient observers? BARBUR JL, RODRIGUEZ-CARMONA M, HARLOW JA—London
18:21	4434	Acquired colour vision deficiency in subjects with ARMD and Diabetes O'NEILL-BIBA M, RODRIGUEZ-CARMONA M, RAUSCHER FG, WOLF JE, BARBUR JL—London
18:33	4435	Chromatic VEP in colour deficient children TEKAVCIC POMPE M, STIRN KRANJC B, BRECELJ J—Ljubljana
18:45	4436	New approach to establish safe colour vision limits for occupational environments RODRIGUEZ-CARMONA M, O'NEILL-BIBA M, BARBUR JL—London

Emerald II **LC: Straylight as quality measure for ophthalmic procedures** 17:45 – 19:15
 SIS Ralph MICHAEL, Tom VAN DEN BERG

17:45	4441	Introduction to straylight as quality measure for ophthalmic procedures VAN DEN BERG TJTP–Amsterdam
18:00	4442	Scattered light and visual acuity after Descemet-stripping with endothelial keratoplasty MCLAREN JW, BOURNE WM, PATEL SV–Rochester, MN
18:15	4443	In-vitro characterisation of corneal scatter in rabbit corneas following PRK GINIS H, DE BROUWERE D, PENTARI I, PALLIKARIS I–Heraklion
18:30	4444	Glare test as indicator for cataract surgery TASSIGNON MJ, ROZEMA JJ–Antwerp
18:45	4445	Pseudophakic dysphotopsia - Counting the stars ASLAM T, ASPINALL P–London, Edinburgh
19:00	4446	Reliability results of straylight measurements using the C-Quant CERVINO A, MONTES-MICO R, FERRER-BLASCO T–Valencia

Mediterranea I **G: Glaucoma diagnosis** 17:45 – 19:15
 FP Selim ORGUL, Thierry ZEYEN

17:45	4451	Effects of repetitive IOP measurements JOHANNESSEN G, LINDEN C, BEHNDIG A, EKLUND A, HALLBERG P–Umea University, University Hospital of Umea
17:57	4452	Risk factors for progression in glaucoma. The Groningen Longitudinal Glaucoma Study JANSONIUS NM, WESSELINK C, HEEG GP–Groningen
18:09	4453	HLA class I haplotypes and progression of primary open angle glaucoma VERONESE RODRIGUES ML, ZENHA F, CASTALDELLI RMOB, DEGHAIDE NHS, DONADI EA–Ribeirão Preto
18:21	4454	Lamina cribrosa and peripapillary scleral histomorphometry in myopic and non myopic glaucomatous chinese eyes JONAS JB, REN R, WANG N, LI B, LI L, GAO F, XU X–Beijing
18:33	4455	Interactions between trabecular meshwork cells and lens epithelial cells – a possible mechanism in infantile aphakic glaucoma INBAL M, SHMOISH M, WALTON DS, LEVENBERG S–Haifa, Boston
18:45	4456	Circulating ether-lipids as an early marker of POAG ACAR N, BERDEAUX O, JUANEDA P, GREGOIRE S, BIDOT S, CREUZOT CP, BRETILLON L, BRON AM–Dijon
18:57	4457	Correlation of optic disc morphology and ocular perfusion parameters in patients with primary open angle glaucoma <i>rf</i> SCHMIDL D, RESCH H, RENSCH F, HOMMER A, VASS C, LUKSCH A, GARHOFER G, JONAS JB, SCHMETTERER L–Vienna, Mannheim

Adria **PO: Pathology / Oncology 1** 17:45 – 19:15
 FP Laurence DESJARDINS, Edoardo MIDENA

17:45	4461	Frequency of melanocytic conjunctival lesions in an ocular oncology unit SANCHEZ-MANNARELLI F, PORTERO-BENITO A, CARRENO-SALAS E, MUNOZ MF, SAORNIL MA–Valladolid
17:57	4462	Results of treatment of conjunctival melanoma in 61 consecutive patients POGRZEBIELSKI A, BOGDALI A, NAPORA-KRAWIEC A, ROMANOWSKA-DIXON B–Krakow
18:09	4463	Collective of patients with conjunctival melanoma treated at the Jules Gonin Eye Hospital (Lausanne) SCHALENBOURG A, CHAMOT L, UFFER S, ZOGRAFOS L–Lausanne
18:21	4464	Genetic predisposition to uveal melanoma DESJARDINS L, LUMBROSO LEROUIC L, LEVY C, STOPPA LYONNET DUE, PLANCHER C, ASSELAIN B, BUECHER B–Paris
18:33	4465	Surgical treatment of severe choroidal detachment after brachytherapy for choroidal melanoma ANGI M, DAMATO BE–Liverpool
18:45	4466	A clinical pathway for episcleral brachytherapy DE FRUTOS-BARAJA JM, DE LUIS-PEREZ FJ, SAORNIL-ALVAREZ MA, LOPEZ-LARA-MARTIN F, GIRALDO-ARGÜELLO A, ESTEBAN-CASADO R, CEBALLOS-GARCIA MA, GARCIA-ALVAREZ C, ANDRES-RODRIGUEZ C–Valladolid

- 401 Philatelic aspects on WHO Year Glaucoma 2008
SVEDBERGH BOC–Uppsala

ANATOMY / CELL BIOLOGY

Moderators: Luc MISSOTTEN, Erich KNOP

- 402 Ghrelin's mRNA levels in the developing rat's eye
ROCHA DE SOUSA A, RAMOS-TAVARES M, TELES A, LEITE-MOREIRA AF–Porto
- 403 Form-deprivation myopia in the guinea pig: scleral myofibroblasts and biomechanics
PHILLIPS JR, BACKHOUSE S–Auckland
- 404 Contribution of Müller cells to blue light injury
WIEDEMANN P, BRINGMANN A–Leipzig
- 405 Quantification of the photoreceptors of healthy retinas in rat by flow cytometry
 TSOKA PA, PAPADAKI EA, TSILIMBARIS MK–Heraklion, Crete
- 406 Localization of cathepsin x in the mouse retina
BERGER ST, STAHL A, GROSS NJ, SEVENICH L, MARTIN G, REINHECKEL T, AGOSTINI HT–Freiburg
- 407 Cx43 internalization is mediated by the ubiquitin-binding adaptor protein Eps15 in retinal endothelial cells
GIRAO H, CATARINO S, LOPES C, PEREIRA P–Coimbra
- 408 Spinule number per cone pedicle is a biomarker of predatory behavior in teleosts
DE JUAN HERRERO J, MARTINEZ-RUIZ N, ROMERO RAMETA A, INIGUEZ LOBETO CM–Alicante
- 409 Receptor retinoid-binding protein (IRBP) binds cone outer segments differentially in light and dark
GONZALEZ-FERNANDEZ F, GARLIPP MA, KEATING AM–Buffalo
- 410 Selective estrogen receptor modulators regulate IL-6 inflammatory response in ARPE-19 cells
PAIMELA T, RYHÄNEN T, VIIRI J, HYTTINEN J, UNKILA M, UUSITALO HMT, SALMINEN A, KAARNIRANTA K–Kuopio, Turku, Tampere
- 411 Activation of autophagy induced by 7-Ketocholesterol and dysfunction of RPE in AMD
OLIVEIRA FERREIRA J, GIRAO H, PEREIRA P–Coimbra
- 412 The role of FGF2 in the in vitro proliferation and angiogenesis of human choroidal endothelial cells
STEWART EA, AMOAKU WMK–Nottingham
- 413 Development of immunostaining of cell cycle related proteins in flat mounted corneal endothelium
HE Z, THURET G, PIPPARELLI A, PISELLI S, DUMOLLARD JM, PEOC'H M, GAIN P–Saint-Etienne
- 414 Cell cycle genes expression in human corneal endothelium: study by microarray and qRT-PCR
PIPPARELLI A, THURET G, PISELLI S, PEOC'H M, ACQUART S, GARRAUD O, GAIN P–Saint-Etienne
- 415 A novel cytocompatible thermoresponsive co-polymer for corneal tissue engineering
HOPKINSON A, VARGHESE VM, KUMARY TV, DUA HS–Nottingham, Trivandrum
- 416 Myofibroblast and smooth muscle actin in scarred corneal stroma
AKHTAR S, ALMUBRAD TM, OGBUEHI KC, BRON AJ–Riyadh, Oxford
- 417 Geometric characterization of anterior segment in the hen's eye
ALIO SANZ JL, PINERO LLORENS DP, SIREROL B, BATAILLE L–Alicante
- 418 Two distinct populations of corneal epithelial cells with limbal stem cell characteristics in the mouse
HOLAN V, KRULOVA M, POKORNA K, LENCOVA A, ZAJICOVA A, FILIPEC M–Prague
- 419 Depth profile study of molecular collagen structure in normal human cornea
KAMMA-LORGER CS, BOOTE C, YOUNG RD, HAYES S, QUANTOCK AJ, MEEK KM–Cardiff

NEURO-OPHTHALMOLOGY / STRABISMOLOGY / PAEDIATRIC / HISTORY

Moderators: Gordon PLANT, Irene GOTTLÖB

- 420 Leber's stellate neuroretinitis. A case report
IDOIPE CORTA M, GIL ARRIBAS L, GARCIA-MARTIN E, FERRER NOVELLA E–Zaragoza

- 421 Evaluation of the retinal nerve fiber layer in patients with multiple sclerosis
GARCIA MARTIN E, PUEYO V, FERNANDEZ TIRADO J, MARTIN J, ARA JR, HONRUBIA FM, PINILLA LOZANO I–Zaragoza
- 422 Unilateral optic neuritis as presenting feature of acute hemorrhagic leukoencephalitis
SKET KONTESTABILE A, SEGA S, SVIGELJ V, HAWLINA M–Ljubljana
- 423 Effect of different antioxidants in experimental alcoholic optic neuropathy
MENEZO ROZALEN JL, AVINO-MARTINEZ JA, PERIS-MARTINEZ C, ESPANA-GREGORI E, ROMERO FJ–Valencia
- 424 Bilateral internuclear ophthalmoplegia in a patient with Devic's neuromyelitis optica
GIL ARRIBAS L, PUEYO V, GARCIA-MARTIN E, IDOPE CORTA M, PINILLA I–Zaragoza
- 425 Binocular vision disturbances and eye movement restrictions in patients with thyroid associated ophthalmopathy(TAO)
rf KLYSIK AB, KOMOROWSKI J, GOS R–Lodz
- 426 Bilateral visual loss and paraplegia in a patient with metastatic carcinoma of stomach
PAJTLER A, SEGA S, ZGONC V, ROS-OPASKAR T, HAWLINA M–Ljubljana
- 427 Clinical variability in a three-generation family with Duane's syndrome
THOMAS S, ROBERTS E, AWAN M, GOTTLÖB I–Leicester
- 428 Strabismus, epilepsy vs. motor & neurological disorders in quadriplegia
TIGANITA S, KOZEIS N, GOGAKI H, STOJANOVIC N, MOUTLIAS A, DIMOPOULOS A–Thessaloniki
- 429 Treatment of acquired periodic alternating nystagmus with memantine
MCLEAN RJ, THOMAS S, FAROOQ SJ, PROUDLOCK FA, GOTTLÖB I–Leicester
- 430 Third nerve palsies without pupil involvement can still be surgical
SKINNER KC, MERRICK CD, HOXHA A, RIZAL E–Hastings
- 431 f-Visual evoked potentials (fVEPs), nystagmus vs. motor & neurological disorders in quadriplegia
TIGANITA S, KOZEIS N, TYRADELIS E, GATZIOUFAS Z, ZAFEIRIOU D–Thessaloniki
- 432 Pupil light reflexes mediated by outer retinal versus inner retinal photoreceptors in normal subjects and patients with neuroretinal visual loss
KAWASAKI A, ANDERSON SC, KARDON RH–Lausanne, Iowa City
- 433 The lot of shaken baby syndrome (SBS) cases: Follow-up of visual outcome and cognitive function
rf PINELLO L, ROSA RIZZOTTO M, MAIMONE P, MAZZAROLLO M, MANEA S, FACCHIN P–Padua

VISION SCIENCES / ELECTROPHYSIOL. / PHYSIOLOGICAL OPTICS

Moderators: Anthony ROBSON, John BARBUR

- 434 Morphofunctional correlates in rhegmatogenous detachment of the retina
ZUEVA MV, NEROEV VV, GRINCHENKO MI, TSAPENKO IV, SARYGINA OI, RYABINA MV, TOLSTIK SI–Moscow
- 435 Microperimetry, PERG and mfERG in patients with Stargardt dystrophy
JARC-VIDMAR M, POPOVIC P, LENASSI E, BRECELJ J, HAWLINA M–Ljubljana
- 436 Cone electroretinograms to blue flashes on various backgrounds
SUSTAR M, BRECELJ J–Ljubljana
- 437 Multifocal ERG and OCT in unexplained visual loss
BASTOS A, NOGUEIRA V, FERREIRA A, CRAVO I, NOVAIS M, CAMPOS F, PINTO F, CASTANHEIRA-DINIS A, MONTEIRO-GRILLO M–Lisboa
- 438 Objective assessment of chromatic and achromatic pattern adaptation reveals the temporal response properties of different visual pathways
ROBSON AG, KULIKOWSKI JJ–London, Manchester
- 439 Pupil reactions in children with strabismic amblyopia in dependence of deviation value
BOYCHUK IM, BUSHUEVA NN, ROMANENKO DV, SLOBODYANIK SB–Odessa
- 440 Visual development in premature infants without serious events in their pre- and perinatal period.
AGGELIDOY E, KOZEIS N, FELEKIDIS A, KAPSOS A, PAPPAS K, HRISOGLIOU M–Thessaloniki
- 441 Accommodation insufficiency in children: are exercises better than reading glasses?
WAHLBERG M, CARLSSON R–Stockholm
- 442 Ametropia in children with regressed retinopathy of prematurity
BHATT UK, ANWAR S–Leicester

- 443 Straylight and the two domains of visual optics; small angle (0-1 degree) and large angle (1-90 degree) — VAN DEN BERG TJTP—Amsterdam
- 444 Variability of pupil behaviour due to different retinal's illumination levels SANCHEZ RAMOS C, DIAZ SERRANO Y, VINAS PENA M, RODRIGO E, BONNIN C, SILLERO QUINTANA M—Madrid
- 445 A screening test for visual disorders based on Rarebit perimetry MARTIN LM, WANGER P—Stockholm
- 446 Quantification of spherocylindrical defocus using refractive data TOUZEAU O, GAUJOUX T, KOPILO R, COSTANTINI E, BORDERIE VM, LAROCHE L—Paris
- 447 Wavefront aberration measurements in dog and cat eyes using an aberrometer designed for human eyes — ROSOLEN SG, LAMORY B, CHATEAU N, PICAUD S, SAHEL JA, LE GARGASSON JF—Paris, Orsay
- 448 Higher-order wavefront aberrations and accommodative response variations with phenylephrine 5% GICQUEL JJ, NGUYEN-KHOA JL, HARMS F, LOPEZ GIL N, LEGRAS R, DIGHIERO PL, LEBUISSON DA, LE GARGASSON JF—Poitiers, Suresne, Orsay, Murcia, Paris
- 449 First results in repeated functional testing in low vision patients with retinitis pigmentosa GEORGI T, IVASTINOVIC D, HORNIG R, KOCH M, VELIKAY-PAREL M—Graz, Bonn
- 450 Accommodative function in school-age children with poor reading skills PALOMO-ALVAREZ C, PUELL MC—Madrid
- 451 Objective measurement of near and distance visions by optokinetic response determination — HAN ER, YEO WE, LEE JH—Seoul
- 452 Effect of the interposition of optical filters with different visible light transmittances in mesopic and scotopic condition pupil size SANCHEZ RAMOS C, VINAS PENA M, DIAZ SERRANO Y, TORETS C—Madrid
- 453 A comparison of intermediate and near visual outcomes and reading ability in patients bilaterally implanted with bifocal ZM900, ReSTOR IOLs and with multifocal ReZoom IOLs — FANNI D, DI LAURO MT, RAVALICO G—Trieste
- 454 Electrogenesis of the retina in proceeding glaucomatous optical neuropathy VAZHENKOV SN, SHAMSHINOVA AM—Moscow
- 455 Effect of litter size and birth weight on naturally occurring myopia in the Labrador retriever PHILLIPS JR, BLACK J, BROWNING SR, COLLINS AV—Auckland
- 456 10 years followup in children affected by various eye diseases: sensibility and specificity of VA, fundus and 30 Hz and mixed response electroretinogram done during anaesthesia as predictors of visual outcome ANGELI R, PEZZOTTA S, BARILLA D, BERTONE C, ANTONINI M, FAZZI E, GUAGLIANO R, BIANCHI PE, TINELLI C, RUBERTO G—Pavia
- 457 Retinal thickness vs. retinal sensitivity at the central human macula BERNARDES R, CUNHA-VAZ J—Coimbra

LENS and CATARACT

Moderators: Jan-Olof KARLSSON, Alfred WEGENER

- 458 Lens cellular culture models obtained after cataract surgery: interest in cytogenetics analysis MILLAZO S, COPIN H, JANY B, BREMOND-GIGNAC D—Amiens
- 459 Application of agar sandwich technique for morphologic studies of anterior lens capsule STUNF S, HVALA A, GLOBOCNIK PETROVIC M, HAWLINA M—Ljubljana
- 460 The acutely isolated human anterior lens capsule as a tool to study the physiology of human lens epithelial cells ANDJELIC S, ROBIC T, PEROVSEK D, ZUPANCIC G, HAWLINA M—Ljubljana
- 461 New non-contact biometer ROHRER K, FRUEH B, CLEMETSON I, WAEELT R, GOLDBLUM D—Bern, Basel
- 462 Anterior chamber morphometric estimation in patients they who underwent CTR implantation using Anterior Segment OCT and ultrasound biomicroscopy MILKA M, WYLEGALA E, JANISZEWSKA D, NOWINSKA A, MANKOWSKI W—Katowice
- 463 Glucose-6-phosphate dehydrogenase (G6PD) deficiency and senile cataract in a sardinian population, Italy PES A, SOLINAS G, PINNA A—Sassari
- 464 Protein quality control and ubiquitin proteasome system: implications on cataract — MARQUES C, SHANG F, PEREIRA P—Coimbra, Boston
- 465 Spontaneous cataract formation in DBA/2J mice OLESZCZUK AK, REJDAK R, RUMMELT C, KICZYNSKA M, ZARNOWSKI T, SCHUETTAUF F, THALER S, ZRENNER E, KRUSE F, JUNEMANN A—Lublin, Erlangen, Tubingen

- 466 Effect of glutathione with sea tangle extract on prevention of selenite-induced cataract formation in rat eyes — KIM K, OH JH—Incheon
- 467 Modifications in conjunctival and limbar epithelium after micro-incision cataract surgery (MICS). Impression cytology study ALIO SANZ JL, RODRIGUEZ AE, WALEWSKA A, FERRER C, RODRIGUEZ-PRATS JL, BATAILLE L—Alicante
- 468 Ophthalmologic surgeries in the one-day surgery unit. A descriptive study evaluating 13 years of activity PEREZ GARCIA D, IBANEZ ALPERTE J, JIMENEZ A, VALYI S, MATEO OROBIA AJ, PEIRO C, ROJO M, CRISTOBAL JA—Zaragoza
- 469 The incidence of endophthalmitis after cataract surgery—a retrospective study: evaluation of risk factors and impact of the introduction of intracameral cefuroxime — IBANEZ J, PEREZ D, MATEO OROBIA AJ, PEIRO C, VALYI S, ROJO M, MINGUEZ E, CRISTOBAL JA—Zaragoza
- 470 In vivo thermographic analysis of clear corneal incision during phacoemulsification: comparison for coaxial, microcoaxial and bimanual techniques DUPONT-MONOD S, LABBE A, CHASSIGNOLA A, GRISE A, BAUDOUIN C—Paris

MOLECULAR BIOLOGY / GENETICS / EPIDEMIOLOGY

Moderators: Amanda CHURCHILL, Marcela VOTRUBA

- 471 Morphologic changes in haptoglobin knockout mice, typical for anterior segment dysgenesis, may be linked to diminished expression of C-Maf VAN GINDERDEUREN R, GALCIAS-ROSAS G, CEUPPENS J, STALMANS I—Leuven
- 472 Single nucleotide polymorphisms of the tenomodulin gene (TNMD) in age-related macular degeneration NEVALAINEN T, TOLPPANEN AM, KOLEHMAINEN M, PULKKINEN L, UUSITUPA M, KAARNIRANTA K—Kuopio
- 473 A novel OPA1 mutation in a patient with severe, acute and late-onset Autosomal Dominant Optic Atrophy NOCHEZ Y, ARSENE S, LE LEZ ML, AMATI-BONNEAU P, REYNIER P, CARDON A, PISELLA PJ—Tours, Angers
- 474 Ophthalmological findings in childhood onset myotonic dystrophy type 1 ARING E, EKSTRÖM AB, TULINIUS MAR, SJÖSTRÖM A—Gothenburg
- 475 Genetic analysis of families with autosomal recessive retinal dystrophies KANNABIRAN C, SINGH H, JALALI S—Hyderabad
- 476 Three Families with Best's Disease and Normal Electro-oculogram Recordings ARNDT C, MEUNIER IA, BEN SALAH S, BAZALGETTE C, VALETTE L, MAZOIR E, SENECHALA, HAMEL C—Montpellier
- 477 Ocular phenotype of CORD5, an autosomal dominant cone-rod dystrophy associated with a Q626H mutation in the PITPNM3 REINIS A, GOLOVLEVA I, KÖHN L, SANDGREN O—Umea
- 478 Cone dystrophy with supernormal rod response – case report VARSANYI B—Budapest
- 479 X-linked retinoschisis GIL ARRIBAS L, PINILLA I, GARCIA MARTIN E, IDOPE CORTA M—Zaragoza
- 480 Spectrum of TGFBI gene mutations among Polish patients with corneal dystrophies — OLDAK M, SZAFLIK JP, MAKSYM RB, KOIODZIEJSKA U, POLLAK A, PIOSKI R, SZAFLIK JP—Warsaw
- 481 Ophthalmic skills – Confidence and knowledge of recently graduated doctors YEUNG AM, YEUNG JM, ASHRAF N, YEUNG TM—Nottingham, Oxford
- 482 Use of mobile-learning amongst ophthalmic tutors and medical students SULEMAN H, MATHEW N, DUA HS, DENNICK R, MATHEW M—Nottingham
- 483 EyeDiagnostics – a collaboration tool in eye care MARTIN LM, DOCKMO Y, SONNSJÖ B, GLÜCKMAN T, WANGER P—Stockholm, Sunne
- 484 Ophthabase: a generic extensible patient registry system TRÖGER E, WILKE R, PROKOFYEVA E, ZRENNER E—Tuebingen
- 485 Prevalence of age-related macular degeneration in the AGES - Reykjavik Study ARNARSSON A, JONASSON F, EIRIKSDOTTIR G, HARRIS T, LAUNER L, KLEIN BEK, KLEIN R, COTCH MF, GUDNASON V—Reykjavik, Kopavogur, Bethesda, MD, Madison WI
- 486 Anthropomorphic measurements and general and ocular parameters in adult Chinese. The Beijing eye study JONAS JB, XU L, WANG Y, ZHANG H—Beijing
- 487 The ocular findings among young males: a 12-year prevalence study of the military service in Poland — NOWAK MS, JUROWSKI P, GOS R, SMIGIELSKI J—Lodz

SOE 2009

www.soe2009.org



THE 17TH CONGRESS OF
THE EUROPEAN SOCIETY
OF OPHTHALMOLOGY

Amsterdam
The Netherlands

13–16 June 2009

NOG NEDERLANDS OOGHEELKUNDIG GEZELSCHAP



European University Professors of Ophthalmology

EUPO2009

**CORNEA, CONJUNCTIVA
AND REFRACTIVE SURGERY**

.....
June 12-13, 2009 RAI Amsterdam, The Netherlands

The EUPO Course 2009 on Cornea, conjunctiva and refractive surgery will take place on Friday 12 and Saturday 13 June 2009 in the RAI in Amsterdam, The Netherlands. This is prior and during the first part of the 17th Congress of the European Society of Ophthalmology.

The course gives an overview and update on recent advances in the above topics.

Programme Directors:

Prof. Dr T. Hoang-Xuan - hoangxuant@aol.com

Prof. Dr F.E. Kruse - friedrich.kruse@augen.imed.uni-erlangen.de

Prof. Dr G. van Rij - g.vanrij@erasmusmc.nl

Prof. Dr B. Seitz - berthold.seitz@uniklinikum-saarland.de

info
www.eupo.eu

registration
www.soe2009.org



excellence in education.



EBO Accredited Courses / EBO 2009 Examination

NEW INITIATIVE:
EBO Accredited Courses

October 1, 2008
12:00 pm - 2:30 pm
"Neuro-ophthalmology"
Course Director: A. Kawasaki
Location: EVER meeting

October 1, 2008
2:45 pm - 4:45 pm
"Ophthalmic Oncology"
Course Director: L. Desjardins
Location: EVER meeting

Interested to organise an EBO Accredited Course?
Please look at our website (www.ebo-online.org) to find the application form and detailed guidelines

When?
May 8-9, 2009

Where?
Paris, Palais des Congrès (Porte Maillot)



Call for Application
From October 1, 2008 till January 31st 2009
Electronic application form (website)

More information...
<http://www.ebo-online.org>



European Association for Vision and Eye Research




EVER 2009

September 30-October 3, 2009 • Portoroz Slovenia



Become member and joint us at the 2009 EVER congress

www.ever.be





EVER

Friday
3 October

08

Europa A **VEP: Mechanisms of the onset, progression and prevention of myopia** 08:15 – 09:45
SIS Elena N IOMDINA, Elena TARUTTA

supported by 

08:15	5111	Impact of continuous myopic defocus on the refractogenesis and myopia progression TARUTTA E–Moscow
08:27	5112	Myopic macular degeneration: classification and treatment WARD B–Campbell
08:39	5113	Pharmacological control of myopia - current options and future possibilities WILDSOET C–United States
08:51	5114	Derangement of pigment epithelium derived factor (PEDF) activity in progressive myopia IOMDINA E, KOSTANYAN I, RADCHENKO V, KAKUEV D, MINKEVICH N, SHEKHTER A, TARUTTA E, KVARATSKHELIJA N–Moscow
09:03	5115	Use of imposed myopic defocus to control the progression of myopia MORGAN IG–Canberra
09:15	5116	Time spent outdoors can prevent the development of myopia ROSE KA–Sydney
09:27	5117	Atropine and plus lenses in the control of myopia - results from clinical trials CHUA WH–Singapore

Europa B **ACB / MBGE / NSPH: Joint free paper session** 08:15 – 09:45
FP Pinar AYDIN, Richard BRUENECH

08:15	5121	Pseudoexfoliation in the Reykjavik Eye Study: 5-year incidence and changes in related ophthalmological variables ARNARSSON A, DAMJI K, JONASSON F–Reykjavik, Ottawa
08:27	5122	Histological analysis of sensory receptors in human extraocular muscles BRUENECH JR, KJELLEVOLD HAUGEN IB–Kongsberg
08:39	5123	Crosstalk between Hsp70 molecular chaperone, lysosomes and proteasomes in autophagy-mediated proteolysis in human retinal pigment epithelial cells KAARNIRANTA K–Kuopio
08:51	5124	A 3 year retrospective case series of temporal arteritis in Portsmouth, United Kingdom TRIKHA S, LOCKWOOD A, BUCHANAN E, KIRWAN JF–Portsmouth
09:03	5125	Clinical Assessment of Disc at Risk LATIES AM, JONAS JB–Philadelphia, Mannheim
09:15	5126	Douglas Argyll Robertson (1837-1909) – what did he do other than describe the Argyll Robertson Pupil? GRZYBOWSKI A, PLANT G–Poznan, London
09:27	5127 <i>rf</i>	Binocular vision disturbances and eye movement restrictions in patients with thyroid associated ophthalmopathy(TAO) KLYSIK AB, KOMOROWSKI J, GOS R–Lodz

Emerald I **COS: New techniques in corneal surgery** 08:15 – 09:45
SIS Leonardo MASTROPASQUA, Jean-Jacques GICQUEL

08:15	5131	Corneal cross-linking for keratoconus MENCUCCI R, PALADINI I–Florence
08:33	5132	New insights in amniotic membrane transplantation GICQUEL JJ–Poitiers
08:51	5133	The use of femtosecond laser in corneal transplantation NUBILE M–Chieti
09:09	5134	Deep anterior lamellar keratoplasty FONTANA L–Bologna
09:27	5135	Options in endothelial transplantation POCOBELLI A, AMATO D, DONATI R, AMICI C, COLABELLI GISOLDI RAM–Rome

Emerald II **LC: Ultraviolet radiation cataract** 08:15 – 09:45
 SIS Per SÖDERBERG, Alfred WEGENER

08:15	5141	UVR-effects in human versus animal eyes: more contradictions or more similarities? WEGENER A–Bonn
08:30	5142	UVR exposure of the lens in the mammalian eye, species difference DILLON J, MERRIAM J, GAILLARD ER–New York, NY, De Kalb, IL
08:45	5143	Oxidative stress in lens epithelial cells after UVR exposure LÖFGREN S, GALICHANIN K, LOU MF, SÖDERBERG PG–Stockholm, Uppsala, Lincoln, NE
09:00	5144	The lens response to daily in vivo exposures to UVR GALICHANIN K, LI Y, MEYER L, LÖFGREN S, SÖDERBERG PG–Stockholm, Uppsala
09:15	5145	Systemic inflammatory response after ocular in vivo UVR-300 nm exposure MEYER L, WEGENER A, LÖFGREN S, GALICHANIN K, HOLZ FG, SÖDERBERG PG–Bonn, Stockholm, Uppsala
09:30	5146	Prevention of UVR cataract with Vitamin-E SÖDERBERG PG, XIAO Y, WANG J, MEYER L, GALICHANIN KONSTANTIN, AL-SAQRY R, DONG X, MODY V, LÖFGREN S–Uppsala, Stockholm

Mediterranea I **G: Blood flow: a practical approach in glaucoma** 08:15 – 09:45
 SIS Ingeborg STALMANS, Leopold SCHMETTERER



08:15	5151	Perfusion pressure and blood flow: difference and relevance ORGUL S–Basel
08:35	5152	Impact of glaucoma medications on IOP, blood pressure and perfusion pressure: relevance for the daily practice QUARANTA L, PIZZOLANTE T–Brescia
08:55	5153	Blood flow and metabolism measurements: are they ready for the clinic? HARRIS A–Indianapolis, IN
09:10	5154	Available educational material from the European Glaucoma Society on ocular blood flow techniques STALMANS I, ORGUL S, SCHMETTERER L, HARRIS A, TRAVERSO C–Basel, Vienna, Indianapolis, Genova

Adria **PO: Conjunctival melanocytic neoplasms** 08:15 – 09:45
 SIS Sarah COUPLAND, Bertil DAMATO

08:15	5161	Epidemiology of conjunctival melanocytic neoplasms KIVELÄ T, TUOMAALA S–Helsinki
08:30	5162	Pathology of conjunctival melanocytic neoplasms COUPLAND SE, DAMATO B–Liverpool
08:45	5163	Treatment of conjunctival melanocytic neoplasms: the Paris experience DESJARDINS L–Paris
09:00	5164	Treatment of conjunctival melanocytic neoplasms: the Liverpool experience DAMATO B, COUPLAND SE–Liverpool
09:15	5165	Combined treatment of conjunctival melanomas. The experience of the Jules-Gonin Eye Hospital of Lausanne ZOGRAFOS L–Lausanne
09:30	5166	Conjunctival melanoma : the Curie experience LEVY-GABRIEL C, DENDALE R, SASTRE X, PLANCHER C, LUMBROSO-LE ROUIC L, ASSELAIN B, DESJARDINS L–Paris

Plenary session **Address from the EU Commissioner of Research**
 10:00 – 10:20
Europa A Dr. Janez POTOČNIK
 Introduction by Marko HAWLINA



Keynote Lecture **Regional Immunity of the Eye: T lymphocytes and ocular pigment epithelial cells**
 10:30 – 11:10
Europa A Prof. Manabu MOCHIZUKI - Tokyo, Japan
 Introduction by Carl HERBORT



Europa A ***RV: Progress in vitreo-retinal surgery : from animals to humans*** 11:30 – 13:00
 SIS Christophe CHIQUET, Catherine CREUZOT



11:30	5211	Experimental principles and indications of internal limiting membrane peeling CREUZOT CP–Dijon
11:48	5212	Visualization drugs for vitreoretinal surgery TADAYONI R–Paris
12:06	5213	Experimental and clinical studies of transconjunctival vitrectomy 20G, 23G and 25G CHIQUET C–GRENOBLE
12:24	5214	Vitrectomy cryo gas for the treatment of pseudophakic retinal detachment POURNARAS CJ, MENDRINOS E–Geneva
12:42	5215	Combined surgery (phacovitrectomy) BERROD JP, HUBERT I–Nancy

Europa B ***VEP: Vision sciences 2*** 11:30 – 13:00
 FP Werner SPILEERS, Marko HAWLINA

11:30	5221	Critical flicker fusion frequency in age-related macular degeneration MAIER MM, GRONEBERG T, SPECHT H, LOHMANN CP–Munich
11:42	5222	The spatial and neural deficit of human amblyopia STEWART CE, MOSELEY MJ, FIELDER AR, MORLAND AB, MACRAE KL–London, York, Egham
11:54	5223	Contact lens wear in strabismic and non-strabismic young patients: sensorial and oculomotor study and quality of life outcome CARDON A, SULTANIM A, ARSENE S, GEORGET M, SANTALLIER M, NOCHEZ Y, PISELLA PJ–Tours
12:06	5224	Can amblyopia treatment be optimised? PRADEEP A, AWAN M, GOTTLÖB I–Leicester, leicester
12:18	5225	Evaluation of contrast sensitivity on monocularly - deprived subjects GIANNAKOPOULOU T, PLAINIS S, PALLIKARIS IG, TSILIMBARIS MK–Heraklion

Emerald I ***COS: Wavefront aberrometry and adaptive optics*** 11:30 – 13:00
 SIS Jean-Jacques GICQUEL, Nicolas CHATEAU

11:30	5231	The basics of wavefront aberrometry LANGMAN ME, GICQUEL JJ–Poitiers
11:45	5232	Custom wavefront optimization of intraocular lens asphericity GICQUEL JJ, COHEN G, CHATEAU N, LEYNAUD P, DONATE D–Poitiers
12:00	5233	Retinal images using adaptive optics LE GARGASSON JF, GLANC M, ROUSSET G, PAQUES M, SAHEL JA–Paris
12:15	5234	Cone mosaic imaging using an adaptive optics flood illumination camera system GOCHO - NAKASHIMA K, MASSAMBA N, ROCHE O, PARIER V, LE GARGASSON JF, LAMORY B, CHATEAU N, SOUBRANE G, DUFIER JL–Paris, Créteil, Orsay
12:30	5235	Optical aberration measurements in dog and cat eyes: interest & limit ROSOLEN SG–Paris
12:45	5236	Effects of higher-order wavefront aberrations on the eye's depth of focus CHATEAU N, MAIA ROCHA K, VABRE L, RAMOS ESTEBAN J, KRUEGER RR–Orsay, Sao Paulo, Cleveland, OH

13:05 – 14:05 **Business Meetings of the scientific sections:**

Sandwiches and refreshments

AGENDA

1. Report of the scientific officer
2. Report of the programme secretary
3. Next year's meeting:
 - nomination of a section programme secretary
 - proposals of Special Interest Symposia (SIS)
4. Comment on the EVER activities
5. Contact with Eastern Europe including Russia
6. Other business

- Anatomy / Cell Biology *Hall Emerald I*
- Cornea / Ocular Surface *Hall Emerald I*
- Glaucoma *Hall Mediteranea I*
- Immunology / Microbiology *Hall Europa B*
- Lens and Cataract *Hall Emerald II*
- Molecular Biology / Genetics / Epidemiology *Hall Emerald II*
- Neuro-ophthalmology / Strabismology / Paediatric ophthalmology / History *Hall Europa B*
- Pathology / Oncology *Hall Adria*
- Physiology / Biochemistry / Pharmacology *Hall Europa A*
- Retina / Vitreous *Hall Europa A*
- Vision Sciences/Electrophysiol./Physiological Optics *Hall Mediteranea I*

In addition to the agenda, the sections **Anatomy / Cell Biology** — **Molecular Biology / Genetics / Epidemiology** — **Vision Sciences / Electrophysiol. / Physiological Optics** will nominate candidates for scientific chair.

Emerald II **IM: EVER – SOIE : Neurological concomitants of uveitis** 11:30 – 13:00
 Joint M. Ilknur TUGAL-TUTKUN, Carl P HERBORT



11:30	5241	Immunological similarities between the eye and the brain THURAU S–München
11:42	5242	Neuroophthalmological findings of sarcoidosis and Vogt-Koyanagi-Harada syndrome AKOVA Y–Ankara
11:54	5243	Multiple sclerosis & Behçet disease TUGAL-TUTKUN I–Istanbul
12:06	5244	Herpes virus infections LABETOULLE M–Kremlin-Bicêtre
12:18	5245	Susac's syndrome BORRUAT FX–Lausanne
12:30	5246	Primary intraocular and CNS lymphoma CASSOUX N–Paris
12:42		Discussion

Mediterranea I **G: Corneal biomechanical properties: Implication for cornea and glaucoma clinicians** 11:30 – 13:00
 SIS Sayeh POURJAVAN



11:30	5251	Corneal biomechanical properties and IOP measurements by ocular response analyzer (ORA) TAYLOR DT–Buffalo, NY
11:52	5252	The characteristics of corneal biomechanics and their correlations with other biophysical parameters POURJAVAN S, DETRY-MOREL M–Brussels
12:14	5253	Corneal biomechanics and IOP measurements: the implications for glaucoma management KOTECHA A–London
12:36	5254	Corneal hysteresis and resistance factor in normal, keratoconus suspects and true keratoconus eyes GATINEL D–Paris

Adria **PO: Ocular lymphoid tissue and ocular lymphoma. Anatomical considerations, development and treatment** 11:30 – 13:00
 SIS Steffen HEEGAARD, Nadja KNOP

11:30	5261	Conjunctiva-associated lymphoid tissue (CALT) – the physiological protective MALT of the conjunctiva KNOP N, KNOP E–Hannover, Berlin
11:48	5262	Eye-Associated Lymphoid Tissue (EALT) – the local branch of the physiological mucosal immune system at the ocular surface and appendage KNOP E, KNOP N–Berlin, Hannover
12:06	5263	Malt lymphoma COUPLAND SE–Liverpool
12:24	5264	Mantle Cell Lymphoma in the Ocular Region HEEGAARD S–Copenhagen
12:42	5265	Current and possible future treatment of ocular adnexal lymphomas PETTITT A–Liverpool

Europa A ***RV: Assessment of functional response of the ocular circulation*** 14:15 – 15:45
 SIS Charles RIVA, Ines LANZL

- 14:15 5311 Dynamic vessel analysis for assessing endothel dysfunction of microcirculatory vessels – method, model and results
 VILSER W, SEIFERT B–Jena
- 14:30 5312 Measurement of time-resolved autofluorescence
 SCHWEITZER D, SCHENKE S, JENTSCH S, QUICK S, GEHLERT S, HAMMER M, BERGMANN N–Jena
- 14:45 5313 Flicker-induced retinal vasodilatation - what does a reduced response mean?
 SCHMETTERER L–Vienna
- 15:00 5314 Is there a role for dynamic retinal vessel analysis in internal medicine?
 LANZL IM, SCHMIDT-TRUCKSÄSS A, KOTLIAR KE–Munich
- 15:15 5315 New optical device for functional studies of the optic nerve head
 GEISER MH, TRUFFER F, KHAYI H, CHIQUET C–Sion, Grenoble
- 15:30 5316 Optic nerve reflectance variations in the near-infrared during neural function
 RIVA CE, BONAIUTI M, ROVATI L–Bologna, Modena

Europa B ***IM: The role of inflammation in diabetic retinopathy*** 14:15 – 15:45
 SIS Ahmed ABU EL ASRAR

- 14:15 5321 The role of leukocytes in ischemia-driven neovascularisation
 SHIMA DT, KRILLEKE D, NISHIJIMA K–London, Kyoto
- 14:27 5322 Mechanisms driving neovascularisation and microangiopathy in DR: VEGF-triggers cell adhesion via endothelial- and leukocyte-induced pathways
 SHIMA DT, ADAMIS AP–London, NYC
- 14:39 5323 Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy
 ABU EL ASRAR AM, STRUYF S, KANGAVE D, GEBOES K, VAN DAMME J–Riyadh, Leuven
- 14:51 5324 The role of arachidonic acid metabolites in DR
 ABU EL ASRAR AM, MISSOTTEN L, GEBOES K–Riyadh, Leuven
- 15:03 5325 The action of pro-inflammatory cytokines on retinal endothelial cell barrier permeability: protective effect of corticosteroids
 AMBROSIO AF, AVELEIRA CA, WOLPERT E, ANTONETTI DA–Coimbra, Hershey, PA
- 15:15 5326 Circulating fibrocytes contribute to the myofibroblast population in proliferative vitreoretinopathy epiretinal membranes
 ABU EL ASRAR AM, STRUYF S, VAN DAMME J, GEBOES K–Riyadh, Leuven
- 15:27 5327 Therapeutic implications and perspectives
 SHIMA DT–London

Emerald I ***COS: Corneal grafting 1*** 14:15 – 15:45
 FP Philippe KESTELYN, Jean-Jacques GICQUEL

- 14:15 5331 Selection and assessment of vital dyes to improve the endothelial quality control of organ cultured corneas
 THURET G, DUBAND S, CAMPOLMI N, PIPPARELLI A, PISELLI S, DUMOLLARD JM, PEOC'H M, ACQUART S, GARRAUD O, GAIN P–Saint-Etienne
- 14:27 5332 Sclerocorneal limbus transplantation
 BARRAQUER J–Barcelona
- 14:39 5333 Long term results of Limbal stem cell transplantation in ocular surface disease
 MIRI A, ALDEIRI B, MATHEW M–Nottingham
- 14:51 5334 Quality of vision following penetrating keratoplasty and deep anterior lamellar keratoplasty for keratoconus
 PARENTE G, FONTANA L, TASSINARI G–Bologna
- 15:03 5335 Impact of culturing on metabolic profile of human corneas
 KRYCZKA T, EHLERS N, MIDELFART A–Trondheim, Århus

Poster session 2

16:45-17:40

Europa C

Posters on pages 50-51

Glaucoma - Cornea/Ocular Surface - Physiology/Biochemistry/Pharmacology

Gabor HOLLO, Luciano QUARANTA, Ilse CLAERHOUT, Erich KNOP, Leopold SCHMETTERER, Neville OSBORNE

Emerald II *LC: Posterior capsule opacification* 14:15 – 15:45
 SIS Michael WORMSTONE, Per SÖDERBERG

- 14:15 5341 MMP involment in TGFbeta-mediated matrix contraction: implications for PCO
 ELDRED JA, HODGKINSON LM, REDDAN JR, EDWARDS DR, WORMSTONE IM—Norwich, Rochester
- 14:33 5342 Promotion of ER stress: a potential therapeutic approach for PCO
 WANG L, DUNCAN G, NEILSON GJ, ZHANG H, WORMSTONE IM—Norwich, Epping
- 14:51 5343 Sealed capsule irrigation to prevent posterior capsule opacification: Results of long-term clinical trials and laboratory studies
 AUFFARTH GU, RABSILBER TM—Heidelberg
- 15:09 5344 Intraocular lens features that affect PCO
 SPALTON DJ—London
- 15:27 5345 Mechanism of PCO prevention in the bag-in-the-lens technique
 TASSIGNON MJ—Antwerp

Mediterranea I *G: Glaucoma treatment* 14:15 – 15:45
 FP Alain BRON, Ingeborg STALMANS

- 14:15 5351 Predictive value of a dexamethasone provocative test prior to intravitreal triamcinolone acetonide injection
 ZEYEN T, BREUSEGEM C, VANDEWALLE E, VAN CALSTER J, FIEUWS S, STALMANS I—Leuven
- 14:27 5352 Increasing IOP decrease with sequential use of travoprost, travoprost/timolol fixed combination and travoprost/timolol fixed combination with adjunctive brinzolamide
 HOLLO G, KOTHY P—Budapest
- 14:39 5353 Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost or timolol
 BHATT UK, BANERJEE S—Leicester
- 14:51 5354 Safety of trabeculectomy with mitomycin C: The ReGAE (research into glaucoma and ethnicity) experience
 GHOURI AJ, SHAH P, SII F, HUSSAIN A, CHIANG M—Birmingham, Brisbane
- 15:03 5355 Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery
 VAN BERGEN T, VAN DE VEIRE S, MOONS L, STALMANS I—Leuven
- 15:15 5356 Micropulse diode laser trabeculoplasty for secondary corticosteroid induced glaucoma
 MELIS R, PILOTTO E, VUJOSEVIC S, DORIGO MT, MIDENA E—Padova, Roma

Adria *PO: Genomic and epigenetic alterations in uveal melanoma* 14:15 – 15:45
 SIS Laurence DESJARDINS, Martine J JAGER

- 14:15 5361 Different techniques to evaluate chromosome aberrations
 COUPLAND SE, DAMATO BERTIL—Liverpool
- 14:33 5362 Epigenetics, chromosome 3 and early detection of metastasis
 VAN DER VELDEN PA, MAAT W, VERSLUIS M, KOUCH-EL FILALI M, JAGER MJ—Leiden
- 14:51 5363 Epigenetic alterations in uveal melanoma
 ZESCHNIGK M, SCHOLZ M, LOHMANN DR, THOMAS S, BORNFELD N—Essen
- 15:09 5364 Genomic profiling and identification of high-risk tumours in uveal melanoma by array-CGH analysis of primary tumours and liver metastases
 COUTURIER J, TROLET J, HUPE P, MARIANI P, SASTRE X, ASSELAIN BERNARD, BARILLOT E, SAULE S, PIPERNO-NEUMANN S, DESJARDINS L—Paris
- 15:27 5365 Identification of molecular markers associated with high metastatic risk in uveal melanoma
 SAULE S, LAURENT C, COUTURIER J, DECRAENE C, DESJARDINS L, SASTRE X, BARILLOT E, ALMEIDA A, PIPERNO-NEUMANN S—Orsay, Paris

**Ophthalmic
 Research Lecture**
 16:00 – 16:40
Europa A

**Functional analysis of mutants of the optineurin gene,
 associated with some forms of glaucoma**
 Dbala BALASUBRAMANIAN - Hyderabad, India
 Introduction by Uwe PLEYER

Ophthalmic
 Research



Europa A ***RV: Vitreoretinal surgery*** 17:45 – 19:15
 FP Constantin POURNARAS, Catherine CREUZOT

17:45	5411	Duration of retinal detachment and central retinal artery hemodynamics: repercussion on logmar visual acuity ROLDAN-PALLARES M, MUSA AS, HERNANDEZ-MONTERO J, BRAVO-LLATAS C–Madrid
17:57	5412	Use of PLGA microparticles for vitreous staining during anterior vitrectomy TINT NL, CHAU DYS, DUA HS, SHAKESHEFF KM, GRIFFIN M, ROSE FRAJ–Nottingham, Aston University, Nottingham
18:09	5413	Idiopathic epiretinal macular membrane and cataract extraction : combined surgery vs consecutive surgery CREUZOT CP, DUGAS B, OULED-MOUSSA R, LAFONTAINE PO, GUILLAUBEY A, HUBERT I, BRON AM, BERROD JP–Dijon, Nancy
18:21	5414	A new method for fixation and explantation of epiretinal implants IVASTINOVIC D, LANGMANN G, HORNIG R, RICHARD G, VELIKAY-PAREL M–Graz, Bonn, Hamburg-Eppendorf
18:33	5415	Perioperative bevacizumab injection: clinical and histological results ROMANO MR, GIBRAN SK, WONG D, HISCOTT P, HEIMANN H–Liverpool
18:45	5416	Standardized surgical procedure in complicated retinal detachment VELIKAY-PAREL M, RICHTER- MÜKSCH S, KISS CH, WEDRICH A–Graz, Vienna
18:57	5417	PASCAL Photocoagulator, is it better ? ISSA M–Oxford

Europa B ***IM: Regional ocular immunity and immune privilege*** 17:45 – 19:15
 SIS Manabu MOCHIZUKI, Sunao SUGITA



17:45	5421	Introduction DE SMET MD–Antwerp
17:55	5422	Eye-derived systemic immune regulation : ACAID TAKEUCHI M–Tokyo
18:15	5423	Role of dendritic cells in the ocular immune response FORRESTER JV–Aberdeen
18:35	5424	Macrophage modulation of inflammatory responses DICK AD–Bristol
18:55	5425	Role of ocular pigment epithelial cells in regional ocular immunity SUGITA S, MOCHIZUKI M–Tokyo

Emerald I ***Keratoconus and corneal grafting 2*** 17:45 – 19:15
 FP Friedrich KRUSE, Ilse CLAERHOUT

17:45	5431	The Royal Victorian Eye and Ear Hospital (RVEEH) technique of DSAEK Triple BELTZ J, JHANJI V, SHARMA N, VAJPAYEE RB–Melbourne, New Delhi
17:57	5432	Full thickness cornea transplantation to lamellar bad managing extensive corneal perforations ASOKLIS R, BUTKIENE L, JUODKAITE G, MAKSELIS A, PAJAUJIS M, CIMBALAS A–Vilnius
18:09	5433	Corneal thickness values in case of patients who underwent lamellar keratoplasty using various evaluation techniques. JANISZEWSKA D, WYLEGALA E, DOBROWOLSKI D, MILKA M–Katowice
18:21	5434	Factors influencing the outcome of the treatment of allograft corneal graft rejection PERERA CM, JHANJI V, BELTZ J, LAMOUREUX E, POLLOCK G, VAJPAYEE RB–Melbourne
18:33	5435	An assersive model for corneal endothelium morphometry by diffraction BUCHT C, SÖDERBERG PG, MANNEBERG G–Stockholm, Uppsala
18:45	5436	Optimisation of amniotic membrane (AM) denuding for tissue engineering HOPKINSON A, SHANMUGANATHAN VA, YEUNG AM, GRAY T, LOWE J, DUA HS–Nottingham

Emerald II *LC: Lens and cataract* 17:45 – 19:15
 FP Jan-Olof KARLSSON, Alfred WEGENER

17:45	5441	Morphological link between accommodation, presbyopia and cortical cataract MICHAEL R, BARRAQUER RI, VRENSSEN G—Barcelona, Leiden
17:57	5442	The time of onset of inherited cataract BRON AJ, HANNAN F, MUSHTAQ B, KORETZ JF—Oxford, NY
18:09	5443	Acute effects of the sigma- receptor agonist on human lens epithelial cells KARLSSON JO, JONHEDE S, PETERSEN A, ZETTERBERG M—Gothenburg
18:21	5444	In vivo high power infrared radiation exposure time dependence of lens light scattering AL-SAQRY R, GALICHANIN K, LI Y, SÖDERBERG PG, SCHULMEISTER K, HUSINSKI J, BUCHT C—Uppsala, Vienna
18:33	5445	In vivo assessment of blue light attenuation of the crystalline lens and tinted and not tinted intraocular lenses KONTADAKIS GA, TSAIKA CI, PLAINIS S, MAKRIDAKI M, MOSCHANDREAS I, TSILIMBARIS MK—Heraklion, Crete, Manchester
18:45	5446	Comparison of parameters in cataract surgery between coaxial microincision and standard coaxial incision GEORGET M, CARDON A, FAVARD A, CONTOUR S, ABID M, PISELLA PJ—Tours

Mediterranea I *MBGE: What can molecular biology and genetics do for me?* 17:45 – 19:15
 SIS Marcela VOTRUBA

17:45	5451	Molecular genetic information - impact on the family CHURCHILL A—Bristol
18:03	5452	Doctor, my baby doesn't fix and follow LEROY BP—Ghent
18:21	5453	Genetic testing in retinal dystrophies DOWNES SM—Oxford
18:39	5454	Molecular diagnosis of X-linked retina diseases HARDCASTLE AJ—London
18:57	5455	Testing and counselling in inherited optic neuropathies VOTRUBA M—Cardiff

Adria *PO: Unusual orbital tumours* 17:45 – 19:15
 SIS Daniel BRISCOE

17:45	5461	Unusual patterns of orbital extension in periorbital squamous cell carcinomas DE KEIZER RJW—Leiden
18:03	5462	Atypical inflammatory lesions in the orbit and adnexae BRISCOE D, TON Y, KIDRON D—Kfar Saba
18:21	5463	Diagnostic difficulties in orbital pathology BONSHEK RE—Manchester
18:39	5464	Unexpected orbital and adnexal masses: Experience of several cases DRAY JP
18:57	5465	Some unusual vascular mass presentations in the orbit and adnexae BONAVOLONTA G—Napoli

- 501 Philatelic aspects on WHO Year Glaucoma 2008
SVEDBERGH BOC—Uppsala

GLAUCOMA

Moderator: Gabor HOLLO, Luciano QUARANTA

- 502 Correlation of optic disc morphology and ocular perfusion parameters in patients with primary open angle glaucoma
rf
SCHMIDL D, RESCH H, RENSCH F, HOMMER A, VASS C, LUKSCH A, GARHOFER G, JONAS JB, SCHMETTERER L—Vienna, Mannheim
- 503 Effect of eye NGF application on NGF-receptor expression in visual cortex and geniculate nucleus of rat with glaucoma
ALOE L, PARISI V, MANNI L, SPOSATO V—Rome
- 504 Aqueous humour ghrelin levels of eyes with and without glaucoma
ROCHA DE SOUSA A, ALVES-FARIA P, FALCAO-PIRES I, FALCAO-REIS F, LEITE-MOREIRA AF—Porto
- 505 Reliability and diagnostic significance of frequency doubling visual field testing
SAEDON H, HAMADA S, TAHHAN M—West Midlands
- 506 Study of suspicious subjects of suffering glaucoma evaluated by means of HRT, OCT and GDx-VCC. Representation by means of Venn's diagram
ALIAS EG, BORQUE E, LARROSA JM, POLO V, HONRUBIA FM—Zaragoza
- 507 Diagnostic ability of glaucoma probability score to discriminate between healthy individuals and glaucoma suspects
FERRERAS A, PAJARIN AB, PINILLA I, FOGAGNOLO P, GUERRI MONCLUS N, EGGA ESTOPINAN MC, GARCIA-MARTIN E—Zaragoza, Rome
- 508 Diagnostic distribution according to the clinical guide of practices of the Finnish Society of Ophthalmology represented by HRT and OCT
ALIAS EG, LARROSA JM, POLO V, BORQUE E, HONRUBIA FM—Zaragoza
- 509 Optic disc and retinal nerve fiber layer analysis in perimetrix unaffected eyes of glaucoma patients: an optical coherence tomography study
DI STEFANO G, DA POZZO S, FANNI D, RAVALICO G—Trieste
- 510 Relationship optical coherence tomography and short-wavelength automated perimetry in glaucoma patients — FERRERAS A, FOGAGNOLO P, PAJARIN AB, PINILLA I, BORQUE E, GARCIA-MARTIN E—Zaragoza, Rome
- 511 Correlation of GDx VCC with standard automated perimetry in glaucoma diagnosis
BORQUE E, FERRERAS A, ALIAS E, PUEYO V, LARROSA JM, POLO V—Zaragoza
- 512 Central corneal thickness effect on GDx VCC parameters
BORQUE E, FERRERAS A, PUEYO V, POLO V, LARROSA JM, ALIAS EG—Zaragoza
- 513 Variability of color doppler imaging parameters and consequences for sample size calculations
VANDEWALLE E, SIESKY B, ZEYEN T, HARRIS A, STALMANS I—Leuven, Indianapolis
- 514 Functional activity of the retina before and after IOP normalization in glaucoma
KAZARYAN AA, SHAMSHINOVA AM—Moscow
- 515 Corneal central and temporal thickness in rabbits
MORAES SILVA MRB, ANDREGHETTI E, DOMINGUES MA, SEGUNDO PR—Botucatu
- 516 Variation of intraocular pressure (IOP) & central corneal thickness (CCT) in neonates
AGGELIDOU E, KOZEIS N, FELEKIDIS A, DROSOU-AGAKIDOU V—Thessaloniki, Xanthi
- 517 Comparison of Tono-Pen Avia with Goldmann applanation tonometer
MUSCHART F, POURJAVAN S—Brussels
- 518 Physiological short-term variability of ocular pulse amplitude (OPA) measured by dynamic contour tonometer (DCT) in healthy subjects
POURJAVAN S, DETRY-MOREL M, MUSTAKA L—Brussels
- 519 Comparison of the Schiøtz indentation tonometer with the Tonopen® tonometer and the influence of two different anaesthetic techniques on the IOP in the porcine eye
BUEHNER E, PIETSCH U, WIEDEMANN P, UHLMANN S—Leipzig
- 520 Intraocular pressure variation during different surgical procedures in rabbit eyes
VIEIRA DE SOUZA N, VIEIRA DE SOUZA E, VERONESE RODRIGUES ML—Ribeirão Preto
- 521 Invasive measurement of outflow facility in the living human eye
GINIS H, DE BROUWERE D, DASTIRIDOU A, TSILIMBARIS MK, PALLIKARIS I—Heraklion
- 522 An opto-mechanical device for the measurement of ocular rigidity and intraocular pressure — GINIS H, DE BROUWERE D, PANAGIOTOGLOU TH, TSILIMBARIS MK, PALLIKARIS I—Heraklion
- 523 The impact of common classes of topical antiglaucoma medications on central corneal thickness — WIERZBOWSKA J, FUKSINSKA B, MATUSIK R, STANKIEWICZ A, SIERDZINSKI J—Warsaw
- 524 The incidence of glaucoma following paediatric cataract surgery
BHATT UK, TATHAM A, WOODRUFF GH—Leicester
- 525 Compliance and knowledge about glaucoma in austrian patients
MANSOURI K, RIGAL K—Lausanne, Vienna
- 526 Is audible alarm useful in increasing adherence?
KOTHY P, HOLLO G—Budapest
- 527 Electronic compliance monitoring in glaucoma patients used to topical therapy — BRON AM, HERMANN M, DIESTELHORST M, CREUZOT CP—Dijon, Cologne
- 528 A patient preference comparison of two fixed combinations, brinzolamide 10 mg/ml+timolol 5 mg/ml suspension and dorzolamide 20 mg/ml +timolol 5 mg/ml solution in patients with open-angle glaucoma or ocular hypertension
NOTIVOL R—Barcelona
- 529 Phase III, 24-month study investigating the efficacy and safety of tafluprost vs latanoprost in patients with open-angle glaucoma or ocular hypertension
UUSITALO HMT, PILLUNAT LE, BAUDOUIN C, TRAVERSO C, BERGSTRÖM A, JENSSEN FT, ZAGORSKI Z, NESHOR R—Tampere, Dresden, Paris, Genova, Lund, Bergen, Lublin, Kfar Saba
- 530 G-probe: results of use on eyes with visual functions with patients in Armenia
BUNIATYAN IY, VARDANYAN AH, VOSKANYAN LA—Yerevan
- 531 Contact transcleral ciliary body photodynamic treatment with verteporfin in cases of refractory glaucoma
CHARISIS SK, VITANOVA VS, DETORAKIS E, TSILIMBARIS MK—Heraklion
- 532 Ocular adverse effects of the pneumatic trabeculoplasty in patients' treatment with open angle glaucoma
PESCE G, AHMETAJ M, ALESSIO T, SCANDALE M, SCORCIA G—Catanzaro
- 533 The reasons of unsuccessful antiglaucoma operations
MILOJKO B—Podgorica
- 534 Subconjunctival injection of bevacizumab in side of filtering bleb in the end of trabeculectomy : first experience
PICCIRILLO V, SAVASTANO A, SBORDONE S, FORTE R, TAMBURRINI L, SAVASTANO MC, SAVASTANO S—Cassino, Naples, Rome
- 535 Long-term results of combined cataract and non perforant sclerectomy surgery supplemented with antimetotics: prospective study
GUTIERREZ G, BLOVIAR G, MIGUEL T—Madrid
- 536 Control of filtering bleb scarring trough tissue bioengineering
APTEL F, DUMAS S, BURILLON C, DENIS P—Lyon

CORNEA / OCULAR SURFACE

Moderators: Ilse CLAERHOUT, Erich KNOP


- 537 In vitro evaluation of adhesion of adipose-derived adult stem cells to chitosan for the treatment of ocular surface pathologies
rf
PASTOR S, ALIO SANZ JL, GAMBOA-MARTINEZ TC, ARNALICH-MONTIEL F, DE MIGUEL MP, GOMEZ-RIBELLES JL, GALLEGU-FERRER G—Alicante, Valencia, Madrid
- 538 No consequence of dietary omega-3 polyunsaturated fatty acid deficiency on the severity of scopolamine-induced dry eye
rf
CREUZOT CP, VIAU S, PASQUIS B, MAIRE MA, BRETILLON L, GREGOIRE S, ACAR N, BRON AM, JOFFRE C—Dijon
- 539 Cyanoacrylate tissue gluing in corneal perforations associated with herpetic keratitis
rf
JHANJHI V, MOORTHY S, BELTZ J, CONSTANTINOU M, VAJPAYEE RB—Melbourne
- 540 Red eye multimedia teaching tool
rf
PETRICEK P, ANDRAS B, HIGAZY M, NEMETH J, PROST ME—Zagreb, Debrecen, Egypt, Budapest, Warsaw
- 541 Analysis of corneal epithelial cells with confocal microscopy after lamellar keratoplasty
GAUJOUX T, TOUZEAU O, KOPITO R, LAROCHE L, BORDERIE VM—Paris
- 542 Outcome of transplanted mesenchymal stem cells in the alkali burned cornea
VERA L, LATOUCHE JB, GUEUDRY J, VANNIER JP, MURAIN M—Rouen

- 543 Experimental models of orthotopic limbal transplantation in the mouse. Evaluation of allo- and xenograft survival and characterization of cytokine response — LENCOVA A, POKORNA K, ZAJICOVA A, FILIPEC M, HOLAN V—Prague
- 544 Effect of VEGF blockade on corneal graft neovascularization and rejection in rats — ROCHER N, BEHAR-COHEN F, RENARD G, BOURGES JL—Paris
- 545 Cis-urocanic acid, a novel anti-inflammatory and cytoprotective drug, decreases effectively UVB-induced IL-6 secretion and cytotoxicity in human corneal and conjunctival epithelial cells in vitro
VIIRI J, RYHÄNEN T, PAIMELA T, LAHIA J, LEINO L, SALMINEN A, KAARNIRANTA K—Kuopio, Turku
- 546 The effect of UVA and UVB irradiation of the rabbit cornea on matrix metalloproteinase 2 and 9 expression in the corneal epithelium
ARDAN T, CEJKOVA J—Prague
- 547 Temperature- and osmosensing by the human corneal endothelium through activation of TRPV channels
MERGLER S, VALTINK M, ENGELMANN K, PLEYER U—Berlin, Dresden, Chemnitz
- 548 The effect of corneal hydration on corneal ablation rate at 193nm and 213nm
PENTARI A, GINIS H, TSATSARONIS D, TSIKLIS N, PALLIKARIS I—Heraklion
- 549 Refractive changes after pterygium surgery
MATEO OROBIA AJ, IBANEZ J, LAFUENTE N, PEREZ D, PEIRO C, DEL BUEY MA, CRISTOBAL JA—Zaragoza
- 550 Confocal microscopy after descemet stripping automated endothelial keratoplasty (DSAEK): morphological findings in short term follow up
SAVASTANO A, SBORDONE S, PICCIRILLO V, FORTE R, TAMBURRINI L, SAVASTANO MC, SAVASTANO S—Naples, Cassino (FR), Rome
- 551 Donor tissue detachment after descemet stripping automated endothelial keratoplasty (DSAEK): a 35 mhz probe ubm study
SAVASTANO A, SBORDONE S, VALERIO P, FORTE R, TAMBURRINI L, SAVASTANO S—Naples, Cassino
- 552 Ultrastructural organisation of arthritis corneal stroma
AKHTAR S, ALMUBRAD TM, OGBUEHI KC, BONSHK RB—Riyadh, Manchester
- 553 Optimisation of diagnostic strategy in severe ocular sicca syndrome
DE MONCHY I, MARIETTE X, GENDRON G, OFFRET H, LABETOULLE M—Le Kremlin Bicêtre
- 554 Comparison of real intraocular pressure (IOP) during LASIK versus Epi-LASIK
CANADAS SUAREZ P, HERNANDEZ - VERDEJO J, DE BENITO L, TEUS M—Madrid
- 555 Analysis of visual outcome with rigid contact lenses in keratoconic eyes
KOPITO R, WAJEMAN S, GAUJOUX T, TOUZEAU O, LAROCHE L—Paris
- 556 Corneal morphology, topography and sensitivity in a family with inherited recurrent corneal erosions — NEIRA W, HAMMAR B, HOLOPAINEN J, TUISKU I, DELLBY A, TERVO T, FAGERHOLM P—Helsinki, Linköping
- 557 Comparison of metabolic profile of normal and keratoconus corneas using HR MAS 1HNMR spectroscopy and HPLC
KRYCZKA T, EHLERS N, MIDELFART A—Trondheim, Århus
- 558 Keratoconic corneas after ferrara rings implantation: histopathological findings — PERIS-MARTINEZ C, MENEZO ROZALEN JL—Valencia
- 559 Tufting enteropathy: ocular surface and conjunctival markers
BREMONT-GIGNAC D, COPIN H, BRIGNOLE-BAUDOUIN F, MILAZZO S, BAUDOUIN C—Amiens, Paris
- 560 The roles of T and natural killer cells in a pig-to-mouse corneal xenotransplantation
OH JY, KWON JW, HAN ER, WEE WR, LEE JH, KIM MK—Seoul
- 561 Study of the corneal endothelial infection after Herpes simplex virus type 1 (HSV1) in a murine model: comparison between in situ confocal microscopy (ISCM) and immunofluorescent analysis on histological sections
POGORZALEK N, HUOT N, CREPIN S, FRANCELLE L, OFFRET H, NAAS T, LABETOULLE M—Kremlin-Bicêtre, Gif-sur-Yvette
- 562 Tear meniscus height and lipid layer pattern in seasonal allergic conjunctivitis patients outside the season
HAGYO K, VERES A, FODOR E, LANG ZS, MEZEI GY, KRASZNAI M, CSAKANY B, NEMETH J—Budapest
- 563 Occult traumatic nasolacrimal duct obstruction causing anophthalmic socket contraction presenting 20 years later
SAEDON H, CHEUNG D—West Midlands
- 564 The use of intraslesional injection of 5 Fluorouracil to induce regression of recurrent pterygium
RAHMAN I, JAYASWAL R, TINT NL, DUA HS, MAHARAJAN VS—Nottingham
- 565 Are ocular response analyzer useful to measure corneal hysteresis in patients with intracorneal rings?
MENEZO ROZALEN JL, PERIS-MARTINEZ C, ARTIGAS JM, DIEZ AJENJO M, FELIPE A—Valencia
- 566 Assessment of visual outcomes of deep anterior lamellar keratoplasty (DALK)
RAHMAN I, JAYASWAL R, DUA HS, MAHARAJAN VS—Nottingham
- 567 In vitro contact angle and coefficient of friction profiles for daily disposable contact lenses — GILES TG—Duluth, Georgia
- 568 Preliminary study of normal tear complement activation in patients with seasonal allergic conjunctivitis outside the season
VERES A, HAGYO K, MEZEI G, LANG ZS, KRASZNAI M, PROHASZKA Z, FUST G, NEMETH J—Budapest
- 569 Conjunctival impression cytology as a tool for clinical diagnosis, follow-up and treatment of a patient affected by severe keratoconjunctivitis
PASTOR S, RODRIGUEZ-PRATS JL, WALEWSKA-SZAFRAN A, RODRIGUEZ AE, ALIO SANZ JL—Alicante, Wejherowo
- 570 Topical and subconjunctival bevacizumab in corneal neovascularization in keratoplasty patients
SCHOLLMAYER P, STUNF S, LAVRIC A, PFEIFER V—Ljubljana

PHYSIOLOGY / BIOCHEMISTRY / PHARMACOLOGY

Moderators: Leopold SCHMETTERER, Neville OSBORNE

- 571 The pulsatile ocular blood flow (POBF) in patients with sleep apnea syndrome (SAS) — NOWAK MS, KLYSIK AB, WASZCZYKOWSKA A, GOS R, SMIGIELSKI J—Lodz
- 572 Pharmacokinetics and ocular tissue penetration of VEGF trap after intravitreal injection in rabbits
STRUBLE C, KOEHLER-STECK E, ZIMMER E, TU W—Madison WI, Tarrytown NY
- 573 Retinal arteriolar vascular reactivity to incremental changes in hyperoxic stimuli during isocapnia
HUDSON C, TONG A, HAN J, MARDIMAE A, WONG T, FISHER J—Toronto
- 574 Short-term effect of topical dorzolamide hydrochloride on intrastromal corneal pressure "in vivo" in rabbit corneas
BOLIVAR G, TEUS M, GUTIERREZ C—Alcala de Henares
- 575 Ophthalmic timolol in a hydrogel vehicle leads to minor interindividual variation in timolol concentration in aqueous humor
VAPAATALO H, VOLOTINEN M, MÄENPÄÄ J, KAUTIAINEN H, TOLONEN A, UUSITALO J, ROPO A, AINE E—Helsinki, Tampere, Äänekoski, Oulu
- 576 Dynamic retinal vessel reaction in diabetes type I — SITNIKOVA D, KOTLIAR K, LANZL I, SIGMUND T, HALLE M, SCHMIDT-TRUCKSÄSS A—Munich
- 577 The effect of four commercially available preserved and unpreserved prostaglandin analogues on human corneal epithelial and human conjunctival epithelial cells in vitro — UUSITALO HMT, HUHTALA A—Tampere
- 578 Retinal changes after acute increase of the intraocular pressure in adult mice
PINILLA I, CUENCA N, SALINAS-NAVARRO M, FERNANDEZ-SANCHEZ L, ALARCON-MARTINEZ L, GARCIA-MARTIN E, AVILES-TRIGUEROS M, VILLEGAS-PEREZ MP, VIDAL-SANZ M—Zaragoza, Alicante, Murcia
- 579 Early hydroxychloroquine retinal toxicity enhanced by laser flare-cell meter
BRAVETTI GO, LEONETTI P, CELLINI M, CAMPOS EC—Bologna
- 580 Dietary prevention of visual function and cognitive decline by omega-3 polyunsaturated fatty acids in senescence accelerated mouse P8 (SAM P8)
ACAR N, GREGOIRE S, MORANIS A, LABROUSSE V, PASQUIS B, JOFFRE C, BRON AM, CREUZOT CP, BRETILLON L, LAYE S—Dijon, Bordeaux
- 581 Choroidal blood flow variations to gas in healthy young subjects before and after intermittent hypoxia
KHAYI H, TONINI M, TAMISIER R, GEISER M, PEPIN JL, LEVY P, ROMANET JP, CHIQUET C—Grenoble, Sion
- 582 Lactate-induced retinal vasodilation implicates neuronal nitric oxide synthesis in minipigs
MENDRINOS E, PETROPOULOS IK, MANGIORIS G, PAPADOPOULOU DN, STANGOS AN, POURNARAS CJ—Geneva
- 583 Intracameral cefuroxime: evaluation of stability in normal saline and balanced salt solutions — RIGAL SASTOURNE JC, MULLOT H, MULLOT JU, SGARI-OTO A, HUART B, GENTES P—Paris
- 584 25-Hydroxycholesterol increases IL-8 production in the RPE by activation of PI3K and p38 MAPK pathways
FERNANDES AF, BRITO A, PEREIRA P—Coimbra
- 585 Flicker induced vasodilatation is reduced in chronic smokers
LASTA M, PEMP B, WEIGERT G, SACU S, SCHMETTERER L, GARHOFER G—Vienna





Saturday
4 October

08

Europa A ***RV: Diabetic retinopathy: novel mechanisms*** 08:15 – 09:45
SIS Irina OBROSOVA, Timothy KERN

supported by 

08:15	6111	Contribution of inflammation to the early stages of diabetic retinopathy KERN T—Cleveland, OH
08:33	6112	Metabolic memory puzzle and progression of diabetic retinopathy KOWLURU R—Detroit
08:51	6113	New insights into the pathogenic role of advanced glycation in diabetic retinopathy STITT AW—Belfast
09:09	6114	Caspase-1/interleukin-1beta signaling in diabetic retinopathy MOHR S—Cleveland
09:27	6115	PARP, Na ⁺ /H ⁺ -exchanger-1, and early diabetes-induced retinal changes OBROSOVA IG—Baton Rouge, LA

Europa B ***IM: Update on developments in uveitis & intraocular inflammation*** 08:15 – 09:45
SIS Carl P HERBORT, Piergiorgio NERI

08:15		Introduction by Carl Herbolt
08:27	6121	Modern exploration of choroidal inflammation HERBORT C—Lausanne
08:40	6122	OCT, a value adding technique (VAT) in the appraisal of macular inflammation DE SMET MD—Antwerp
08:53	6123	The role of gamma-interferon tests for suspected tuberculous ocular inflammation CIMINO L, LOSI M, RICHELDI L, BOIARDI L, CAPPUCINI L, SALVARANI C—Reggio Emilia, Modena
09:06	6124	The role of interferon alpha in uveitis therapy BODAGHI B, GUEUDRY J, TERRADA C, CASSOUX N, PIETTE JC, LEHOANG P—Paris
09:19	6125	The role of mycophenolate mofetil in uveitis therapy NERI P—Ancona
09:32	6126	The role of TNF-alpha blockers in uveitis therapy ABU EL ASRAR AM—Riyadh

Emerald I ***COS: Refractive surgery and contact lenses. The best of both worlds*** 08:15 – 09:45
FP Catherine CREUZOT, William BOURNE

08:15	6131	Corneal keratocyte density after mechanical versus femtosecond laser in situ keratomileusis CANADAS SUAREZ P, ARRANZ E, GIL-CAZORLA R, TEUS M—Madrid
08:27	6132	Structural and optical changes in the eye after soft contact lens wear MIRANDA MA, O'DONNELL C, RADHAKRISHNAN H—Manchester
08:39	6133	Effectiveness of moisturizing daily disposable lenses with additives GILES TG—Duluth, Georgia
08:51	6134	Re-treatment after LASIK for correction of myopia and myopic astigmatism FARES U, BRAGHEETH MA, DUA HS—Nottingham
09:03	6135	Refractive surgery using CustomVis Solid State Laser 213nm. One year post-op clinical evaluation supported by an experimental study PALLIKARIS IG—Heraklion
09:15	6136	Endothelial cell loss 9 years after PRK and LASIK and its importance for eye banks BOURNE WM, PATEL SV—Rochester, Minnesota
09:27	6137	Intracorneal lenses for the treatment of presbyopia: visual outcomes and safety PALLIKARIS IG, BOUZOUKIS DI, KYMIONIS GD, PANAGOPOULOU S, PALLIKARIS AI—Heraklion

Keynote Lecture ***Recognition and treatment of herpes simplex keratitis***
10:00– 10:40
Europa A Peter LAIBSON - Wills Eye Institute, Philadelphia, USA
Introduction by Philippe KESTELYN



EVA 2008 ***European Vision Award - Announcement of the EVA 2008 Winner:***
10:45– 11:05
Europa A PD. Dr. Hendrik P.N. Scholl - Dept of Ophthalmology, University of Bonn
Introduction by Harminder DUA and Eberhart ZRENNER

Emerald II **LC: New IOL technology - restoring accommodation** 08:15 – 09:45
 SIS Rafael I. BARRAQUER, Ralph MICHAEL

08:15	6141	Multifocality and focus shift IOLs - theoretical aspects HULL CC–London
08:33	6142	Clinical use of multifocal and focus shift IOLs BARRAQUER RI, MICHAEL R–Barcelona
08:51	6143	Straylight effects in diffractive multifocal IOL compared to monofocal IOL NUIJTS RMMA, FRANSSSEN L, DE VRIES NE, TJIA KF, VAN DEN BERG TJTP–Maastricht, Amsterdam, Zwolle
09:09	6144	Visiogen Synchrony dual-optic lens AUFFARTH GU–Heidelberg
09:27	6145	Innovative IOL accommodative technologies: NuLens and TekClear ALIO SANZ JL, BEN-NUN J–Alicante

Mediterranea I **LV Prasad Eye Institute:** 08:15 – 09:45
A non-profit comprehensive centre for community eye care in India
 Workshop D BALASUBRAMANIAN



08:15	6151	Introduction RAO GN–Hyderabad
08:20	6152	Epidemiological study of the blindness burden in the state of AP, India KHANNA R–Hyderabad
08:35	6153	Molecular and functional genetics of inherited eye disorders in India KANNABIRAN C–Hyderabad
08:50	6154	Stem cell therapy at LVPEI SANGWAN V–Hyderabad
09:05	6155	Clinical research and trials SANGWAN V–Hyderabad
09:20	6156	Outreach programmes of LVP RAO GN–Hyderabad
09:35	6157	"Vision care at all levels: From bench to bedside to the community" - A working model by L. V. Prasad Eye Institute, Hyderabad, India BALASUBRAMANIAN D, KANNABIRAN C, KHANNA R, RAO GN–Hyderabad

Adria **PO: OOG: Protocols 1** 08:15 – 09:45
 Joint M. Edoardo MIDENA



08:15	6161	Upper eyelid tumour LOEFFLER KU–Bonn
08:27	6162	Natural killer/T-cell lymphoma with primarily orbital involvement: case report NOVAK ANDREJIC K, DRNOVSEK OLUP B, PECARIC MEGLIC N, BRACKO M, JEZERSEK NOVAKOVIC B
08:39	6163	Topical 5-FU vs. mitomycin C in conjunctival squamous cell tumours PE'ER J, MIDENA E–Jerusalem, Padova
08:51	6164	Change of the diagnosis after retinal involvement in "CNS lymphoma" SOUCEK P, SOUCKOVA I
09:03	6165	Choroidal collision tumour COUPLAND SE, DAMATO BE–Liverpool
09:15	6166	Fundus autofluorescence imaging of choroidal tumors PILOTTO E, PARROZZANI R, MIDENA E–Padova
09:27	6167	Panoramic ICG and angiography in ocular oncology: new observations ZOGRAFOS L–Lausanne

Europa A ***RV: Screening of diabetic retinopathy: facts and perspectives*** 11:30 – 13:00
SJS Stela VUJOSEVIC, Edoardo MIDENA

11:30	6211	Diabetic retinopathy : facts and resources MIDENA E–Padova
11:52	6212	Methods of screening VUJOSEVIC S–Rome
12:14	6213	Timing of diabetic retinopathy screening STEFANSSON E–Reykjavik
12:36	6214	The Moorfields diabetes survey: lessons learnt PETO T, POWLING A, DIABETES RETINOPATHY SCREENING TEAM THPCT–London

Europa B ***How to get your work published ?*** 11:30 – 13:00
Workshop Uwe PLEYER

The goal of this course will be to provide some keys to write a high quality paper that will help to transform innovative ideas into a research article. The panelists will discuss major aspects of the editorial process including basic decisions: where to submit the work, how to organize and prepare a manuscript, how to deal the review process in particular the revision process for eventual resubmission.

The panelists will raise the discussion on issues like:

- How to choose a journal ?
- How to organize your paper ?
- What are the characteristics of a good manuscript ?
- Delayed response: When is it appropriate to ask for the status of your manuscript ?
- How to interpret the letter from the editor ?
- How to write a good reply to the reviewers ?
- What to do when your paper is rejected ?
- When can it be appropriate to request a reevaluation of a rejected paper ?

In addition, the personal view from an authors and editors perspective will be given in a vivid discussion with the participants.

Emerald I ***COS: Ocular surface*** 11:30 – 13:00
FP Harminder S DUA, Mario NUBILE

11:30	6231	In vivo confocal microscopy of abnormal cornea: a clinical and pathological correlation ALOMAR TS, LOWE J, DUA HS–Nottingham
11:42	6232	In vivo confocal microscopy in the diagnosis of corneal conjunctivalization LANZINI M, NUBILE M, CALIENNO R, COLESANTI E, CIAFRE M, CURCIO C, MASTROPASQUA L–Chieti-Pescara
11:54	6233	Antimicrobial peptides expression in activated human corneal keratocytes MUSHTAQ F, MOHAMMED I, TINT NL, HOPKINSON A, DUA HS–Nottingham
12:06	6234	Diagnostic and therapeutic applications of alcohol delamination (ALD) of the corneal epithelium RAJ A, SAID DG, RAJ DEV, DUA HS–Nottingham
12:18	6235	Amniotic membrane transplantation (AMT): Implications for corneal wound healing SAID DG, NUBILE M, HOPKINSON A, GRAY T, LOWE J, DUA HS–Nottingham, University of Chieti-Pescara
12:30	6236	Comparison between liposomes spray and non preserved tears substitutes in patients with meibomian gland dysfunction LANGMAN ME, AMOUROUX GICQUEL N, GICQUEL JJ–St Jean d'Angély, Villeneuve la Comtesse, Poitiers
12:42	6237 <i>rf</i>	In vitro evaluation of adhesion of adipose-derived adult stem cells to chitosan for the treatment of ocular surface pathologies PASTOR S, ALIO SANZ JL, GAMBOA-MARTINEZ TC, ARNALICH-MONTIEL F, DE MIGUEL MP, GOMEZ-RIBELLES JL, GALLEGO-FERRER G–Alicante, Valencia, Madrid
12:48	6238 <i>rf</i>	No consequence of dietary omega-3 polyunsaturated fatty acid deficiency on the severity of scopolamine-induced dry eye CREUZOT CP, VIAU S, PASQUIS B, MAIRE MA, BRETILLON L, GREGOIRE S, ACAR N, BRON AM, JOFFRE C–Dijon
12:54	6239 <i>rf</i>	Cyanoacrylate tissue gluing in corneal perforations associated with herpetic keratitis JHANJI V, MOORTHY S, BELTZ J, CONSTANTINOU M, VAJPAYEE RB–Melbourne
13:00	623a <i>rf</i>	Red eye multimedia teaching tool PETRICEK P, ANDRAS B, HIGAZY M, NEMETH J, PROST ME–Zagreb, Debrecen, Egypt, Budapest, Warsaw

Emerald II SIS	PBP: Nutrition and the eye - Potential role of supplementation Leopold SCHMETTERER	11:30 – 13:00
-------------------	--	---------------



11:30	6241	Lutein supplementation - the rationale NOLAN JM, LOANE E, LOUGHMAN J, BEATTY S—Waterford, Dublin
11:52	6242	Lutein supplementation - the mechanisms WELGE-LUSSEN U—München
12:14	6243	Reducing mitochondrial dysfunction and ganglion cell death: focus on use of α -lipoic acid OSBORNE NN—Oxford
12:36	6244	Role of oxidative stress in glaucoma ERB C—Berlin

Mediterranea I SIS	MBGE: Imaging techniques in population-based epidemiologic studies Marcela VOTRUBA, Seang Mei SAW	11:30 – 13:00
-----------------------	---	---------------

11:30	6251	Retinal microvascular signs as biomarkers of cardiovascular disease KAWASAKI R—East Melbourne
11:45	6252	Spherical equivalent versus AL/CR ratio - a tool for classifying refractive error MORGAN IG, ROSE KA—Canberra, Sydney
12:00	6253	The predictive risk factors and grading of pathologic myopia for retinal photographs SAW SM—Singapore
12:15	6254	The measurement of light intensities and effects on myopia development ROSE KA—Sydney
12:30	6255	Cornea biomechanical characteristics measured using the Ocular Response Analyzer in Singapore children LIM LS, GAZZARD G, CHAN Y, FONG A, KOTECHA A, SIM E, TAN D, TONG L, SAW SM—Singapore, London
12:45	6256	Grading techniques for the assessment of retinal GROSSO A—Torinese

Adria FP	PO: Pathology / Oncology 2 Charlotta ALL-ERIKSSON, Steffen HEEGAARD	11:30 – 13:00
-------------	---	---------------

11:30	6261	Infrared reflectance in choroidal melanoma and its correlation with fundus autofluorescence AMSELEM L, PULIDO JS, GUNDUZ K—Rochester
11:42	6262	Follow up of a slowly growing melanocytic lesion during 12 years VAN GINDERDEUREN R, BLANCKAERT J, LEYS A, SPILEERS W, VAN DEN OORD J—Leuven
11:54	6263	Photodynamic therapy of circumscribed choroidal hemangioma: comparison of dosage and timing URBAN F, PILOTTO E, PARROZZANI R, MIDENA E—Padova
12:06	6264	Regulatory T-cells induce an immune escape in a murine model of primary intraocular B-cell lymphoma TOUITOU V, BODAGHI B, DAUSSY C, DONNOU S, LEHOANG P, FRIDMAN WH, FRIDMAN C, FISSON S—Paris
12:18	6265	Structural and cellular diagnosis of ocular surface squamous neoplasia using in-vivo confocal microscopy PARROZZANI R, GHIRLANDO A, CORTESE M, MIOTTO S, URBAN F, MIDENA E—Padova
12:30	6266	An unusual lid/orbital tumour in infants IRION LD, BONSHK R, LEATHERBARROW B, BHATT P, MCCORMICK A—Manchester
12:42	6267	Foreign body conjunctival granuloma MACHOWICZ-MATEJKO E, RYMGAYLLO-JANKOWSKA B—Lublin

Europa A CIS	Lunchtime CIS by SANTEN - In search of improved glaucoma therapy Hannu UUSITALO	13:05 – 14:05
-----------------	---	---------------



13:05	6271	Unmet needs in the treatment of glaucoma related to compliance, tolerability and concomitant dry eye HOLLO G—Budapest
13:15	6272	Ocular surface and glaucoma therapy BROADWAY D—Norwich
13:25	6273	Switching from latanoprost to preservative-free tafluprost KAARNIRANTA K—Kuopio
13:35	6274	Overview of the profile of tafluprost UUSITALO HMT—Tampere

Europa A ***RV: Antiangiogenic treatments and PDT*** 14:15 – 15:45
 FP Gisèle SOUBRANE, Jean - Jacques DE LAEY

- 14:15 6311 Anti-PlGF (placental growth factor) as a safer alternative for anti-VEGF in the treatment of age-related macular degeneration (AMD)?
 VAN DE VEIRE S, VINOES S, PERIC A, MAZZONE M, MOONS L, CARMELIET P, STALMANS I—Leuven, Baltimore
- 14:27 6312 The in vitro effects of anti-angiogenic AMD treatments on human choroidal endothelial cells
 STEWART EA, AMOAKU WMK—Nottingham
- 14:39 6313 Intravitreal bevacizumab versus triamcinolone acetonide for exudative age-related macular degeneration
 LIBONDI T, JONAS JB, IHLOFF AK, HARDER B, KREISSIG I, SCHLICHTENBREDE F, SPANDAU UHM, VOSSMERBAEUMER U—Mannheim
- 14:51 6314 Intravitreal bevacizumab (Avastin®) in wet AMD: the OCT-assisted “wait and see” management
 NERI P, HERBORT CP—Ancona, Lausanne
- 15:03 6315 Analysis of intravitreal ranibizumab injections effects on exudative reaction complicating subfoveal choroidal neovascular age related macular degeneration (AMD)
 GONZALEZ CG—Toulouse
- 15:15 6316 Lessons learned in setting up a reading centre network for high volume grading in Europe
 PATTON WP, MULDER KA, HARDING SP, CHAKRAVARTHY U, PETO T—Belfast, Liverpool, London
- 15:27 6317 Photodynamic therapy for choroidal neovascularization secondary to choroidal nevi
 GAMBRELLE J, MAUGET FAYSSÉ M, QUARANTA EL, MAFTOUHI M, GRANGE JD—Lyon
- 15:39 6318 Investigation of the effect of the Alcon AcrySof Natural (ANIOL) blue-filtering intraocular lens on macular pigment
rf O'REILLY P, LOANE E, LOUGHMAN J, BEATTY S, NOLAN J—Waterford

Europa B ***IM: Progress in immunology / microbiology - Research*** 14:15 – 15:45
 FP Uwe PLEYER, Francois WILLERMAIN

- 14:15 6321 RNase-7 expression mediated by IL-1 beta in human ocular surface cells via multiple signalling pathways
 MOHAMMED I, ABEDIN A, HOPKINSON A, DUA HS—Nottingham
- 14:27 6322 Aquaporins expression on blood retinal barrier cells during experimental autoimmune uveitis
 MOTULSKY E, WILLERMAIN F, JANSSENS S, KOCH P, LIENART M, VANBELLINGHEN A, CASPERS L, MARTIN-MARTINEZ M, DELPORTE C—Brussels
- 14:39 6323 Expression of galectin molecules in intraocular tissue and inflammation
 YAMAKI K, AMANO M—Inba, Sapporo
- 14:51 6324 Expression pattern of antimicrobial peptides (AMPs) in acanthamoeba keratitis
 OTRI AM, ABEDIN A, MOHAMMED I, PANJWANI N, HOPKINSON A, DUA HS—Nottingham, Boston
- 15:03 6325 Profile of antimicrobial peptides (AMPs) at the ocular surface
 ABEDIN A, OTRI M, MOHAMMED I, HOPKINSON A, DUA HS—Nottingham
- 15:15 6326 Microbiological culture and panbacterial PCR yield of diluted or undiluted vitreous from vitrectomy are comparable in acute postsurgery endophthalmitis (FRIENDS group)
 CHIQUET C, VINH MOREAU GAUDRY V, CORNUT PL, CREUZOT CP, THURET G, DENIS P, MAURIN M, VANDENESCH F, BRON AM, PECHINOT A, ROMANET JP—Grenoble, Lyon, Dijon, Saint-Etienne
- 15:27 6327 Lack of association of the Toll-like receptor 4 gene polymorphisms Asp299Gly in Italian patients with Fuchs uveitis
rf CIMINO L, FARNETTI E, CASALI B, NICOLI D, BOIARDI L, CAPPUCCINI L, SALVARANI C—Reggio Emilia

Emerald I ***COS: Keratoprotheses*** 14:15 – 15:45
 SIS Christopher LIU

- 14:15 6331 The narrowing choice of keratoprotheses
 LIU C—Brighton
- 14:33 6332 Developing a recovery psychological model for patients undergoing KPro surgery
 BUSUTTIL A, LIU C—Brighton
- 14:51 6333 More than 50 years of experience with keratoprotheses
 BARRAQUER J—Barcelona
- 15:09 6334 Boston KPro experience in Barcelona
 DE LA PAZ M, ALVAREZ DE TOLEDO J, MICHAEL R, BARRAQUER R, BARRAQUER J—Barcelona
- 15:27 6335 Biosynthetic corneas - an update
 FAGERHOLM P, LAGALI N, GRIFFITH M—Linköping, Ottawa

Poster session 3

15:50-16:40

Europa C

Posters on pages 62-63

Retina/Vitreous - Pathology/Oncology - Immunology/Microbiology - in Europa C

Charles RIVA, Jean-Jacques DE LAEY, Einar STEFANSSON, Jan Ulrik PRAUSE, R. BONSHK, Friederike MACKENSEN, François WILLERMAIN

Emerald II **PBP: Physiology / Pharmacology 1** 14:15 – 15:45
 FP Leopold SCHMETTERER, Anthony J. BRON

14:15	6341	Retinal blood flow in patients with diabetes during normalized insulin and glucose plasma levels WEIGERT G, POLSKA E, GARHOFER G, SCHMETTERER L–Vienna
14:27	6342	Retinal vessel pulse amplitude in health and disease PAQUES M, TICK S, GENEVOIS O, ADAM P, SAHEL JA–Paris, Rouen
14:39	6343	Is pulse-wave velocity in retinal arteries of healthy volunteers age dependent? KOTLIAR KE, LANZL IM–Munich
14:51	6344	Association between flicker-induced vasodilatation and flow mediated vasodilatation in patients with diabetes, systemic hypertension and hypercholesterolemia GARHOFER G, PEMP B, PETZL U, WOLZT M, SCHMETTERER L–Vienna
15:03	6345	A new invasive method of measuring pulsatile ocular blood flow DASTIRIDOU AI, TSILIMBARIS MK, GINIS HS, DE BROUWERE D, PALLIKARIS IG–Heraklion
15:15	6346	Retinal oximetry: clinical studies HARDARSON SH, TRAUASTASON S, GOTTFREDSDOTTIR MS, KARLSSON RA, HALLDORSSON GH, EYSTEINSSON T, BEACH JM, BENEDIKTSSON JA, STEFANSSON E–Reykjavik
15:27	6347 <i>rf</i>	The pulsatile ocular blood flow (POBF) in patients with sleep apnea syndrome (SAS) NOWAK MS, KLYSIK AB, WASZCZYKOWSKA A, GOS R, SMIGIELSKI J–Lodz
15:33	6348 <i>rf</i>	Pharmacokinetics and ocular tissue penetration of VEGF trap after intravitreal injection in rabbits STRUBLE C, KOEHLER-STECK E, ZIMMER E, TU W–Madison WI, Tarrytown NY
15:39	6349 <i>rf</i>	Retinal arteriolar vascular reactivity to incremental changes in hyperoxic stimuli during isocapnia HUDSON C, TONG A, HAN J, MARDIMAE A, WONG T, FISHER J–Toronto

Mediterranea I **MBGE: Genotypes & Phenotypes** 14:15 – 15:45
 FP Susan DOWNES, Alison HARDCASTLE

14:15	6351	The novel Col8a2G257D mutant mouse line Aca23 – a model for endothelial corneal dystrophies PUK O, AHMAD N, GRAW J–Neuherberg
14:27	6352	Hereditary opacification of the anterior and posterior cornea: a new corneal dystrophy? LAGALI NS, FAGERHOLM P–Linköping
14:39	6353 	Genetics of high myopia in Polish families GAJECKA M, SWAPAN N, PODFIGURNA-MUSIELAK M, MRUGACZ M, FRAJDEMBERG A, UPPALA R, BEJANI BA, RYDZANICZ M–Poznan, Oklahoma City, Leszno, Bialystok, NE, Spokane
14:51	6354	DNA profile strongly associated with exudative age-related macular degeneration CARTER JG, ARISTODEMOU P, CHERRY J, CHURCHILL AJ–Bristol
15:03	6355	The role of factor h macular degeneration secondary to pathologic myopia BARBAZETTO I, YANNUZZI L, ALLIKMETS R–New York
15:15	6356	Distribution and clinical peculiarities of monogenic retinal dystrophies at the Center for Ophthalmology, University of Tuebingen PROKOFYEVA E, WILKE R, LOTZ G, TROEGER E, STRASSER T, ZRENNER E–Tuebingen
15:27	6357	Phenotyping parallel visual pathways in autosomal dominant optic atrophy REIS AA, VIEGAS T, MATEUS CD, SILVA ED, CASTELO-BRANCO M–Coimbra

Adria **PO: OOG : Protocols 2** 14:15 – 15:45
 Joint M. Edoardo MIDENA



14:15	6361	OCT and small melanocytic tumors GRANGE JD, GARNIER S, KODJIKIAN L, BENBOUZID F–Lyon
14:27	6362	PDT for amelanotic choroidal melanoma BLASI MA, VALENTE P, TIBERTI AC, SCUPOLA A, BALESTRAZZI E
14:39	6363	Modified enucleation for choroidal melanoma with large extrascleral extension PARROZZANI R, URBAN F, GURABARDHI M, MIDENA E–Padova
14:51	6364	A relevant panel of human uveal melanoma xenografts directly established from primary and/or metastatic patient's tumor for pharmacological preclinical assays DESJARDINS L, NEMATI F, SASTRE X, COUTURIER J, PIPERNO-NEUMANN S, LANTZ O, DAHIANI A, ARRUFAT S, POUPON MF, DECAUDIN D–Paris
15:03	6365	Small, fatal choroidal melanoma: a retrospective study of patients treated in Liverpool DAMATO B, COUPLAND S–Liverpool
15:15	6366	Ten smallest melanomas that killed the patient – a very long-term analysis KIVELÄ T, KUJALA E, TOIVONEN P–Helsinki

Europa A		<i>RV: Macular imaging - Macular edema</i>	17:45 – 19:15
FP		Charles RIVA, Frank VERBRAAK	
17:45	6411	Mapping of photoreceptor dysfunction using high resolution, three-dimensional spectral optical coherence tomography SIKORSKI BL, SZKULMOWSKI M, KALUZNY JJ, SZKULMOWSKA A, KOWALCZYK A, WOJTKOWSKI M—Bydgoszcz, Torun	
17:57	6412	Assessment of macular pigment optical density (MPOD) among patients with wet age-related macular degeneration (AMD) in one eye and the dry form in the fellow eye TSIKA CI, KONTADAKIS GA, MAKRIDAKI M, PLAINIS S, MOSCHANDREAS J, TSILIMBARIS MK—Heraklion, Manchester	
18:09	6413	Assessment of fixation locus with microperimetry and OCT in patients with Stargardt disease LENASSI E, JARC-VIDMAR M, HAWLINA M—Ljubljana	
18:21	6414	Macular retinal thickness in amblyopic and normal eyes of children evaluated with spectral domain OCT KOK PHB, BESSELINK YC, DE KINKELDER R, VAN DIJK HW, VAN VELTHOVEN MEJ, VERBRAAK FD—Amsterdam	
18:33	6415	A new slitlamp mounted Fourier domain-OCT (SL-FD-OCT) for flexibility in daily clinical practice VERBRAAK FD, KOK PHB, VAN VELTHOVEN MEJ, VAN DIJK HW, FABER DJ, DE VRIES HR, VAN LEEUWEN AG—Amsterdam	
18:45	6416	Use of intravitreal Ketorolac tromethamine for postoperative cystoid macular edema TSILIMBARIS MK, TSIKA CI, PANDELEONIDIS V, PANAGIOTOGLOU T, KYMIONIS G—Heraklion, Crete	
18:57	6417 <i>rf</i>	Orbital floor triamcinolone acetonide in the treatment of pseudophakic cystoid macular oedema SULEMAN H, MATHEW M, LAKSHMANAN A, ABEDIN A, ORR GM—Nottingham	

Europa B		<i>IM: Immunology / Microbiology: Clinical aspects</i>	17:45 – 19:15
FP		Piergiorgio NERI, Ilknur TUGAL-TUTKUN	
17:45	6421	Ophthalmic microsporidiosis: Emerging pathogens or emerging awareness? BONSHEK RE, IRION LD, CURRY A—Manchester	
17:57	6422	Efficacy and tolerance of early high-dose corticosteroid therapy in Vogt-Koyanagi-Harada disease BOUCHENAKI N, HERBORT CP—Lausanne	
18:09	6423	Interest of an interferon-gamma release assay for diagnosing tuberculosis-related ocular inflammation GINEYS R, TRAD S, TERRADA C, LE THI HUONG DU, FARDEAU C, CASSOUX N, LE HOANG P, BODAGHI B—Paris	
18:21	6424	Lyme borreliosis: different ocular aspects of the same disease in North-West of Italy ALLEGRI P, MASTROMARINO A, RISSOTTO R, MURIALDO U—Genova	
18:33	6425	Developments in diagnosing the tubulointerstitial nephritis and uveitis (TINU) syndrome MACKENSEN F, DAVID F, SCHWENGER V, LEVINSON R, RAJALINGAM R, BECKER MD, MARTIN TM, ROSENBAUM JT—Heidelberg, Los Angeles, CA, Portland, OR	
18:45	6426 <i>rf</i>	Presentation of orbital aspergillosis MISSOTTEN GS, DE KEIZER RJW—Leiden, Antwerp	
18:51	6427 <i>rf</i>	Management of ocular disease in epidermolysis bullosa variant: Laryngo-onycho-cutaneous (LOC) syndrome ARALIKATTI A, KADYAN A, SHAH S—Birmingham	

Emerald I		<i>LC: New IOL technology - new modalities</i>	17:45 – 19:15
SIS		Per SÖDERBERG, Christopher LIU	
17:45	6431	IOL filters, is there an optimal absorption? SÖDERBERG PG, ZOEGA G—Uppsala	
18:03	6432	Aspheric optics, theoretical considerations UNSBÖ P—Stockholm	
18:21	6433	Clinical experience in aspheric IOLs - a review of the world literature LIU C—Brighton	
18:39	6434	Purkinje based IOL centration TASSIGNON MJ—Antwerp	
18:57	6435	Long-term results of cataract surgery with implantation of a mechanically, reversibly adjustable intraocular lens: *Acri.Tec AR-1 PC/IOL JAHN CE, STEFIKOVA K—Kempten	

Emerald II **PBP: Physiology / Pharmacology 2** 17:45 – 19:15
 FP Neville OSBORNE, Alain BRON

17:45	6441	Effect of dietary omega-3 and omega-6 fatty acids on IOP elevation, electroretinographic changes and retinal ganglion cell loss in a rat model of glaucoma induced by laser BRON AM, SCHNEBELEN C, SALINAS-NAVARRO M, ACAR N, PASQUIS B, CREUZOT CP, VILLEGAS-PEREZ MP, VIDAL-SANZ M, BRETILLON L—Dijon, Murcia
17:57	6442	Effects of antioxidants on ocular blood flow in the LPS-induced inflammation model in humans FUCHSJÄGER-MAYRL G, POLSKA E, MINNICHMAYER A, WEIGERT G, RESCH H, PEMP B, LASTA M, SCHMETTERER L—Vienna
18:09	6443	No-induced retinal vasodilatation is maintained in type 1 diabetes PEMP B, GARHOFER G, WEIGERT G, KARL K, WOLZT M, SCHMETTERER L—Vienna
18:21	6444	Intracameral moxifloxacin (Vigamox): in vitro safety on human ocular cells KERNT M, NEUBAUER AS, LIEGL R, DE KASPAR H, EIBL KH, LACKERBAUER CA, ALGE CS, KAMPIK A—Munich, Stanford
18:33	6445	Lipid and fatty acid profile of the retina, RPE/choroid and lacrimal gland, and associations with dietary fatty acids in human subjects BRETILLON L, THURET G, GREGOIRE S, ACAR N, JOFFRE C, BRON AM, GAIN P, CREUZOT CP—Dijon, Saint Etienne, Dijon
18:45	6446	Automatic estimation of the arteriolar-to-venular diameter ratio (AVR) in retinal images RUGGERI A, TRAMONTAN L, GRISAN E—Padova
18:57	6447	Changes in ocular signs and symptoms when switching from preserved latanoprost 0.005% to preservative-free tafluprost 0.0015%: phase IIIb study in patients with open-angle glaucoma or ocular hypertension UUSITALO HMT, CHEN E, PFEIFFER N, BAUDOUIN C, ROPO A—Tampere, Stockholm, Mainz, Paris
19:09	6448	Comparison of Lucentis monotherapy vs. combination therapy for neovascular AMD PHAN AP, JACOBS DJ, BOWMAN KB, FORSEY ZF—Winston-Salem

Mediterranea I **International networking in ophthalmology research** 17:45 – 19:15
 Workshop Andrzej GRZYBOWSKI

17:45	6451	Scientific Community - contact networking, research collaboration on a global scale GRACZYNSKI M—Warsaw
18:15	6452	Open evaluation of science: can we simply say "no, thank you?" STEFANO G—Old Westbury
18:45	6453	Community Services enter professional territory - what is in there for us? GRZYBOWSKI A—Poznan

Adria **PO: OOG: Business meeting** 17:45 – 19:15
 Joint M. Edoardo MIDENA



General Assembly
 16:45 – 17:40
Europa A

EVER General assembly and prize giving

Agenda

1. President's address
2. Minutes of the General Assembly 2007
3. Approval by the General Assembly of the proposal of the Board to amend the Bye Laws – 'Nomination of scientific representatives' (art. 8.01).
4. Report of the General Secretary
5. Report of the Programme Secretary
6. Report of the Treasurer, approval of the accounts 2007, discharge to the directors, budget for 2008
7. Results of the elections
8. Presentation of the BOARD 2008-2009
9. President Elect, Vice President Elect
10. Presentation and report of the scientific sections meetings
11. Future congresses
12. Prize giving
13. Miscellanea



Social
 20:00-23:00
 in S. Bernardin

EVER Farewell dinner
 with musical entertainment by Kontrabant
www.kud-kontrabant.si



- 601 Philatelic aspects on WHO Year Glaucoma 2008
SVEDBERGH BOC—Uppsala

RETINA / VITREOUS

Moderators: Charles RIVA, Jean-Jacques DE LAEY, Einar STEFANSSON

- 602 Investigation of the effect of the Alcon AcrySof Natural (ANIOL) blue-filtering intraocular lens on macular pigment
rf
O'REILLY P, LOANE E, LOUGHMAN J, BEATTY S, NOLAN J—Waterford
- 603 Orbital floor triamcinolone acetonide in the treatment of pseudophakic cystoid macular oedema
rf
SULEMAN H, MATHEW M, LAKSHMANAN A, ABEDIN A, ORR GM—Nottingham
- 604 Flame-shaped hemorrhage seen in diabetic retinopathy is indicative of macular ischemia — KABASAWA SK, SIBUYA MS, YONEYA SY—Saitama
- 605 Intravitreal bevacizumab for vitreous hemorrhage
LIBONDI T, JONAS JB, VON BALTZ S, VOSSMERBAEUMER U—Mannheim
- 606 Electroretinography and macular edema in diabetic retinopathy
SHAMSHINOVA AM, ARAKELYAN MA, MANSURINA NB, KARLOVA IZ—Moscow
- 607 Posterior sub-tenon injection of triamcinolone acetonide as a pretreatment of focal laser photocoagulation for diabetic macular edema
OGATA N, SHIMA C, MINAMINO K, YOSHIKAWA T, MATSUYAMA K, MATSUMURA M—Moriguchi, Hirakata
- 608 Calcium dobesilate prevents changes in tight junction proteins in the retina induced by diabetes
LEAL EC, MARTINS J, CHIAVAROLI C, CUNHA-VAZ J, AMBROSIO AF—Coimbra, Meyrin
- 609 Effect of diabetes mellitus on NGF and NGF-receptor distribution in retinal ganglion cells and vascularity in adult rats
COLAFRANCESCO V, BUCCI M, ALOE L—Rome
- 610 A pilot study of prevalence of diabetic retinopathy in diabetic patients using non-mydiatic retinography and telemedicine
CASTRO MCR, VLEMING EN, TEUS M—Alcala de Henares
- 611 VEGF/Ang-2 imbalance: the crosslinking between methylglyoxal and vascular dysfunction in diabetic retinopathy
BENTO C, FERNANDES R, PEREIRA P—Coimbra
- 612 Utility of retinal photography in the diagnosis of diabetic macular edema
IBANEZ J, MATEO OROBIA AJ, PEIRO C, PEREZ D, VALYI S, ROJO M, SAINZ A, CRISTOBAL JA—Zaragoza
- 613 Evolution of the laser treatment of diabetic retinopathy (DR): from laser surgery to laser therapy
DORIN G, BUZAWA D, MERCEREAU J—Mountain View, California
- 614 Retinal fiber layer measured by oct in patients with type I diabetes without retinopathy — PINILLA I, GARCIA-MARTIN E, IDOPE CORTA M, GIL ARRIBAS L, FERRERAS A, HONRUBIA FM—Zaragoza
- 615 The difference in focal photocoagulation treatment decisions of clinically significant macular edema between different medical retina specialists
VAN DIJK HW, KOK PHB, SCHLINGEMANN RO, LESNIK OBERSTEIN SY, TAN HS, ABRAMOFF MD, VERBRAAK FD—Amsterdam, Iowa City
- 616 Nerve fiber layer thickness measured with polarimetry (GDX) in patients with type I diabetes — IDOPE CORTA M, GARCIA-MARTIN E, GIL ARRIBAS L, FERRERAS A, ABECIA E, PINILLA I—Zaragoza
- 617 Non mydiatic retinograph for the diagnosis and follow-up of diabetic retinopathy — PEREZ GARCIA D, MATEO OROBIA AJ, IBANEZ J, PEIRO C, SAINZ A, CRISTOBAL JA—Zaragoza
- 618 Intravitreal pegaptanib sodium (Macugen) for diabetic macular edema
QUERQUES G, BUX AV, MARTINELLI D, IACULLI C, DELLE NOCI N—Foggia, Bari
- 619 Specificity and sensitivity of Heidelberg retina tomograph macular edema maps and the effect of exudate and hemorrhage
HUDSON C, SU L, KANCHANARANYA N, GUAN K, LAM WC, DEVENYI RG, MANDEL CORN M, HARVEY P, FLANAGAN JG—Toronto
- 620 TOPCON 3D OCT 1000 reproducibility in normal and diabetic patients
PEROVSEK D, URBANCIC M, HAWLINA M—Ljubljana
- 621 Choroideal neovascularisation in age related maculopathy and high myopia. A Laser Flare-Cell Meter study
CELLINI M, RICCETTI A, LEONETTI P, CAMPOS EC—Bologna
- 622 Improvements in visual acuity within one year following intravitreal bevacizumab in neovascular age-related macular degeneration
JAKI MEKJAVIC P, KRAUT A, URBANCIC M, LENASSI E, HAWLINA M—Ljubljana
- 623 A novel murine model of aging of the human retina
BRETILLON L, ACAR N, SEELIGER MW, MAIRE MA, GREGOIRE S, JUANEDA P, MARTINE L, JOFFRE C, BRON AM, CREUZOT CP—Dijon, Tuebingen
- 624 Intravitreal injection of bevacizumab to treat choroidal neovascularization with large submacular hemorrhage secondary to age-related macular degeneration
DI STEFANO G, IACONO P, BATTAGLIA PARODI M, RAVALICO G—Trieste, Rome
- 625 Intravitreal bevacizumab (Avastin) treatment in neovascular age-related macular degeneration: 6 months results
CIMBALAS A, BAGDONIENE R, SIRTAUTIENE R, LIVEIKIENE A, ASOKLIS R—Vilnius
- 626 Efficacy of pegaptanib sodium in occult or minimally classic
ZOURDANI A, HADDAD W, SOUIED E, COSCAS G, SOUBRANE G—Creteil
- 627 No functional vision improvement after intravitreal ranibizumab injections (IVT) for retrofoveal choroidal neovascular age-related macular degeneration, why? — GONZALEZ C—Toulouse
- 628 To investigate the effectiveness of transpupillary thermotherapy (TTT) for neovascular age-related macular degeneration (ARMD)
THIAGARAJAN M, MATTHEWS N—Portsmouth, Bournemouth
- 629 Preliminary reading centre concordance in OCT grading in the UK IVAN Study
PATTON WP, MULDREW KA, PETO T, LENFESTY P, HARDING SP, CHAKRAVARTHY U—Belfast, London, Liverpool
- 630 Treatment of myopic neovascularization with ranibizumab
EGEA ESTOPINAN MC, TORRON C, GUERRI MONCLUS N, BORQUE E, RUIZ O, FERRER E, HONRUBIA FM—Zaragoza
- 631 Evidence for association of HTRA1 promoter polymorphism in Polish patients with age-related macular degeneration
OLDAK M, SZAFLIK JP, MAKSYM RB, FRANSZCZYK M, SZAFLIK J, PIOSKI R—Warsaw
- 632 Effects of photodynamic therapy on subfoveal blood flow in neovascular age-related macular degeneration patients
CHIQUET C, VINH MOREAU GAUDRY V, ROMANET JP, HERA R, MILLET JY, GEISER M—Grenoble, Sion
- 633 Neovascular AMD; Effect of intravitreal ranibizumab on the retinal arteries
PAPADOPOULOU DN, MANGIORIS GF, MENDRINOS E, DONATI G, POURNARAS CJ—Geneva
- 634 Choroidal neovascularization management in uveitic patients – our experience
URBANCIC M, KRAUT A—Ljubljana
- 635 To investigate the association between visual acuity and visual function questionnaire in patients having ranibizumab treatment
THIAGARAJAN M, TRIKHA S—Portsmouth
- 636 Clinical features of serous pigment epithelial detachment using optical coherence tomography
CHOI M, YOU Y, LEE D, LEE J, CHO S—Seoul
- 637 Effect of paclitaxel labeled cationic liposomes (EndoTAG1) and succinyl-paclitaxel labeled cationic liposomes (EndoTAG SPA) in laser-induced choroidal neovascularisation (L-CNV) of mice — GROSS NJ—Freiburg
- 638 Subcutaneous nadroparin calcium in the treatment of retinal vein occlusion
PINNA A, SIMULA P, SALVO M, DEVILLA L, ZINELLU A, CARTA A—Sassari, Parma
- 639 Case of ischemic retinopathy induced by chemotherapy with paclitaxel and carboplatin — MATSUYAMA K, ANDO A, WADA M, OGATA N, NISHIMURA T—Osaka
- 640 Treatment of patients with central retinal vein occlusion by anticoagulation
REHAK M, LANGOVA K, FRIC E, REHAK J—Leipzig, Olomouc
- 641 Fast accurate measurement of macular pigment with a novel technique for setting flicker thresholds
BERENDSCHOT TJM, VAN DER VEEN LP, CARDEN D, MAKRIDAKI M, MURRAY IJ—Maastricht, Manchester
- 642 The relationship between macular pigment optical density and ApoE genotype
LOANE E, NOLAN JM, MCKAY G, STACK J, BEATTY S—Waterford, Belfast
- 643 Changes in macular pigment optical density and serum concentrations of lutein and zeaxanthin, in response to weight loss
KIRBY M, HARRISON M, BEATTY S, NOLAN J—Waterford

- 644 **Macular pigment and its contribution to spatial vision**
MUKUNDA CHAITANYA A, LOUGHMAN J, NOLAN JM, BEATTY S, O'DWYER V, DAVISON PA—Waterford, Dublin
- 645 **Quantifying the abnormal macular pigment distribution in macular telangiectasia type 2** — VAN DER VEEN LP, CHARBEL-ISSA P, STIJFS A, HOLZ FG, SCHOLL HPN, BERENDSCHOT TJM—Maastricht, Bonn
- 646 **Relationship between macular pigment and straylight on the retina**
PUELL MC, PEREZ-CARRASCO MJ, BARRIO AR, PALOMO-ALVAREZ C, SANCHEZ R—Madrid
- 647 **Macular pigment and its correlation with colour vision and SWAP perimetry**
DAVISON PA, LOUGHMAN J, SCANLON G, NOLAN J, BEATTY S—Dublin, Waterford
- 648 **Neuronal plasticity and macular edema**
TICK S, GIRMENS JF, SAHEL JA, PAQUES M—Paris
- 649 **Photodynamic therapy without verteporfin for central serous chorioretinopathy**
MATEO OROBIA AJ, IBANEZ ALPERTE J, SALINAS ALAMAN A, MATEO GABAS J, LAFUENTE N, CRISTOBAL JA—Zaragoza, Pamplona
- 650 **Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for central serous chorioretinopathy: a case series**
MAIER M, VALET V, FEUCHT N, FIORE B, WINKLER VON MOHRENFELS C, LOHMANN CP—Munich
- 651 **Dynamic phototherapy as a treatment of central serous chorioretinopathy**
BERTHOUT A, MALTHIEU D, JANY B, THOMAS F, MILAZZO S—Amiens
- 652 **EphB4 is expressed in preretinal neovascularization in a mouse model of oxygen-induced retinopathy**
EHLKEN C, MARTIN G, LEINWEBER M, HANSEN LL, AGOSTINI HT—Freiburg
- 653 **Indocyanine green-induced toxicity to retinal neurones in cultures is enhanced by light** — LASCARATOS G, OSBORNE NN—Oxford
- 654 **Morphological features of abnormal fundus autofluorescence (FAF) using Spectral Domain OCT** — PICCIRILLO V, SAVASTANO A, SBORDONE S, FORTE R, TAMBURRINI L, SAVASTANO MC, SAVASTANO S—Cassino, Naples, Rome
- 655 **Maculopathy associated with angioid streaks**
GUERRI MONCLUS N, TORRON FERNANDEZ-BLANCO C, EGEE ESTOPINAN MC, HONRUBIA F—Zaragoza
- 656 **Retinopathy in intravenous coaxial drug dependents**
ARAKELYAN MA, BARDEEVA YUN, RYABTSEVA AA—Moscow
- 657 **Retinal thickness and age - optical coherence tomography study**
RADOVIC N, BEKO M, GOLUBOVIC N—Belgrade
- 658 **Visual loss following scoliosis surgery. A case report**
TODOROVA MG, MESSERLI J, FLAMMER J, ORGUL S—Basel

PATHOLOGY / ONCOLOGY

Moderators: Jan Ulrik PRAUSE, Richard BONSHK

- 659 **Malignancies after Tacrolimus therapy in the management of ocular inflammatory disease** — MATHEW MANU, RAJ D, MOHAMMED K, ABEDIN A, SULEMAN H, DUA HS—Nottingham
- 660 **Non-surgical treatments to periocular basal cell carcinomas. Imiquimod versus photodynamic therapy**
GARCIA MARTIN E, IDOPE CORTA M, GIL ARRIBAS L, FERNANDEZ TIRADO J, ALFARO J, PUEYO V, PINILLA LOZANO I—Zaragoza
- 661 **Apocrine hidradenocarcinoma in eyelid with corneal invasion**
EGEE ESTOPINAN MC, SOTA P, GUERRI MONCLUS N, ALFARO J, BORQUE E, PRIETO E—Zaragoza
- 662 **Clinical presentation of reactive lymphoid hyperplasia (RLH) on the ocular surface – report of 6 cases**
HERWIG MC, FISCHER HP, HOLZ FG, LOEFFLER KU—Bonn
- 663 **Lymphoma of the conjunctiva**
MISSOTTEN GS, DE WOLFF-ROUENDAAL D, DE KEIZER RJW—Leiden
- 664 **Imaging features of orbital and ocular adnexal lymphomas**
RYSANEK B, MOURIAUX F—Caen
- 665 **International review of orbital diffuse large B cell lymphoma**
IRION LD, BONSHK R, LEATHERBARROW B, MCCORMICK A, PATEL I, MADGE S, PRABHAKARAN V, SELVA D, HATEF E, ESMAELI B, MENON V, HONAVAR S—Manchester, Adelaide, Houston, Hyderabad
- 666 **Isolated optic nerve involvement in chronic lymphocytic leukaemia**
BONSHK RE, COOK A, IRION LD—Manchester

- 667 **Spectrum of conjunctival tumors in an ocular oncology unit: review of 314 cases**
PORTERO-BENITO A, SANCHEZ-MANNARELLI F, CARRENO-SALAS E, MUNOZ MF, SAORNIL MA—Valladolid
- 668 **Iodine -125 episcleral brachytherapy for uveal melanoma : 133 cases**
CEBALLOS GARCIA A, GARCIA ALVAREZ C, SAORNIL MA, LOPEZ-LARA-MARTIN F, MUNOZ MF, DE FRUTOS-BARAJA JM, ALMARAZ A, GIRALDO-ARGÜELLO A—Valladolid
- 669 **Case of choroidal melanoma with massive extraocular extension through sclera**
KIMURA M, OGATA N, TAKAHASHI K, SHIMA C, NISHIMURA T—Moriguchi, Hirakata
- 670 **Imaging techniques in the dosimetry of episcleral brachytherapy**
DE FRUTOS-BARAJA JM, DE LUIS-PEREZ FJ, SAORNIL-ALVAREZ MA, LOPEZ-LARA-MARTIN F, CEBALLOS GARCIA MA, GARCIA-ALVAREZ C—Valladolid
- 671 **Electronic vs paper based clinical pathway for episcleral brachytherapy. Preliminary results**
DE FRUTOS-BARAJA JM, DE LUIS-PEREZ FJ, SAORNIL-ALVAREZ MA, LOPEZ-LARA-MARTIN F, CEBALLOS-GARCIA MA, GARCIA-ALVAREZ C, ANDRES RODRIGUEZ C—Valladolid

IMMUNOLOGY / MICROBIOLOGY

Moderators: Friederike MACKENSEN, François WILLERMAIN

- 672 **Lack of association of the Toll-like receptor 4 gene polymorphisms Asp299Gly in Italian patients with Fuchs uveitis**
rf
CIMINO L, FARNETTI E, CASALI B, NICOLI D, BOIARDI L, CAPPUCCINI L, SALVARANI C—Reggio Emilia
- 673 **Presentation of orbital aspergillosis**
rf
MISSOTTEN GS, DE KEIZER RJW—Leiden, Antwerp
- 674 **Management of ocular disease in epidermolysis bullosa variant: Laryngo-onycho-cutaneous (LOC) syndrome**
rf
ARALIKATTI A, KADYAN A, SHAH S—Birmingham
- 675 **In vivo confocal microscopy of keratic precipitates in anterior uveitis related to Herpesviridae**
LABETOULLE M, LABBE A, DUPAS B, DE MONCHY I, POGORZALEK N, GENDRON G, OFFRET H, BAUDOUIN C—Kremlin-Bicêtre, Paris
- 676 **Retrospective study of 40 cases of sarcoid uveitis**
COUVIDAT M, MOURIAUX F—Caen
- 677 **Human papillomavirus DNA in pterygia**
PIECYK-SIDOR M, POLZ-DACEWICZ M, ZAGORSKI Z, ZARNOWSKI T—Lublin
- 678 **Cytokine profile in intermediate uveitis**
VIDOVIC VALENTINCIC N, KRAUT A, KOROSEK P, HAWLINA M, ROTHOVA A—Ljubljana, Golnik, Utrecht
- 679 **Can tumor necrosis factor inhibitors induce scleritis ?**
LE GARREC J, MARCELLI C, MOURIAUX F—Caen
- 680 **Topical use of Nerve Growth Factor on ocular flora and cytology in dogs eye surface**
DODI PL, ZANOTTI C, COSTA N, ALOE L—Parma, Forli, Catanzaro, Rome
- 681 **One year analysis of the cost of uveitis treatment in France: a retrospective chart review**
BODAGHI B, KOBELT G, RICHARD B, PLESNILLA C, BUCHHOLZ P, BREZIN A, HERON E, LABETOULLE M, SAHEL JA—Paris, Speracedes, Munich, Ettlingen, le Kremlin Bicêtre
- 682 **Genetic analysis of pseudomonas aeruginosa isolates from patients with post-operative endophthalmitis**
PINNA A, USAI D, SECHI LA, ZANETTI S, KALIAMURTHY J—Sassari, Tiruchirappalli
- 683 **The corneal endothelium in an endotoxin-induced uveitis model: Correlation between in vivo confocal microscopy and immunohistochemistry**
TRINH L, BRIGNOLE-BAUDOUIN F, LABBE A, RAPHAEL M, BOURGES JL, BAUDOUIN C—Paris
- 684 **Patient demographic data for phase 2/3 clinical trials of a novel calcineurin inhibitor, Ix 211, for the treatment of non-infectious uveitis**
BODAGHI B—Paris
- 685 **Clinical and microbiological features of acute bacterial conjunctivitis at the primary eye care unit in a hospital of central Italy**
FRUSCHELLI M, MONTAGNANI F, PARADISO A, STOLZUOLI L, ZANCHI A, MOTOLESE I, MOTOLESE E—Siena
- 686 **Changes on optic nerve with sarcoidosis patients**
RADUNOVIC M, VUKSANOVIC A—Podgorica

Why you need to be reading



Acta Ophthalmologica

- **Impact** – our impact factor continues to increase and now stands at 1.848, placing us amongst the most highly cited ophthalmology journals
- **Coverage that's relevant to you** – encompassing all aspects of the anatomy, function and diseases of the eye
- **Official publication** of EVER and all five Nordic Ophthalmological Societies

MEMBERS OF EVER RECEIVE FREE ONLINE ACCESS TO ACTA OPHTHALMOLOGICA

To make sure *Acta Ophthalmologica* is part of your collection, or to submit an article visit: www.actaophthalmologica.com



European Association for Vision and Eye Research

Future Congresses

2009 ➔ September 30-October 3, Portoroz Slovenia

2010 ➔ October 6-9*


2011 ➔ October 5-8*

2012 ➔ October 3-6*

updated information
www.ever.be

* Venue for 2010-2012 to be decided in Portoroz





REDUCING DISPARITIES in Eye Disease and Treatment

ARVO 2009 ANNUAL MEETING

FORT LAUDERDALE, FLORIDA
MAY 3-7, 2009

IMPORTANT DATES

October 15–December 5, 2008
Abstract submission

June 2, 2008–March 17, 2009
Hotel reservations

September 15, 2008–March 17, 2009
Early meeting registration



The Association for Research in
Vision and Ophthalmology

+1.240.221.2900

+1.240.221.0370 (fax)

www.arvo.org

Reminder: request a letter of invitation
(arvo@arvo.org) as soon as possible if you need a
visa for travel to the US

EVA 2008

European Vision Award

by the European Vision Institute EEIG // www.europeanvisioninstitute.org


The winner of the inaugural European Vision Award 2008, PD Dr Hendrik Scholl of the University Eye Hospital Bonn in Germany will be presented during the EVER 2008 Congress on **Friday, October 3, 2008, 16:00 h** and on **Saturday, October 4, 2008, 10:45 h** after the Keynote lecture.


The public ceremony takes place in the Main Hall.


The European Vision Institute's mission is to support programs and projects that develop, integrate and conduct vision research to prevent and treat eye diseases as well as to develop new therapeutic strategies to improve the quality of life for those suffering.


www.europeanvisioninstitute.org











KEYNOTE LECTURES

BALASUBRAMANIAN, D: Friday, 16:00
 HAGEMAN, G: Thursday, 10:00
 HAWLINA, M: Wednesday, 18:05
 JONASSON, F: Thursday, 16:00
 LAIBSON, P: Saturday, 10:00
 MOCHIZUKI, M: Friday, 10:30
 PLEYER, U: Wednesday, 18:25
 VRENSSEN, G: Wednesday, 17:20

ABEDIN A: 6325
 ABU EL ASRAR AM: 3215, 5323, 5324, 5326, 6126
 ACAR N: 580, 4456
 AGGELIDOY E: 440, 516
 AKHTAR S: 416, 552, 4235
 AKOVA Y: 5242
 ALIAS E: 506, 508
 ALIO SANZ JL: 417, 467, 6145
 ALLEGRI P: 6424
 ALOE L: 503
 ALOMAR TS: 6231
 AL-SAQRY R: 5444
 AMBROSIO AF: 4114, 5325
 AMSELEM L: 6261
 ANDJELIC S: 460
 ANGELI R: 456
 ANGI M: 4465
 ANGLE J: 4212
 APTEL F: 536
 ARAKELYAN MA: 656
 ARALIKATTI A: 674, 6427
 ARDAN T: 546
 ARING E: 474
 ARNARSSON A: 485, 5121
 ARNDT C: 476, 4415
 ASLAM T: 4445
 ASOKLIS R: 5432
 AUFFARTH GU: 5343, 6144
 BALASUBRAMANIAN D: 4213, 6157
 BANDELLO F: 4116
 BARBAZETTO I: 6355
 BARBUR JL: 4433
 BARRAQUER J: 5332, 6333
 BARRAQUER R: 6142
 BASTOS A: 437
 BAUER SM: 4355
 BELTZ J: 5431
 BENTO C: 611
 BERENDSCHOT TJM: 641
 BERGER ST: 406
 BERK AT: 4123
 BERNARDES R: 457, 4112
 BERROD JP: 5215
 BERTHOUT A: 651
 BHATT UK: 442, 524, 5353
 BISHOP PN: 4312
 BLASI MA: 6362
 BLAZEJEWSKA EA: 4233
 BODAGHI B: 681, 684, 3212, 4274, 6124
 BOLIVAR G: 574
 BONAVOLONTA G: 5465
 BONSHK R: 666, 5463, 6421
 BORQUE E: 511, 512
 BORRUAT FX: 3263, 4224, 5245
 BOSCHI A: 3264, 4221

BOTTEGA E: 4412
 BOUCHENAKI N: 3214, 6422
 BOURCIER T: 3313
 BOURNE WM: 6136
 BOYCHUK IM: 439
 BRAVETTI GO: 579
 BREMOND-GIGNAC D: 559
 BRETILLON L: 623, 6445
 BRISCOE D: 5462
 BROADWAY D: 6272
 BRON AJ: 4333, 5442
 BRON AM: 527, 6441
 BRUENECH JR: 5122
 BUCHT C: 5435
 BUEHNER E: 519
 BUNIATYAN IY: 530
 BURSTEDT MSI: 4252
 BUSUTTIL A: 6332
 CAMPARINI M: 4344
 CAMPOS E: 4124
 CANADAS SUAREZ P: 554, 6131
 CARDON A: 5223
 CARTER JG: 6354
 CASSOUX N: 5246
 CASTELO-BRANCO M: 4431
 CASTRO MCR: 610
 CEBALLOS GARCIA A: 668
 CELLINI M: 621
 CERVINO A: 4446
 CHARISIS SK: 531
 CHATEAU N: 5236
 CHAUHAN B: 4152
 CHIQUET C: 632, 5213, 6326
 CHOI M: 636
 CHTARTO A: 4161
 CHUA WH: 5117
 CHURCHILL A: 5451
 CIMBALAS A: 625
 CIMINO L: 672, 6123, 6327
 COCHEREAU I: 4272
 COLAFRANCESCO V: 609
 COPPIETERS F: 4162
 COUPLAND S: 5162, 5263, 5361, 6165
 COUTURIER J: 5364
 COUVIDAT M: 676
 CREUZOT CP: 538, 3311, 5211, 5413, 6238
 CUNHA-VAZ J: 4111
 DAMATO B: 3242, 3352, 5164, 6365
 DANIELSON L: 2163
 DASTIRIDOU A: 6345
 DAVISON PA: 647
 DAWES LJ: 4143
 DE FRUTOS-BARAJA JM: 670, 671, 4466
 DE JUAN HERRERO J: 408
 DE KEIZER RJW: 5461
 DE LA PAZ M: 6334
 DELONGH R: 4142
 DE MONCHY I: 553
 DESJARDINS L: 3353, 4464, 5163, 6364
 DE SMET MD: 3211, 4314, 5421, 6122
 DE SOUZA RAMALHO P: 4416
 D'HAENE B: 4163
 DICK AD: 5424
 DILLON J: 5142
 DI STEFANO G: 509, 624
 DODI PL: 680
 DORIN G: 613
 DOWNES SM: 5453
 DRAY JP: 5464
 DUA HS: 3316
 DUPONT-MONOD S: 470
 EDELMAN JL: 4115
 EGEE ESTOPINAN MC: 630, 661
 EHLKEN C: 652
 ELDRED JA: 5341
 ERB C: 6244
 FAGERHOLM P: 6335
 FANNI D: 453
 FARES U: 6134
 FERNANDES AF: 584
 FERRERAS A: 507, 510
 FONTANA L: 5134
 FORRESTER JV: 5423
 FRUSCHELLI M: 685
 FUCHSJÄGER-MAYRL G: 6442
 FULTON AB: 4257
 GAJECKA M: 6353
 GALICHANIN K: 5144
 GAMBRELLE J: 6317
 GARCIA-MARTIN E: 421, 660
 GARHOFER G: 6344
 GATINEL D: 5254
 GAUJOUX T: 541
 GEISER M: 5315
 GEORGET M: 5446
 GEORGI T: 449
 GHAURI AJ: 5354
 GIANNAKOPOULOU T: 5225
 GICQUEL JJ: 448, 3314, 4335, 5132, 5232
 GIL ARIBAS L: 424, 479
 GILES TG: 567, 6133
 GINEYS R: 6423
 GINIS H: 521, 522, 4443
 GIRA O: 407
 GOCHO - NAKASHIMA K: 5234
 GOLNIK K: 3261, 4225
 GONZALEZ C: 627, 6315
 GONZALEZ-FERNANDEZ F: 409
 GRACZYNSKI M: 6451
 GRANGE JD: 6361
 GRAW J: 4241, 4341
 GROSS NJ: 637
 GROSSO A: 6256
 GRZYBOWSKI A: 4121, 5126, 6453
 GUERRI MONCLUS N: 655
 GUNHAGA L: 4141
 GUTIERREZ G: 535
 HAGYO K: 562
 HAN ER: 451
 HARDARSON SH: 6346
 HARDCASTLE AJ: 5454
 HARRIS A: 5153
 HAWLINA M: 3323, 4363
 HE Z: 413
 HEEGAARD S: 5264
 HERBERT C: 3213, 3218, 4273, 6121
 HERWIG MC: 662
 HOLAN V: 418
 HOLDER GE: 3321, 3324, 4324
 HOLLO G: 5352, 6271
 HOPKINSON A: 415, 5436
 HUDSON C: 573, 619, 6349
 HULL CC: 6141
 IBANEZ J: 469, 612
 IDOPE CORTA M: 420, 616
 IMMONEN I: 4134

INBAL M: 4455
 IOMDINA E: 4354, 5114
 IRION LD: 665, 6266
 ISSA M: 5417
 IVASTINOVIC D: 5414
 JAHN CE: 6435
 JAKI MEKJAVIC P: 622
 JANISZEWSKA D: 5433
 JANSONIUS NM: 4452
 JANSSENS S: 4164
 JARC-VIDMAR M: 435
 JHANJI V: 539, 6239
 JOHANNESSEN G: 4451
 JONAS JB: 486, 4454
 JONASSON F: 4342
 JUDICE DE MENEZES RELVAS L: 4165
 KAARNIRANTA K: 5123, 6273
 KABASAWA SK: 604
 KAMMA-LORGER CS: 419
 KANNABIRAN C: 475, 6153
 KARLSSON JO: 5443
 KAWASAKI A: 432, 3262, 3265, 4223
 KAWASAKI R: 6251
 KAZARYAN AA: 514
 KERN T: 6111
 KERNT M: 6444
 KESTELYN P: 3315
 KHANNA R: 6152
 KHAYI H: 581
 KIM K: 466
 KIMURA M: 669
 KIRBY M: 643
 KIVELÄ T: 3241, 3243, 3351, 4361, 5161, 6366
 KLYSIK AB: 425, 5127
 KNOP E: 4331, 5262
 KNOP N: 4332, 5261
 KOCH P: 4166
 KOK PHB: 6414
 KONTADAKIS GA: 5445
 KOPITO R: 555
 KOTECHA A: 5253
 KOTHY P: 526
 KOTLIAR K: 4351, 6343
 KOWLURU R: 6112
 KRUPIN T: 4153
 KRYCZKA T: 557, 5335
 KULKARNI B: 4232
 KUMAR AS: 4424
 LABETOUILLE M: 675, 3312, 5244
 LACHAPPELLE P: 4253
 LAGALI N: 6352
 LANGMAN ME: 5231, 6236
 LANZINI M: 6232
 LANZL I: 5314
 LASCARATOS G: 653
 LASTA M: 585
 LATIES AM: 5125
 LAZUTINA E: 4234
 LEAL EC: 608
 LEE A: 3266, 4222
 LE GARGASSON JF: 5233
 LE GARREC J: 679
 LENASSI E: 6413
 LENCOVA A: 543
 LEROY BP: 3322, 4322, 5452
 LEVY-GABRIEL C: 5166
 LEYSEN I: 4261

INDEX – PRESENTING FIRST AUTHORS

- LIBONDI T: 605, 6313
 LIM LS: 6255
 LIU C: 6331, 6433
 LOANE E: 642
 LOEFFLER KU: 6161
 LÖFGREN S: 5143
 MACHOWICZ-MATEJKO E: 6267
 MACKENSEN F: 6425
 MAENHAUT N: 4262
 MAIER M: 650, 5221
 MANSOURI K: 525
 MARAINI G: 4345
 MARQUES C: 464
 MARTIN LM: 445, 483
 MATEO OROBIA AJ: 549, 649
 MATHEW M: 659
 MATSUYAMA K: 639
 MCCARTY CA: 4343
 MCLAREN JW: 4442
 MCLEAN RJ: 429
 MELIS R: 5356
 MENCUCCI R: 5131
 MENDRINOS E: 582
 MENEZO ROZALEN JL: 423, 565
 MERGLER S: 547
 MEYER L: 5145
 MICHAEL R: 5441
 MICHELS D: 4417
 MIDENA E: 3354, 6211
 MILEA D: 4323
 MILKA M: 462
 MILLAZO S: 458
 MILOJKO B: 533
 MIRANDA MA: 6132
 MIRI A: 5333
 MISSOTTEN GS: 663, 673, 6426
 MOHAMMED I: 6321
 MOHR S: 6114
 MORAES SILVA MRB: 515
 MORGAN IG: 5115, 6252
 MOTULSKY E: 6322
 MUKUNDA CHAITANYA A: 644
 MUSCH D: 2165
 MUSCHART F: 517
 MUSHTAQ F: 6233
 NEIRA W: 556
 NERI P: 3217, 6125, 6314
 NEVALAINEN T: 472
 NOCHEZ Y: 473
 NOLAN J: 6241
 NOTIVOL R: 528
 NOVAK ANDREJIC K: 6162
 NOWAK JZ: 4131
 NOWAK MS: 487, 571, 6347
 NOWINSKA A: 4236
 NUBILE M: 5133
 NUJITS RMMA: 6143
 OBROSOVA IG: 6115
 OGATA N: 607
 OH JY: 560
 OLDAK M: 480, 631
 OLESZCZUK AK: 465
 OLIVEIRA FERREIRA J: 411
 O'NEILL-BIBA M: 4434
 O'REILLY P: 602, 6318
 ORGUL S: 5151
 OSBORNE NN: 6243
 OTRI AM: 6324
- PAIMELA T: 410
 PAJTLER A: 426
 PALLIKARIS I: 4352, 6135, 6137
 PALOMO-ALVAREZ C: 450
 PAPADOPOULOU DN: 633
 PAPAGEORGIOU E: 4421
 PAQUES M: 4151, 6342
 PARENTE G: 5334
 PARROZZANI R: 6265, 6363
 PASTOR S: 537, 569, 6237
 PATTON WP: 629, 6316
 PEDROSA DOMELLOF F: 4423
 PE'ER J: 6163
 PEMP B: 6443
 PENTARI A: 548
 PEREIRA I: 4414
 PEREIRA P: 4242
 PERERA CM: 5434
 PEREZ GARCIA D: 468, 617
 PERIS-MARTINEZ C: 558
 PEROVSEK D: 620
 PES A: 463
 PESCE G: 532
 PETO T: 6214
 PETRICEK P: 540, 623a
 PETTIT A: 5265
 PHAN AP: 6448
 PHILLIPS JR: 403, 455
 PICCIRILLO V: 534, 654
 PIECYK-SIDOR M: 677
 PILOTTO E: 6166
 PINELLO L: 433, 4427
 PINILLA I: 578, 614
 PINNA A: 638, 682
 PIPPARELLI A: 414
 PLANT G: 3331
 PLEYER U: 4271
 POCOBELLI A: 5135
 POGORZALEK N: 561
 POGRZEBIELSKI A: 4462
 PORTERO-BENITO A: 667
 POURJAVAN S: 518, 5252
 POURNARAS CJ: 5214
 PRADEEP A: 5224
 PRAUSE J: 3356
 PRESCOTT AR: 4243
 PROKOFYEVA E: 6356
 PROUDLOCK FA: 4425
 PUELL MC: 646
 PUK O: 6351
 PULT H: 4334
 QUARANTA L: 5152
 QUERQUES G: 618
 RADOVIC N: 657, 4426
 RADUNOVIC M: 686
 RAHMAN I: 564, 566
 RAJ A: 6234
 RAO GN: 6151, 6156
 REHAK M: 640
 REINIS A: 477
 REIS AA: 6357
 RIBEIRO L: 2164
 RIGAL SASTOURNE JC: 583
 RIVA CE: 5316
 RIZZO S: 4315
 ROBSON AG: 438, 4251, 4432
 ROCHA DE SOUSA A: 402, 504
 ROCHER N: 544
- RODRIGUEZ-CARMONA M: 4436
 ROHRER K: 461
 ROLDAN-PALLARES M: 5411
 ROMANO MR: 5415
 ROSE KA: 5116, 6254
 ROSOLEN SG: 447, 5235
 ROSSETTI L: 2162
 RUBERTO G: 4255
 RUGGERI A: 6446
 RYSANEK B: 664
 SAEDON H: 505, 563
 SAHEL JA: 4113
 SAID DG: 6235
 SALMINEN A: 4132
 SANCHEZ-MANNARELLI F: 4461
 SANCHEZ RAMOS C: 444, 452
 SANGWAN V: 6154, 6155
 SAULE S: 5365
 SAVASTANO A: 550, 551
 SAW SM: 6253
 SCHALENBOURG A: 4463
 SCHAUVVLIEGHE PP: 4263
 SCHMETTERER L: 5313
 SCHMIDL D: 502, 4457
 SCHOLLMAYER P: 570
 SCHWEITZER D: 5312
 SEREGARD S: 3355, 4364
 SHALCHI Z: 4411
 SHAMSHINOVA AM: 606
 SHIMA DT: 5321, 5322, 5327
 SIBTAIN N: 3332
 SIKORSKI BL: 6411
 SITNIKOVA D: 576
 SJÖSTRAND JB: 4122
 SJÖSTROM A: 4256
 SKET KONTESTABILE A: 422
 SKINNER KC: 430
 SÖDERBERG PG: 5146, 6431
 SOUCEK P: 6164
 SPALTON DJ: 5344
 SPILEERS W: 4321
 SPIVEY B: 4362
 SPOERL E: 4353
 STALMANS I: 5154
 STEFANO G: 6452
 STEFANSSON E: 6213
 STEWART CE: 5222
 STEWART EA: 412, 6312
 STITT AW: 6113
 STRASSER T: 4254
 STRUBLE C: 572, 6348
 STUNF S: 459
 SUGITA S: 5425
 SULEMAN H: 482, 603, 6417
 SUSTAR M: 436
 SVEDBERGH BOC: 401, 501, 601
 TADAYONI R: 5212
 TAKEUCHI M: 3216, 5422
 TARUTTA E: 5111
 TASSIGNON MJ: 4365, 4444, 5345, 6434
 TAYLOR DT: 5251
 TEKAVCIC POMPE M: 4435
 THIAGARAJAN M: 628, 635
 THOMAS MG: 4422
 THOMAS S: 427
 THURAU S: 5241
 THURET G: 5331
 TICK S: 648
- TIGANITA S: 428, 431
 TINT NL: 5412
 TODOROVA MG: 658
 TOUITOU V: 6264
 TOUZEAU O: 446
 TRIKHA S: 5124
 TRINH L: 683
 TRÖGER E: 484
 TSIKA CI: 6412
 TSILIMBARIS MK: 6416
 TSOKA PA: 405
 TUGAL-TUTKUN I: 5243
 UNSBO P: 6432
 URBAN F: 6263
 URBANCIC M: 634
 UUSITALO HMT: 529, 577, 6274, 6447
 VAN AKEN E: 4313
 VAN BERGEN T: 4264, 5355
 VAN DEN BERG TJTP: 443, 4441
 VAN DER VEEN LP: 645
 VAN DER VELDEN PA: 5362
 VAN DE VEIRE S: 4265, 6311
 VANDEWALLE E: 513
 VAN DIJK HW: 615, 4413
 VAN GINDERDEUREN R: 471, 6262
 VAN GRASDORFF S: 4266
 VAPAATALO H: 575
 VARSANYI B: 478
 VAZHENKOV SN: 454
 VECKENEER M: 4311
 VELIKAY-PAREL M: 5416
 VERA L: 542
 VERBRAAK FD: 6415
 VERES A: 568
 VERONESE RODRIGUES ML: 4453
 VIDOVIC VALENTINCIC N: 678
 VIEIRA DE SOUZA N: 520
 VIIRI J: 545
 VILSER W: 5311
 VON BONHORST C: 4211
 VORONKOVA E: 4356
 VOTRUBA M: 5455
 VUJOSEVIC S: 6212
 WAHLBERG M: 441
 WANG L: 5342
 WARD B: 5112
 WEGENER A: 5141
 WEIGERT G: 6341
 WELGE-LUSSEN U: 6242
 WHEELER LA: 4154
 WIEDEMANN P: 404
 WIERZBOWSKA J: 523
 WILDISOET C: 5113
 WORMALD R: 2161, 2166
 WORMSTONE IM: 4144
 WRIDE MA: 4244
 XU H: 4133
 YAMAKI K: 6323
 YEUNG AM: 481, 4231
 ZAKARIA N: 4267
 ZESCHNIGK M: 5363
 ZEYEN T: 5351
 ZOGRAFOS L: 5165, 6167
 ZOURDANI A: 626
 ZRENNER E: 4214
 ZUEVA MV: 434

THANK YOU SPONSORS

EVER wishes everyone of its past and present sponsors good future for the coming years and thanks especially the following companies, many of which are our long-term supporters, for their generous sponsorship. Thanks to their support EVER can continue to encourage research and dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

Main sponsor

Alcon[®]



Major sponsor

Santen

CD sponsor

 **Pfizer Ophthalmics**

SIS sponsors

Alcon[®]

 **ALLERGAN**


Bausch & Lomb

Reichert[®]

Santen

SENJU

CIS sponsor



Exhibitors





Welcome reception




Farewell dinner



This programme book is organised chronologically



The sessions are colour-coded



FP = Free Paper session

SIS = Special Interest Symposium

rf = Rapid Fire presentation

CIS = Commercial Interest Symposium

 = Travel grant recipient

Scientific sections

ACB = Anatomy/Cell Biology

COS = Cornea/Ocular Surface

G = Glaucoma

IM = Immunology/Microbiology

LC = Lens and Cataract

MBGE = Molecular Biology/Genetics/ Epidemiology


NSPH = Neuro-ophthalmology/Strabismology/ Paediatric Ophthalmology/History of Ophthalmology

PBP = Physiology/Biochemistry/Pharmacology

PO = Pathology/Oncology

RV = Retina/Vitreous

VEP = Vision Sciences/Electrophysiol/Physiological Optics



BE IN A POSITION
TO SUCCEED.

DUOTRAV™ Solution, combining two powerful agents into a single bottle, decreases IOP by up to 38% (12mmHg) from baseline¹. DUOTRAV™ Solution's convenient once-a-day dosing, either morning or evening, enhances patient compliance. BE IN A POSITION TO SUCCEED in the management of glaucoma.

DUOTRAV™
40 micrograms/ml + 5 mg/ml eye drops solution (travoprost/timolol)

Reference: 1. Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. *Am J Ophthalmol.* 2005;140:1-7. ©2006 Alcon, Inc.

Consult the Summary of Product Characteristics before prescribing, particularly in relation to side-effects, precautions and contraindications.

DuoTrav™ (travoprost and timolol maleate). **Presentation** Plastic bottle containing 2.5ml eye drops. Each 1 ml contains 40 micrograms of travoprost, 5 mg of timolol (as timolol maleate), benzalkonium chloride 0.15 mg, and polyoxyethylene hydrogenated castor oil 40 (HCO-40) 5 mg. **Indication** Decrease of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues. **Dosage/Administration Adults, including the elderly** One drop into affected eye(s) once daily, morning or evening. Administer at same time each day. **Paediatric patients** Not recommended. **Use in hepatic and renal impairment** No studies conducted with DuoTrav. **Contraindications** Hypersensitivity to any component of product. Bronchial asthma, severe chronic obstructive pulmonary disease. Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock. Severe allergic rhinitis, bronchial hyper reactivity; corneal dystrophies, hypersensitivity to other beta-blockers. **Warnings and precautions** Systemic effects Cardiovascular and pulmonary adverse reactions as seen with systemic beta-blockers may occur. Cardiac failure should be adequately controlled before beginning therapy with timolol. Patients with a history of severe cardiac disease should be watched for signs of cardiac failure and have pulse rates checked. Respiratory and cardiac reactions, including death due to bronchospasm in patients with asthma and cardiac failure, have been reported following administration of timolol. Beta-blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or to diabetic patients (especially those with labile diabetes) as beta-blockers may mask the signs and symptoms of acute hypoglycaemia and hyperthyroidism, and cause worsening of Prinzmetal angina, severe peripheral and central circulatory disorders and hypotension. **Anaphylactic reactions** While taking beta-blockers, patients with a history of atopy or

severe anaphylactic reaction to a variety of allergens may be unresponsive to usual doses of adrenaline used to treat anaphylactic reactions. **Concomitant Therapy** Timolol may interact with other products. Effect on IOP or known effects of systemic beta-blockade may be potentiated when DuoTrav is given to patients already taking oral beta-blockers. Use of two local beta-blockers or local prostaglandins is not recommended. **Ocular effects** Travoprost may increase brown pigment within the iris leading to a gradual change in eye colour. Predominantly seen in patients with mixed coloured irides, may be permanent. Unilateral treatment can result in permanent heterochromia. Eyelash changes (length, thickness, pigmentation and/or number of lashes). Long-term consequences unknown. Caution in patients with inflammatory ocular conditions, other types of glaucoma (including neovascular, angle-closure, narrow-angle, congenital, pigmentary or pseudoexfoliative glaucoma), thyroid eye disease, open-angle glaucoma of pseudophakic patients, aphakic patients, pseudophakic patients with a torn posterior lens capsule or anterior chamber lenses, patients with known risk factors for cystoid macular oedema, or in patients with known predisposing risk factors for iritis/uveitis. **Contact lenses** Avoid use of soft contact lenses. Instruct patients to remove contact lenses prior to drop application and wait 15 minutes after instillation before reinsertion. Polyoxyethylene hydrogenated castor oil 40 may cause skin reactions. **Interactions** No interaction studies have been performed. Potential for additive effects resulting in hypotension and/or marked bradycardia when eye drops with timolol are administered concomitantly with oral calcium channel blockers, guanethidine or beta-blockers, antiarrhythmics, digitalis glycosides or parasympathomimetics. Hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking beta-blockers. **Women of childbearing potential** Do not use unless adequate contraceptive measures are in place. **Pregnancy** Do not use unless clearly necessary. **Lactation** Not recommended. **Driving /use of machines** Eye drop instillation may blur vision. **Undesirable effects** No serious undesirable effects related to DuoTrav were reported. Most frequently reported

treatment-related undesirable effect was ocular hyperaemia (15%). 98% of patients who experienced ocular hyperaemia did not discontinue therapy as a result. **Other very common/common undesirable effects reported in clinical trials with DuoTrav** Nervousness, dizziness, headache, eye (irritation, pain, swelling, discomfort, abnormal sensation, dryness, pruritus) punctate keratitis, anterior chamber cells and flare, photophobia, conjunctival haemorrhage, corneal staining, vision (acuity reduced, disturbance, blurred) conjunctivitis allergic, lacrimation increased, eyelid (erythema, irritation, dermatitis), asthenopia, growth of eyelashes, heart rate and blood pressure changes, bronchospasm, urticaria, skin hyperpigmentation (periocular), pain in extremity. **Additional undesirable treatment-related effects have been reported in clinical trials with concomitant therapy (travoprost and timolol) or with monotherapy with travoprost, or postmarketing events reported in the SPC for travoprost or timolol that have not been reported with DuoTrav:** Refer to SPC for additional information and before prescribing. **Overdose** Treat symptomatically. Timolol does not dialyse readily. **Incompatibilities** Not applicable. **Shelf life** 3 years, discard 4 weeks after first opening. **Special precautions for storage/disposal** None. **PL Holder and Further Information** Alcon Laboratories (UK) Ltd., Boundary Way, Hemel Hempstead, Herts HP2 7UD, United Kingdom. **PL Number** EU/1/06/338/001-003 **Date of Preparation of Prescribing Information** March 2006 **Packaging Quantities and Basic NHS and GMS price(s)** Cartons containing 1 x 2.5ml (€13.20, €19.66) 3 x 2.5ml (€37.62, €56.02), 6 x 2.5ml not marketed. **Legal Category** POM.

Adverse events should be reported to Alcon (UK) Medical Information on 01442 341234. Information about adverse event reporting can also be found on www.yellowcard.uk

Date of preparation: August 2006.

DUO:EVER:0708(HC)

Alcon

	Europa A	Europa B	Emerald I	Emerald II	Mediterranea I	Adria
MONDAY	08:30-17:30 — Educating the Educators Conference — The following organisations will contribute ICO / EBO / SOE / EUPO / EVER — By invitation — in Hall AUBORA					
TUESDAY	08:00-16:30 — Educating the Educators Conference — The following organisations will contribute ICO / EBO / SOE / EUPO / EVER — By invitation — in Hall AUBORA					
WEDNESDAY	08:00-17:00 — ARVO Foundation: Design, conduct and management of clinical trials in eye research — in Hall ADRIA					
08:30-11:30	EGS: Neuroprotection Special Interest Group MF CORDEIRO					
12:00-14:15	IM: Course 1: OCT CP HERBERT, MD DE SMET	NSPH: Course 2: Visual field U SCHEFFER, E PAPAGEORGIOU, M MONHART	PO: Course 3: Time-to-event data T KIVELA, B DAMATO	NSPH: Course 4: EBO Course: Neuro (12:00-14:30) FX BORRIJAT, A BOSCHI, K GOINIK, A KAWASAKI, A LEE		
14:30-16:45	COS: Course 5: Corneal JJ GICQUEL, HS DUA	VEP: Course 6: Electrophysiology G HOLDER	NSPH: Course 7: MRI P AYDIN	PO: Course 8: EBO Course: Oncology (14:45-16:45) L DESJARDINS		
17:00-19:00	Opening ceremony: 17:00: Welcome by the President EVER 2008, Harminder DUA — 17:20: AER Lecture, Gijs Vrensen — 18:05: European Ophthalmologic Heritage, Maiko HAWLINA — 18:25: EVER Lecture, Uwe PLEYER					
19:00-21:00	EVER welcome reception with musical entertainment by Miha Debevec					
THURSDAY	in S. Bernardin					
08:15-09:45	RV: EURETINA: Role of inflammation in the progression of diabetic macular edema — J CUNHA-VAZ	NSPH: Amblyopia P AYDIN, L MARTIN	ACB: Retinal pigment epithelium K KAARNIRANTA, H UUSITALO	LC: Cell signalling in the lens - part I M WRIDE	G: Stop glaucoma: progression in neuroprotection I STALMANS, MF CORDEIRO	
10:00-10:40	Keynote Lecture 1 — A new era for age-related macular degeneration: insights pertaining to a key role for the complement system — Gregory HAGEMAN					
10:45-11:05	EVER Strategic planning session — Harminder S DUA					
11:30-13:00	ARVO Session: Making the case for funding eye Research — JANGLE	NSPH: Neuro-ophthalmic diagnoses not to be missed — A KAWASAKI, FX BORRIJAT	ACB: Functional anatomy of anterior segment E KNOP, P DOMELLOF	LC: Cell signalling in the lens - part II M WRIDE	ISCEV session C BARBER, AP TORMENE	
13:05-14:05	THEA Lunchtime SIS — Ocular inflammation and infection, what's new in 2008 — Bahram BODAGHI					
14:15-15:45	RV: Novelities in basic research in vitreoretinal surgery E VAN AKEN, MD DE SMET	NSPH: Dr. the eyes won't keep still G HOLDER	ACB: The lid margin - the ultimate border of the tear film — E KNOP, N KNOP, AJ BRON	LC: Epidemiology of cataract G MARAINI, P SODERBERG	G: Biomechanical aspects of intraocular pressure measurements — K KOTILAR	
16:00-16:40	EVER - Acta Lecture — Unravelling the genetics of exfoliation glaucoma — Fridbert JONASSON					
16:45-17:40	Poster Session 1: Anatomy / Cell Biology RV: Diabetic retinopathy - Growth factors F BANDELLO, J CUNHA-VAZ	Neuro-Ophthalmology / Strabismology / Paediatric Ophthalmology / History Vision Sciences / Electrophysiology / Physiological Optics Lens / Cataract	VCOS: New techniques in corneal surgery L MASTROPASQUA, JJ GICQUEL	LC: Straylight as quality measure for ophthalmic procedures — R MICHAEL, T VAN DEN BERG	Molecular Biology / Genetics / Epidemiology G: Glaucoma diagnosis S ORGUL, T ZEYEN	
17:45-19:15	VEP: Mechanisms of the onset, progression and prevention of myopia — EN IOMIDINA, E TARUITA	ACB / MBGE / NSPH joint session P AYDIN, R BRUENECH	VCOS: Vision sciences 1 G HOLDER, B LEROY	LC: Ultraviolet radiation cataract P SODERBERG, A WEGENER	G: Blood flow: a practical approach in glaucoma I STALMANS, L SCHMETTERER	
FRIDAY	PO: Conjunctival melanocytic neoplasms S COUPLAND, B DAMATO					
08:15-09:45	Address from the EU Commissioner of Research — Jarez POTOCNIK					
10:00-10:20	Keynote Lecture 2 — Regional immunity of the eye: T lymphocytes and ocular pigment epithelial cells — Manabu MOCHIZUKI					
10:30-11:10	RV: Progress in vitreo-retinal surgery: from animals to humans — C CHIQUET, C CREUZOT	VEP: Vision sciences 2 W SPILLEERS, M HAWLINA	COS: Wavefront aberrometry and adaptive optics JJ GICQUEL, N CHATEAU	IM: EVER — SOIE: Neurological concomitants of uveitis ITUGAL-TUTKUN, CP HERBERT	G: Corneal biomechanical properties: Implication for cornea and glaucoma clinicians — S POURJAVAN	
13:05-14:05	RV / PBP	IM / NSPH	COS / ACB	LC / MBGE	G / VEP	PO
14:15-15:45	RV: Assessment of functional response of the ocular circulation — C RIVA, I LANZL	IM: The role of inflammation in diabetic retinopathy — A ABU EL ASRAR	COS: Corneal grafting 1 P KESTELYN, JJ GICQUEL	LC: Posterior capsule opacification M WORMSTONE, P SODERBERG	G: Glaucoma treatment A BRON, J STALMANS	PO: Genomic and epigenetic alterations in uveal melanoma — L DESJARDINS, M J JAGER
16:00-16:40	Ophthalmic Research Lecture - Functional analysis of mutants of the optineurin gene, associated with some forms of glaucoma — Dbala BALASUBRAMANIAN					
16:45-17:40	Poster Session 2: Glaucoma RV: Vitreoretinal surgery C POURWARAS, C CREUZOT	Cornea / Ocular Surface Physiology / Biochemistry / Pharmacology	COS: Keratoconus and corneal grafting 2 F KRUSE, T CLAERHOUT	LC: Lens and cataract JO KARLSSON, A WEGENER	MBGE: What can molecular biology and genetics do for me? — M YOTRUBA	
17:45-19:15	EVER General Assembly and prize giving					
08:15-09:45	RV: Diabetic retinopathy: novel mechanisms I OBROSOVA, T KERN	IM: Update on developments in uveitis & intraocular inflammation — CP HERBERT, P NERI	COS: Refractive surgery and contact lenses. The best of both worlds — C CREUZOT, W BOURNE	LC: New iOL technology - restoring accommodation RI BARRAQUER, R MICHAEL	PO: OOG: Protocols 1 E MIDENA	
10:00-10:40	Keynote Lecture 3 - Recognition and treatment of herpes simplex keratitis — Peter LAIBSON					
10:45-11:05	EVA 2008 - European Vision Award					
11:30-13:00	RV: Screening of diabetic retinopathy: facts and perspectives — S VUJOSEVIC, E MIDENA	How to get your work published? U PLEYER	COS: Ocular surface HS DUA, M NUBILE	PBP: Nutrition and the eye - Potential role of supplementation — L SCHMETTERER	PO: Pathology / Oncology 2 C ALL-ERIKSSON, S HEEGAARD	
13:05-14:05	SANTEN Lunchtime SIS — In search of improved glaucoma therapy — Hannu UUSITALO					
14:15-15:45	RV: Antiangiogenic treatments and PDT G SOUBRANIC, JJ DE LAEY	IM: Progress in immunology / microbiology - Research U PLEYER, F WILLERMAIN	COS: Keratoprotheses CH LIU	PBP: Physiology / Pharmacology 1 N OSBORNE, A BRON	PO: OOG: Protocols 2 E MIDENA	
15:50-16:40	Poster Session 3: Retina / Vitreous RV: Macular imaging - Macular edema C RIVA, F VERBAAK	Pathology / Oncology Immunology / Microbiology	LC: New iOL technology - new modalities P SODERBERG, CH LIU	International networking in ophthalmology research A GRZYBOWSKI		
16:45-17:40	EVER Farewell Dinner with musical entertainment by Kontrabast					
17:45-19:15	in S. Bernardin					
20:00-23:00	in S. Bernardin					